US20190388442A1 - Acyclic Nucleoside Phosphonate Diesters - Google Patents
Acyclic Nucleoside Phosphonate Diesters Download PDFInfo
- Publication number
- US20190388442A1 US20190388442A1 US16/567,092 US201916567092A US2019388442A1 US 20190388442 A1 US20190388442 A1 US 20190388442A1 US 201916567092 A US201916567092 A US 201916567092A US 2019388442 A1 US2019388442 A1 US 2019388442A1
- Authority
- US
- United States
- Prior art keywords
- substituted
- unsubstituted
- benzyl
- compound
- phosphonomethoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- -1 Acyclic Nucleoside Phosphonate Diesters Chemical class 0.000 title abstract description 602
- 150000001875 compounds Chemical class 0.000 claims abstract description 361
- 238000000034 method Methods 0.000 claims abstract description 92
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 158
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 140
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 129
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 126
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 101
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 claims description 95
- 125000003118 aryl group Chemical group 0.000 claims description 93
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims description 93
- 125000000217 alkyl group Chemical group 0.000 claims description 87
- 229940035893 uracil Drugs 0.000 claims description 79
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 77
- 229960000643 adenine Drugs 0.000 claims description 72
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 71
- 229930024421 Adenine Natural products 0.000 claims description 71
- 125000001072 heteroaryl group Chemical group 0.000 claims description 68
- 229940104302 cytosine Drugs 0.000 claims description 65
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 64
- 229940113082 thymine Drugs 0.000 claims description 63
- 150000003839 salts Chemical class 0.000 claims description 62
- 125000001424 substituent group Chemical group 0.000 claims description 53
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 51
- 241000701806 Human papillomavirus Species 0.000 claims description 51
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 claims description 41
- 125000001624 naphthyl group Chemical group 0.000 claims description 41
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 35
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 34
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 24
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 239000001257 hydrogen Substances 0.000 claims description 20
- 229910052736 halogen Inorganic materials 0.000 claims description 18
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 17
- 150000002367 halogens Chemical class 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 9
- 206010008263 Cervical dysplasia Diseases 0.000 claims description 9
- 208000007951 cervical intraepithelial neoplasia Diseases 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
- 206010051999 Anogenital dysplasia Diseases 0.000 claims description 5
- 125000001153 fluoro group Chemical group F* 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
- 208000018777 Vulvar intraepithelial neoplasia Diseases 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 claims description 2
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 54
- 238000002360 preparation method Methods 0.000 abstract description 46
- 230000000840 anti-viral effect Effects 0.000 abstract description 38
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 38
- 201000010099 disease Diseases 0.000 abstract description 31
- 230000003612 virological effect Effects 0.000 abstract description 26
- 206010028980 Neoplasm Diseases 0.000 abstract description 20
- 201000011510 cancer Diseases 0.000 abstract description 19
- 230000001093 anti-cancer Effects 0.000 abstract description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 382
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 120
- 210000004027 cell Anatomy 0.000 description 107
- 125000003294 thymin-1-yl group Chemical group [H]N1C(=O)N(*)C([H])=C(C1=O)C([H])([H])[H] 0.000 description 76
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 72
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 62
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 60
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 40
- 239000002904 solvent Substances 0.000 description 39
- 239000012453 solvate Substances 0.000 description 35
- 239000000243 solution Substances 0.000 description 32
- 238000005160 1H NMR spectroscopy Methods 0.000 description 31
- VKKXEIQIGGPMHT-UHFFFAOYSA-N 7h-purine-2,8-diamine Chemical compound NC1=NC=C2NC(N)=NC2=N1 VKKXEIQIGGPMHT-UHFFFAOYSA-N 0.000 description 31
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 30
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 30
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 30
- 241000700605 Viruses Species 0.000 description 30
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 29
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 27
- 239000000741 silica gel Substances 0.000 description 27
- 229910002027 silica gel Inorganic materials 0.000 description 27
- 125000000845 uracil-1-yl group Chemical group [*]N1C(=O)N([H])C(=O)C([H])=C1[H] 0.000 description 27
- 125000003738 guanin-9-yl group Chemical group O=C1N([H])C(N([H])[H])=NC2=C1N=C([H])N2[*] 0.000 description 26
- 239000011734 sodium Substances 0.000 description 26
- 241000700721 Hepatitis B virus Species 0.000 description 24
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 24
- 241000725303 Human immunodeficiency virus Species 0.000 description 23
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 description 21
- 239000003814 drug Substances 0.000 description 21
- 241000701460 JC polyomavirus Species 0.000 description 20
- 238000004440 column chromatography Methods 0.000 description 20
- 241000701022 Cytomegalovirus Species 0.000 description 19
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 241000829111 Human polyomavirus 1 Species 0.000 description 18
- 241000700618 Vaccinia virus Species 0.000 description 18
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 18
- 239000002777 nucleoside Substances 0.000 description 18
- 239000000126 substance Substances 0.000 description 18
- 0 *OP(=O)(COC(C)CC)OC Chemical compound *OP(=O)(COC(C)CC)OC 0.000 description 17
- 241000711549 Hepacivirus C Species 0.000 description 17
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 17
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 17
- 241000700647 Variola virus Species 0.000 description 17
- 239000010410 layer Substances 0.000 description 16
- 241000701161 unidentified adenovirus Species 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 241000713800 Feline immunodeficiency virus Species 0.000 description 15
- 241000714165 Feline leukemia virus Species 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 230000012010 growth Effects 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 12
- IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 description 12
- 150000003254 radicals Chemical class 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 125000002947 alkylene group Chemical group 0.000 description 11
- 238000003818 flash chromatography Methods 0.000 description 11
- 230000029812 viral genome replication Effects 0.000 description 11
- HQOSHKMMTMDUSQ-UHFFFAOYSA-N CCC(C)OCP(=O)(OC)OC Chemical compound CCC(C)OCP(=O)(OC)OC HQOSHKMMTMDUSQ-UHFFFAOYSA-N 0.000 description 10
- 206010008342 Cervix carcinoma Diseases 0.000 description 10
- 235000019445 benzyl alcohol Nutrition 0.000 description 10
- 201000010881 cervical cancer Diseases 0.000 description 10
- 239000007822 coupling agent Substances 0.000 description 10
- 230000003013 cytotoxicity Effects 0.000 description 10
- 231100000135 cytotoxicity Toxicity 0.000 description 10
- 210000002950 fibroblast Anatomy 0.000 description 10
- 125000005842 heteroatom Chemical group 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 125000004474 heteroalkylene group Chemical group 0.000 description 9
- 125000005549 heteroarylene group Chemical group 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 150000003833 nucleoside derivatives Chemical class 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 230000001988 toxicity Effects 0.000 description 9
- 231100000419 toxicity Toxicity 0.000 description 9
- 241000341655 Human papillomavirus type 16 Species 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 238000012054 celltiter-glo Methods 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- 239000013078 crystal Substances 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- GDWACIIOPAIYAK-UHFFFAOYSA-N 2-[2-(2-octadecoxyethylamino)-6-oxo-3h-purin-9-yl]ethoxymethylphosphonic acid Chemical compound O=C1NC(NCCOCCCCCCCCCCCCCCCCCC)=NC2=C1N=CN2CCOCP(O)(O)=O GDWACIIOPAIYAK-UHFFFAOYSA-N 0.000 description 7
- 241000701828 Human papillomavirus type 11 Species 0.000 description 7
- 208000009608 Papillomavirus Infections Diseases 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000011529 RT qPCR Methods 0.000 description 6
- 125000000732 arylene group Chemical group 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 231100000433 cytotoxic Toxicity 0.000 description 6
- 230000001472 cytotoxic effect Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 125000006588 heterocycloalkylene group Chemical group 0.000 description 6
- 230000003211 malignant effect Effects 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 229910052698 phosphorus Inorganic materials 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000002194 synthesizing effect Effects 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 208000036142 Viral infection Diseases 0.000 description 5
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000001028 anti-proliverative effect Effects 0.000 description 5
- 239000003443 antiviral agent Substances 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 229960000724 cidofovir Drugs 0.000 description 5
- 150000005690 diesters Chemical class 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 210000003953 foreskin Anatomy 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000002062 proliferating effect Effects 0.000 description 5
- 239000012047 saturated solution Substances 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 125000003107 substituted aryl group Chemical group 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 230000009385 viral infection Effects 0.000 description 5
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 4
- HXTCSYUQJHCNFK-UHFFFAOYSA-N 1-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOC(C)O HXTCSYUQJHCNFK-UHFFFAOYSA-N 0.000 description 4
- BPWCCWCIXWXIEA-UHFFFAOYSA-N 6-tritylpurin-6-amine Chemical compound N1=CN=C2N=CN=C2C1(N)C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 BPWCCWCIXWXIEA-UHFFFAOYSA-N 0.000 description 4
- NZVORGQIEFTOQZ-UHFFFAOYSA-N 9-[2-(phosphonomethoxy)ethyl]guanine Chemical compound N1C(N)=NC(=O)C2=C1N(CCOCP(O)(O)=O)C=N2 NZVORGQIEFTOQZ-UHFFFAOYSA-N 0.000 description 4
- 208000003174 Brain Neoplasms Diseases 0.000 description 4
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 4
- HQOSHKMMTMDUSQ-SSDOTTSWSA-N CC[C@@H](C)OCP(=O)(OC)OC Chemical compound CC[C@@H](C)OCP(=O)(OC)OC HQOSHKMMTMDUSQ-SSDOTTSWSA-N 0.000 description 4
- 241000341657 Human papillomavirus type 18 Species 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000013553 cell monolayer Substances 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 125000002993 cycloalkylene group Chemical group 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 210000001842 enterocyte Anatomy 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 230000000873 masking effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 150000003212 purines Chemical class 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- QSCNDYRHLAEBAY-UHFFFAOYSA-N 2-[2-(2,3-dihydroxypropylamino)-6-oxo-3h-purin-9-yl]ethoxymethylphosphonic acid Chemical compound O=C1NC(NCC(O)CO)=NC2=C1N=CN2CCOCP(O)(O)=O QSCNDYRHLAEBAY-UHFFFAOYSA-N 0.000 description 3
- LWYZWVNVHLONOO-UHFFFAOYSA-N 2-[4-(2,3-dihydroxypropylamino)-2-oxopyrimidin-1-yl]ethoxymethylphosphonic acid Chemical compound OCC(O)CNC=1C=CN(CCOCP(O)(O)=O)C(=O)N=1 LWYZWVNVHLONOO-UHFFFAOYSA-N 0.000 description 3
- UCJNCXNVPPIOFF-UHFFFAOYSA-N 2-[6-amino-2-(2,3-dihydroxypropyl)purin-9-yl]ethoxymethylphosphonic acid Chemical compound NC1=NC(CC(O)CO)=NC2=C1N=CN2CCOCP(O)(O)=O UCJNCXNVPPIOFF-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 206010059313 Anogenital warts Diseases 0.000 description 3
- INJOWKZVHNIUQZ-UHFFFAOYSA-N C(C(O)CO)CC=1C(NC(N(C=1)CCOCP(=O)(O)O)=O)=O Chemical compound C(C(O)CO)CC=1C(NC(N(C=1)CCOCP(=O)(O)O)=O)=O INJOWKZVHNIUQZ-UHFFFAOYSA-N 0.000 description 3
- MWXNQRXJOUEXNY-UHFFFAOYSA-N CCC(CC(C)C)OCC1=CC=CC=C1 Chemical compound CCC(CC(C)C)OCC1=CC=CC=C1 MWXNQRXJOUEXNY-UHFFFAOYSA-N 0.000 description 3
- 208000000907 Condylomata Acuminata Diseases 0.000 description 3
- GJAARPKBDFKHFS-UHFFFAOYSA-N Gerin Natural products COC(=O)C(=C)C1CC2C(=C)C(=O)C=CC2(C)CC1OC(=O)C GJAARPKBDFKHFS-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 3
- 208000000389 T-cell leukemia Diseases 0.000 description 3
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 3
- 108020005202 Viral DNA Proteins 0.000 description 3
- ZPJYBXZJRWMZEE-UHFFFAOYSA-N [1-[6-amino-2-(2-octadecoxyethyl)purin-9-yl]-3-methoxypropan-2-yl]oxymethylphosphonic acid Chemical compound CCCCCCCCCCCCCCCCCCOCCC1=NC(N)=C2N=CN(CC(COC)OCP(O)(O)=O)C2=N1 ZPJYBXZJRWMZEE-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 125000003710 aryl alkyl group Chemical group 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 229940088679 drug related substance Drugs 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 3
- 229960001627 lamivudine Drugs 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- AVIFKOIVNVRTPE-NDEPHWFRSA-N (2s)-3-octadecoxy-2-phenylmethoxypropan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCOC[C@H](CO)OCC1=CC=CC=C1 AVIFKOIVNVRTPE-NDEPHWFRSA-N 0.000 description 2
- PDSNPWHWGWNHML-UHFFFAOYSA-N (4-methylphenyl)sulfonyloxymethyl-phenylmethoxyphosphinic acid Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCP(O)(=O)OCC1=CC=CC=C1 PDSNPWHWGWNHML-UHFFFAOYSA-N 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
- GEJNZFUHMKBCEB-UHFFFAOYSA-N 1-[6-amino-2-(2-octadecoxyethyl)purin-9-yl]propan-2-yloxymethylphosphonic acid Chemical compound CCCCCCCCCCCCCCCCCCOCCC1=NC(N)=C2N=CN(CC(C)OCP(O)(O)=O)C2=N1 GEJNZFUHMKBCEB-UHFFFAOYSA-N 0.000 description 2
- CWHTWRIJUHKMAH-UHFFFAOYSA-N 2-[2-[benzyl(2-octadecoxyethyl)amino]-6-oxo-3h-purin-9-yl]ethoxymethylphosphonic acid Chemical compound N=1C=2N(CCOCP(O)(O)=O)C=NC=2C(=O)NC=1N(CCOCCCCCCCCCCCCCCCCCC)CC1=CC=CC=C1 CWHTWRIJUHKMAH-UHFFFAOYSA-N 0.000 description 2
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- ZGTGIWJYILOTQU-UHFFFAOYSA-M C.CCC(C)O.CCC(C)OCP(=O)(O)OC.CCC(C)OCP(=O)(O)OC.CCC(C)OCP(=O)(OC)OC.CCP(=O)([O-])OC.CO.[Na+] Chemical compound C.CCC(C)O.CCC(C)OCP(=O)(O)OC.CCC(C)OCP(=O)(O)OC.CCC(C)OCP(=O)(OC)OC.CCP(=O)([O-])OC.CO.[Na+] ZGTGIWJYILOTQU-UHFFFAOYSA-M 0.000 description 2
- HZSQHQAXVNQQFE-UHFFFAOYSA-N C.CCCCCCCCCCCCCCCCCCOCC(COP(=O)(COC(CO)CN1C=CC(N)=NC1=O)OCC1=CC=CC=C1)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COC(CCO)CN1C=NC2=C(N)N=CN=C21)OC1=C2C=CC=CC2=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COC(CCO)CN1C=NC2=C(N)N=CN=C21)OC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COC(CCO)CN1C=NC2=C(N)N=CN=C21)OCC1=CC=CC=C1 Chemical compound C.CCCCCCCCCCCCCCCCCCOCC(COP(=O)(COC(CO)CN1C=CC(N)=NC1=O)OCC1=CC=CC=C1)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COC(CCO)CN1C=NC2=C(N)N=CN=C21)OC1=C2C=CC=CC2=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COC(CCO)CN1C=NC2=C(N)N=CN=C21)OC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COC(CCO)CN1C=NC2=C(N)N=CN=C21)OCC1=CC=CC=C1 HZSQHQAXVNQQFE-UHFFFAOYSA-N 0.000 description 2
- XHAWONSBTLMKRS-UHFFFAOYSA-N C1=CC(C)=CC=C1S(=O)(=O)OCOP(=O)OCC1=CC=CC=C1 Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCOP(=O)OCC1=CC=CC=C1 XHAWONSBTLMKRS-UHFFFAOYSA-N 0.000 description 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 2
- WVSVAKHQHRGDHB-UHFFFAOYSA-N CC(C)N1C=CC(=O)NC1=O.CC(C)N1C=CC(N)=NC1=O.CC1=CN(C(C)C)C(=O)NC1=O.CC1=NC2=C(N=CN2C(C)C)C(=O)N1.CC1=NC2=C(N=CN2C(C)C)C(N)=N1.CC1=NC2=C(N=CN2C(C)C)C(N)=N1 Chemical compound CC(C)N1C=CC(=O)NC1=O.CC(C)N1C=CC(N)=NC1=O.CC1=CN(C(C)C)C(=O)NC1=O.CC1=NC2=C(N=CN2C(C)C)C(=O)N1.CC1=NC2=C(N=CN2C(C)C)C(N)=N1.CC1=NC2=C(N=CN2C(C)C)C(N)=N1 WVSVAKHQHRGDHB-UHFFFAOYSA-N 0.000 description 2
- IXNZTPVSZORIFS-UHFFFAOYSA-N CCCCCCCCCCCCCCCCCCOCC(COP(=O)(COC(CO)CN1C=NC2=C(N)N=CN=C21)OCC1=CC=CC=C1)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COC(CO)CN1C=CC(=O)NC1=O)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COC(CO)CN1C=CC(N)=NC1=O)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COC(CO)CN1C=NC2=C(N)N=CN=C21)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COCCN1C=NC2C(=O)N=C(N)N=C21)OCC1COC(C)(C)O1 Chemical compound CCCCCCCCCCCCCCCCCCOCC(COP(=O)(COC(CO)CN1C=NC2=C(N)N=CN=C21)OCC1=CC=CC=C1)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COC(CO)CN1C=CC(=O)NC1=O)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COC(CO)CN1C=CC(N)=NC1=O)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COC(CO)CN1C=NC2=C(N)N=CN=C21)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COCCN1C=NC2C(=O)N=C(N)N=C21)OCC1COC(C)(C)O1 IXNZTPVSZORIFS-UHFFFAOYSA-N 0.000 description 2
- XVCOKIUCTXHPFO-UHFFFAOYSA-N CCCCCCCCCCCCCCCCCCOCCOP(=O)(COC(CF)CN1C=NC2=C1N=C(N)NC2=O)OCC1=CC=CC=C1 Chemical compound CCCCCCCCCCCCCCCCCCOCCOP(=O)(COC(CF)CN1C=NC2=C1N=C(N)NC2=O)OCC1=CC=CC=C1 XVCOKIUCTXHPFO-UHFFFAOYSA-N 0.000 description 2
- RBSMSPFYZQIFCH-UHFFFAOYSA-N CCCCCCCCCCCCCCCCCCOCCOP(=O)(COCCN1C=NC2=C(N)N=CN=C21)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COCCN1C=NC2C(=O)N=C(N)N=C21)OC1=C2C=CC=CC2=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COCCN1C=NC2C(=O)N=C(N)N=C21)OC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COCCN1C=NC2C(=O)N=C(N)N=C21)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCOCCCOP(=O)(COCCN1C=NC2C(=O)N=C(N)N=C21)OCC1=CC=CC=C1 Chemical compound CCCCCCCCCCCCCCCCCCOCCOP(=O)(COCCN1C=NC2=C(N)N=CN=C21)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COCCN1C=NC2C(=O)N=C(N)N=C21)OC1=C2C=CC=CC2=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COCCN1C=NC2C(=O)N=C(N)N=C21)OC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COCCN1C=NC2C(=O)N=C(N)N=C21)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCOCCCOP(=O)(COCCN1C=NC2C(=O)N=C(N)N=C21)OCC1=CC=CC=C1 RBSMSPFYZQIFCH-UHFFFAOYSA-N 0.000 description 2
- XKEUEKKGUVRTKX-UHFFFAOYSA-N CCCOCP(=O)(OC)OC Chemical compound CCCOCP(=O)(OC)OC XKEUEKKGUVRTKX-UHFFFAOYSA-N 0.000 description 2
- NVKSFNHBQNRCHC-HHPRCQOSSA-N CC[C@@H](C)OCP(=O)(OC)OC.CC[C@@H](C)OCP(=O)(OC)OC.CC[C@H](C)OCP(=O)(OC)OC.CC[C@H](C)OCP(=O)(OC)OC Chemical compound CC[C@@H](C)OCP(=O)(OC)OC.CC[C@@H](C)OCP(=O)(OC)OC.CC[C@H](C)OCP(=O)(OC)OC.CC[C@H](C)OCP(=O)(OC)OC NVKSFNHBQNRCHC-HHPRCQOSSA-N 0.000 description 2
- YJFBZNKFPFPWDZ-ZETCQYMHSA-N CC[C@@H](CF)OCP(=O)(OC)OC Chemical compound CC[C@@H](CF)OCP(=O)(OC)OC YJFBZNKFPFPWDZ-ZETCQYMHSA-N 0.000 description 2
- AEBYBQOBJGLNAT-VGMFFHCQSA-N CC[C@@H](CF)OCP(=O)(OC)OC.CC[C@@H](CF)OCP(=O)(OC)OC Chemical compound CC[C@@H](CF)OCP(=O)(OC)OC.CC[C@@H](CF)OCP(=O)(OC)OC AEBYBQOBJGLNAT-VGMFFHCQSA-N 0.000 description 2
- TYCWLORLXQVELN-ZETCQYMHSA-N CC[C@@H](CO)OCP(=O)(OC)OC Chemical compound CC[C@@H](CO)OCP(=O)(OC)OC TYCWLORLXQVELN-ZETCQYMHSA-N 0.000 description 2
- QDEWPUSKSQNDMP-VGMFFHCQSA-N CC[C@@H](CO)OCP(=O)(OC)OC.CC[C@@H](CO)OCP(=O)(OC)OC Chemical compound CC[C@@H](CO)OCP(=O)(OC)OC.CC[C@@H](CO)OCP(=O)(OC)OC QDEWPUSKSQNDMP-VGMFFHCQSA-N 0.000 description 2
- WCFSCVYLVRCPHK-QMMMGPOBSA-N CC[C@@H](COC)OCP(=O)(OC)OC Chemical compound CC[C@@H](COC)OCP(=O)(OC)OC WCFSCVYLVRCPHK-QMMMGPOBSA-N 0.000 description 2
- HQOSHKMMTMDUSQ-ZETCQYMHSA-N CC[C@H](C)OCP(=O)(OC)OC Chemical compound CC[C@H](C)OCP(=O)(OC)OC HQOSHKMMTMDUSQ-ZETCQYMHSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- KZUGHQWNFSZLLP-RXMQYKEDSA-N [(2s)-1-(2-amino-6-oxo-3h-purin-9-yl)-3-fluoropropan-2-yl]oxymethylphosphonic acid Chemical compound N1C(N)=NC(=O)C2=C1N(C[C@@H](CF)OCP(O)(O)=O)C=N2 KZUGHQWNFSZLLP-RXMQYKEDSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000036436 anti-hiv Effects 0.000 description 2
- 238000002832 anti-viral assay Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000001177 diphosphate Substances 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 238000000119 electrospray ionisation mass spectrum Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 108010052305 exodeoxyribonuclease III Proteins 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000008696 hypoxemic pulmonary vasoconstriction Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- DRAVOWXCEBXPTN-UHFFFAOYSA-N isoguanine Chemical compound NC1=NC(=O)NC2=C1NC=N2 DRAVOWXCEBXPTN-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000012342 propidium iodide staining Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000001044 red dye Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 238000011285 therapeutic regimen Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- STPKWKPURVSAJF-LJEWAXOPSA-N (4r,5r)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-4-ol Chemical compound O[C@H]1C(CCCC)(CCCC)CS(=O)(=O)C2=CC=C(N(C)C)C=C2[C@H]1C(C=C1)=CC=C1OCC(C=C1)=CC=C1C[N+]1(CC2)CCN2CC1 STPKWKPURVSAJF-LJEWAXOPSA-N 0.000 description 1
- 125000000923 (C1-C30) alkyl group Chemical group 0.000 description 1
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- NGEGKEJNKJVDPO-QEOLEHNRSA-N *.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COCCN1C=NC2=C1N=C(N)NC2=O)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCO[P@@](=O)(COCCN1C=NC2=C1N=C(N)NC2=O)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCO[P@](=O)(COCCN1C=NC2=C1N=C(N)NC2=O)OCC1=CC=CC=C1.S Chemical compound *.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COCCN1C=NC2=C1N=C(N)NC2=O)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCO[P@@](=O)(COCCN1C=NC2=C1N=C(N)NC2=O)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCO[P@](=O)(COCCN1C=NC2=C1N=C(N)NC2=O)OCC1=CC=CC=C1.S NGEGKEJNKJVDPO-QEOLEHNRSA-N 0.000 description 1
- NKHAYGHBSIVSKV-UHFFFAOYSA-N 1-[2-(3-hexadecoxypropylamino)-6-oxo-3h-purin-9-yl]propan-2-yloxymethylphosphonic acid Chemical compound O=C1NC(NCCCOCCCCCCCCCCCCCCCC)=NC2=C1N=CN2CC(C)OCP(O)(O)=O NKHAYGHBSIVSKV-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- RCQMOSJJIVCPJO-UHFFFAOYSA-N 2-(5-methyl-2,4-dioxopyrimidin-1-yl)ethoxymethylphosphonic acid Chemical compound CC1=CN(CCOCP(O)(O)=O)C(=O)NC1=O RCQMOSJJIVCPJO-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- KAMFFKLCKFPOFO-UHFFFAOYSA-N 2-[2-[benzyl(3-hexadecoxypropyl)amino]-6-oxo-3h-purin-9-yl]ethoxymethylphosphonic acid Chemical compound N=1C=2N(CCOCP(O)(O)=O)C=NC=2C(=O)NC=1N(CCCOCCCCCCCCCCCCCCCC)CC1=CC=CC=C1 KAMFFKLCKFPOFO-UHFFFAOYSA-N 0.000 description 1
- FBLSGXTUUAWDMH-UHFFFAOYSA-N 2-[2-[n-(2-octadecoxyethyl)anilino]-6-oxo-3h-purin-9-yl]ethoxymethylphosphonic acid Chemical compound N=1C=2N(CCOCP(O)(O)=O)C=NC=2C(=O)NC=1N(CCOCCCCCCCCCCCCCCCCCC)C1=CC=CC=C1 FBLSGXTUUAWDMH-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- WVFIORFLPAJFRV-UHFFFAOYSA-N 2-[6-amino-2-(2-octadecoxyethyl)purin-9-yl]ethoxymethylphosphonic acid Chemical compound CCCCCCCCCCCCCCCCCCOCCC1=NC(N)=C2N=CN(CCOCP(O)(O)=O)C2=N1 WVFIORFLPAJFRV-UHFFFAOYSA-N 0.000 description 1
- IINLJHWTFOCWDY-UHFFFAOYSA-N 2-[6-amino-8-benzyl-2-(2-octadecoxyethyl)purin-9-yl]ethoxymethylphosphonic acid Chemical compound OP(=O)(O)COCCN1C2=NC(CCOCCCCCCCCCCCCCCCCCC)=NC(N)=C2N=C1CC1=CC=CC=C1 IINLJHWTFOCWDY-UHFFFAOYSA-N 0.000 description 1
- AHSNBFKBLUUKAW-UHFFFAOYSA-N 2-amino-9-[2-[[2-octadecoxyethoxy(phenylmethoxy)phosphoryl]methoxy]ethyl]-3h-purin-6-one Chemical compound C1=NC(C(N=C(N)N2)=O)=C2N1CCOCP(=O)(OCCOCCCCCCCCCCCCCCCCCC)OCC1=CC=CC=C1 AHSNBFKBLUUKAW-UHFFFAOYSA-N 0.000 description 1
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- CFBVWCHTNQHZLT-UHFFFAOYSA-N 4-methoxy-5-[3-(2-methoxy-4-nitro-5-sulfophenyl)-5-(phenylcarbamoyl)tetrazol-3-ium-2-yl]-2-nitrobenzenesulfonate Chemical compound COC1=CC([N+]([O-])=O)=C(S([O-])(=O)=O)C=C1N1[N+](C=2C(=CC(=C(C=2)S(O)(=O)=O)[N+]([O-])=O)OC)=NC(C(=O)NC=2C=CC=CC=2)=N1 CFBVWCHTNQHZLT-UHFFFAOYSA-N 0.000 description 1
- VTDOEFXTVHCAAM-UHFFFAOYSA-N 4-methylpent-3-ene-1,2,3-triol Chemical compound CC(C)=C(O)C(O)CO VTDOEFXTVHCAAM-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- PFTBVGXFDODLIP-ODAVUKQRSA-N 6-[[[(1S)-1-(2-hydroxy-3-trityloxypropyl)cyclohexa-2,4-dien-1-yl]-diphenylmethyl]-methoxyamino]-1H-pyrimidin-2-one Chemical compound C(C1=CC=CC=C1)(C1=CC=CC=C1)(C1=CC=CC=C1)OCC(C[C@@]1(C(C2=CC=CC=C2)(C2=CC=CC=C2)N(C2=NC(NC=C2)=O)OC)CC=CC=C1)O PFTBVGXFDODLIP-ODAVUKQRSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- PEYAHTCADCHDCR-UHFFFAOYSA-N C(C)(C)=C(CN(C=1NC(C=2N=CN(C=2N=1)CCOCP(=O)(O)O)=O)CC(O)CO)OCCCCCCCCCCCCCCCCCC Chemical compound C(C)(C)=C(CN(C=1NC(C=2N=CN(C=2N=1)CCOCP(=O)(O)O)=O)CC(O)CO)OCCCCCCCCCCCCCCCCCC PEYAHTCADCHDCR-UHFFFAOYSA-N 0.000 description 1
- XIALTZJEBNTXQE-VFBIQEGASA-N C.C.CCCCCCCCCCCCCCCCCCOCC(COP(=O)(COC(CO)CN1C=CC(N)=NC1=O)OCC1=CC=CC=C1)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCC(COP(=O)(COC(CO)CN1C=NC2=C(N)N=CN=C21)OCC1=CC=CC=C1)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCC(COP(=O)(COCCN1C=NC2=C1N=C(N)NC2=O)OCC1=CC=CC=C1)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCC(COP(=O)(CO[C@H](CO)CN1C=NC2=C1N=C(N)NC2=O)OCC1=CC=CC=C1)OCC1=CC=CC=C1 Chemical compound C.C.CCCCCCCCCCCCCCCCCCOCC(COP(=O)(COC(CO)CN1C=CC(N)=NC1=O)OCC1=CC=CC=C1)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCC(COP(=O)(COC(CO)CN1C=NC2=C(N)N=CN=C21)OCC1=CC=CC=C1)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCC(COP(=O)(COCCN1C=NC2=C1N=C(N)NC2=O)OCC1=CC=CC=C1)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCC(COP(=O)(CO[C@H](CO)CN1C=NC2=C1N=C(N)NC2=O)OCC1=CC=CC=C1)OCC1=CC=CC=C1 XIALTZJEBNTXQE-VFBIQEGASA-N 0.000 description 1
- VXEXXPJKILAHTL-UHFFFAOYSA-N C.C.CCCOCP(=O)(OC)OC.CCCOCP(=O)(OC)OC Chemical compound C.C.CCCOCP(=O)(OC)OC.CCCOCP(=O)(OC)OC VXEXXPJKILAHTL-UHFFFAOYSA-N 0.000 description 1
- GTLQZLKEWOQHEY-MQIYEYLPSA-N C.C.CC[C@@H](C)OCP(=O)(OC)OC.CC[C@@H](C)OCP(=O)(OC)OC Chemical compound C.C.CC[C@@H](C)OCP(=O)(OC)OC.CC[C@@H](C)OCP(=O)(OC)OC GTLQZLKEWOQHEY-MQIYEYLPSA-N 0.000 description 1
- DQZWHXALWMFHJC-OWJCAWTQSA-N C.C.CC[C@@H](COC)OCP(=O)(OC)OC.CC[C@@H](COC)OCP(=O)(OC)OC Chemical compound C.C.CC[C@@H](COC)OCP(=O)(OC)OC.CC[C@@H](COC)OCP(=O)(OC)OC DQZWHXALWMFHJC-OWJCAWTQSA-N 0.000 description 1
- WTEUFTMUIOJCNA-BINSQEMJSA-M C.C1=CC=C2C(=C1)N=NN2O[PH](N1CCCC1)(N1CCCC1)N1CCCC1.CCC(C)O.CCC(C)OCP(=O)(O)OC.CCC(C)OCP(=O)(O)OC.CCC(C)OCP(=O)(OC)OC.CCP(=O)([O-])OC.CO.F[P-](F)(F)(F)(F)F.N[2H]CF.[Na+] Chemical compound C.C1=CC=C2C(=C1)N=NN2O[PH](N1CCCC1)(N1CCCC1)N1CCCC1.CCC(C)O.CCC(C)OCP(=O)(O)OC.CCC(C)OCP(=O)(O)OC.CCC(C)OCP(=O)(OC)OC.CCP(=O)([O-])OC.CO.F[P-](F)(F)(F)(F)F.N[2H]CF.[Na+] WTEUFTMUIOJCNA-BINSQEMJSA-M 0.000 description 1
- VWBJKWQOVZEOJN-UHFFFAOYSA-N C.CCC(C)O.CCC(C)OCP(=O)(OC)OC.CCP(=O)(OC)OC Chemical compound C.CCC(C)O.CCC(C)OCP(=O)(OC)OC.CCP(=O)(OC)OC VWBJKWQOVZEOJN-UHFFFAOYSA-N 0.000 description 1
- JUKVHDORAAUZPH-UHFFFAOYSA-N C.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COC(C)CN1C=NC2=C(N)N=CN=C21)OC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COC(C)CN1C=NC2=C(N)N=CN=C21)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COC(C)CN1C=NC2C(=O)N=C(N)N=C21)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COC(CCO)CN1C=NC2=C(N)N=C(N)N=C21)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COC(CCO)CN1C=NC2=C(N)N=CN=C21)OCC Chemical compound C.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COC(C)CN1C=NC2=C(N)N=CN=C21)OC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COC(C)CN1C=NC2=C(N)N=CN=C21)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COC(C)CN1C=NC2C(=O)N=C(N)N=C21)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COC(CCO)CN1C=NC2=C(N)N=C(N)N=C21)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COC(CCO)CN1C=NC2=C(N)N=CN=C21)OCC JUKVHDORAAUZPH-UHFFFAOYSA-N 0.000 description 1
- BHCDIWXKWVQRAC-UHFFFAOYSA-N C.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COC(C)CN1C=NC2=C(N)N=CN=C21)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COC(C)CN1C=NC2C(=O)N=C(N)N=C21)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COC(C)CN1C=NC2C1=NC=NC2N)OC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COC(CCO)CN1C=NC2=C(N)N=C(N)N=C21)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COC(CCO)CN1C=NC2=C(N)N=CN=C21)OCC Chemical compound C.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COC(C)CN1C=NC2=C(N)N=CN=C21)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COC(C)CN1C=NC2C(=O)N=C(N)N=C21)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COC(C)CN1C=NC2C1=NC=NC2N)OC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COC(CCO)CN1C=NC2=C(N)N=C(N)N=C21)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COC(CCO)CN1C=NC2=C(N)N=CN=C21)OCC BHCDIWXKWVQRAC-UHFFFAOYSA-N 0.000 description 1
- JUNISPSYKLMKJZ-NXCCNVLFSA-N C.COC[C@@H](CN1C=NC2=C1N=C(N)NC2=O)OCP(C)(=O)OC1=CC=CC=C1.CP(=O)(CO[C@@H](CF)CN1C=NC2=C1N=CN=C2N)OC1=CC=CC=C1 Chemical compound C.COC[C@@H](CN1C=NC2=C1N=C(N)NC2=O)OCP(C)(=O)OC1=CC=CC=C1.CP(=O)(CO[C@@H](CF)CN1C=NC2=C1N=CN=C2N)OC1=CC=CC=C1 JUNISPSYKLMKJZ-NXCCNVLFSA-N 0.000 description 1
- SQDFWJQHVGEGPV-VHLLKCEXSA-N C1=CC=C2C(=C1)N=NN2O[PH](N1CCCC1)(N1CCCC1)N1CCCC1.CCC(C)OCP(=O)(O)OC.CCC(C)OCP(=O)(OC)OC.CO.F[P-](F)(F)(F)(F)F.N[2H]CF Chemical compound C1=CC=C2C(=C1)N=NN2O[PH](N1CCCC1)(N1CCCC1)N1CCCC1.CCC(C)OCP(=O)(O)OC.CCC(C)OCP(=O)(OC)OC.CO.F[P-](F)(F)(F)(F)F.N[2H]CF SQDFWJQHVGEGPV-VHLLKCEXSA-N 0.000 description 1
- 125000004406 C3-C8 cycloalkylene group Chemical group 0.000 description 1
- LLJSHWXYMLPIIG-UHFFFAOYSA-N CC(C)(C)N1C=CC(=O)NC1=O.CC(C)(C)N1C=CC(N)=NC1=O.CC1=CN(C(C)(C)C)C(=O)NC1=O.CC1=NC2=C(N=CN2C(C)(C)C)C(=O)N1.CC1=NC2=C(N=CN2C(C)(C)C)C(N)=N1.CC1=NC2=C(N=CN2C(C)(C)C)C(N)=N1 Chemical compound CC(C)(C)N1C=CC(=O)NC1=O.CC(C)(C)N1C=CC(N)=NC1=O.CC1=CN(C(C)(C)C)C(=O)NC1=O.CC1=NC2=C(N=CN2C(C)(C)C)C(=O)N1.CC1=NC2=C(N=CN2C(C)(C)C)C(N)=N1.CC1=NC2=C(N=CN2C(C)(C)C)C(N)=N1 LLJSHWXYMLPIIG-UHFFFAOYSA-N 0.000 description 1
- IPMISRNGSJZXTL-HYWVYIHUSA-N CC1(C)OCC(CO)O1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COCCN1C=NC2=C1N=C(N)NC2=O)OCC1COC(C)(C)O1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(O)COCCN1C=NC2=C1N=C(N)NC2=O.N[2H]CF Chemical compound CC1(C)OCC(CO)O1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(COCCN1C=NC2=C1N=C(N)NC2=O)OCC1COC(C)(C)O1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(O)COCCN1C=NC2=C1N=C(N)NC2=O.N[2H]CF IPMISRNGSJZXTL-HYWVYIHUSA-N 0.000 description 1
- SETTVPNXWKSSBB-FNQLPSDDSA-N CC1(C)OCC(OP(C)(=O)COCCN2C=NC3=C2N=C(N)NC3=O)O1.COC[C@@H](CN1C=NC2=C1N=C(N)NC2=O)OCP(C)(=O)OCC1=CC=CC=C1.CP(=O)(COCCN1C=NC2=C1N=C(N)NC2=O)OC(O)CO.CP(=O)(COCCN1C=NC2=C1N=C(N)NC2=O)OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O Chemical compound CC1(C)OCC(OP(C)(=O)COCCN2C=NC3=C2N=C(N)NC3=O)O1.COC[C@@H](CN1C=NC2=C1N=C(N)NC2=O)OCP(C)(=O)OCC1=CC=CC=C1.CP(=O)(COCCN1C=NC2=C1N=C(N)NC2=O)OC(O)CO.CP(=O)(COCCN1C=NC2=C1N=C(N)NC2=O)OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O SETTVPNXWKSSBB-FNQLPSDDSA-N 0.000 description 1
- STVMOOJWCOEBHW-QHAJIHRVSA-M CC1=CC=C(S(=O)(=O)OCP(=O)([O-])OCC2=CC=CC=C2)C=C1.CCCCCCCCCCCCCCCCCCOCC(CO)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOC[C@@H](COP(=O)(CO[C@H](CO)CN1C=NC2=C1N=CN=C2N)OCC1=CC=CC=C1)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOC[C@@H](COP(=O)(CO[C@H](COC)CN1C=NC2=C1N=CN=C2NC)OCC1=CC=CC=C1)OCC1=CC=CC=C1.CNC1=NC=NC2=C1N=CN2C[C@@H](COC)OCP(=O)(O)OCC1=CC=CC=C1.CNC1=NC=NC2=C1N=CN2C[C@H](O)COC.N[2H]CF.N[2H]CF.S.S.S.S.S.S.[Na+] Chemical compound CC1=CC=C(S(=O)(=O)OCP(=O)([O-])OCC2=CC=CC=C2)C=C1.CCCCCCCCCCCCCCCCCCOCC(CO)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOC[C@@H](COP(=O)(CO[C@H](CO)CN1C=NC2=C1N=CN=C2N)OCC1=CC=CC=C1)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOC[C@@H](COP(=O)(CO[C@H](COC)CN1C=NC2=C1N=CN=C2NC)OCC1=CC=CC=C1)OCC1=CC=CC=C1.CNC1=NC=NC2=C1N=CN2C[C@@H](COC)OCP(=O)(O)OCC1=CC=CC=C1.CNC1=NC=NC2=C1N=CN2C[C@H](O)COC.N[2H]CF.N[2H]CF.S.S.S.S.S.S.[Na+] STVMOOJWCOEBHW-QHAJIHRVSA-M 0.000 description 1
- KOJUADYQXJCRPX-NRJJCFQESA-M CC1=CC=C(S(=O)(=O)OCP(=O)([O-])OCC2=CC=CC=C2)C=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(CO[C@H](CO)CN1C=CC(N)=NC1=O)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(CO[C@H](COC)CN1C=CC(NC(C2=CC=CC=C2)(C2=CC=CC=C2)C2=CC=C(OC)C=C2)=NC1=O)OCC1=CC=CC=C1.COC[C@@H](O)CN1C=CC(NC(C2=CC=CC=C2)(C2=CC=CC=C2)C2=CC=C(OC)C=C2)=NC1=O.COC[C@H](CN1C=CC(NC(C2=CC=CC=C2)(C2=CC=CC=C2)C2=CC=C(OC)C=C2)=NC1=O)OCP(=O)(O)OCC1=CC=CC=C1.N[2H]CF.N[2H]CF.[Na+] Chemical compound CC1=CC=C(S(=O)(=O)OCP(=O)([O-])OCC2=CC=CC=C2)C=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(CO[C@H](CO)CN1C=CC(N)=NC1=O)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(CO[C@H](COC)CN1C=CC(NC(C2=CC=CC=C2)(C2=CC=CC=C2)C2=CC=C(OC)C=C2)=NC1=O)OCC1=CC=CC=C1.COC[C@@H](O)CN1C=CC(NC(C2=CC=CC=C2)(C2=CC=CC=C2)C2=CC=C(OC)C=C2)=NC1=O.COC[C@H](CN1C=CC(NC(C2=CC=CC=C2)(C2=CC=CC=C2)C2=CC=C(OC)C=C2)=NC1=O)OCP(=O)(O)OCC1=CC=CC=C1.N[2H]CF.N[2H]CF.[Na+] KOJUADYQXJCRPX-NRJJCFQESA-M 0.000 description 1
- ZMHQYQGBXKBTHB-UEEIRJRGSA-M CC1=CC=C(S(=O)(=O)OCP(=O)([O-])OCC2=CC=CC=C2)C=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(CO[C@H](CO)CN1C=NC2=C1N=CN=C2N)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(CO[C@H](COC)CO1C=NC2=C1N=CN=C2NC)OCC1=CC=CC=C1.CNC1=NC=NC2=C1N=CN2C[C@@H](COC)OCP(=O)(O)OCC1=CC=CC=C1.CNC1=NC=NC2=C1N=CN2C[C@H](O)COC.N[2H]CF.N[2H]CF.[Na+] Chemical compound CC1=CC=C(S(=O)(=O)OCP(=O)([O-])OCC2=CC=CC=C2)C=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(CO[C@H](CO)CN1C=NC2=C1N=CN=C2N)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(CO[C@H](COC)CO1C=NC2=C1N=CN=C2NC)OCC1=CC=CC=C1.CNC1=NC=NC2=C1N=CN2C[C@@H](COC)OCP(=O)(O)OCC1=CC=CC=C1.CNC1=NC=NC2=C1N=CN2C[C@H](O)COC.N[2H]CF.N[2H]CF.[Na+] ZMHQYQGBXKBTHB-UEEIRJRGSA-M 0.000 description 1
- OVHSVQKWKHXNRK-UHFFFAOYSA-N CCCCCCCCCCCCCCCCCCOCC(COP(=O)(COCCN1C=NC2=C1N=C(N)NC2=O)OCC1=CC=CC=C1)OCC1=CC=CC=C1 Chemical compound CCCCCCCCCCCCCCCCCCOCC(COP(=O)(COCCN1C=NC2=C1N=C(N)NC2=O)OCC1=CC=CC=C1)OCC1=CC=CC=C1 OVHSVQKWKHXNRK-UHFFFAOYSA-N 0.000 description 1
- LCMCMRVNRWZYMC-NDWKIVRMSA-N CCCCCCCCCCCCCCCCCCOCC(COP(=O)(CO[C@H](CO)CN1C=NC2=C1N=C(N)NC2=O)OCC1=CC=CC=C1)OCC1=CC=CC=C1 Chemical compound CCCCCCCCCCCCCCCCCCOCC(COP(=O)(CO[C@H](CO)CN1C=NC2=C1N=C(N)NC2=O)OCC1=CC=CC=C1)OCC1=CC=CC=C1 LCMCMRVNRWZYMC-NDWKIVRMSA-N 0.000 description 1
- LODJPZKADNXPIA-UHFFFAOYSA-N CCCCCCCCCCCCCCCCCCOCCOP(=O)(COCCN1C=NC2=C1N=C(N)NC2=O)OC1=C2C=CC=CC2=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(O)COCCN1C=NC2=C1N=C(N)NC2=O Chemical compound CCCCCCCCCCCCCCCCCCOCCOP(=O)(COCCN1C=NC2=C1N=C(N)NC2=O)OC1=C2C=CC=CC2=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(O)COCCN1C=NC2=C1N=C(N)NC2=O LODJPZKADNXPIA-UHFFFAOYSA-N 0.000 description 1
- SFICULVINFZJSQ-UHFFFAOYSA-N CCCCCCCCCCCCCCCCCCOCCOP(=O)(COCCN1C=NC2=C1N=C(N)NC2=O)OC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(O)COCCN1C=NC2=C1N=C(N)NC2=O Chemical compound CCCCCCCCCCCCCCCCCCOCCOP(=O)(COCCN1C=NC2=C1N=C(N)NC2=O)OC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(O)COCCN1C=NC2=C1N=C(N)NC2=O SFICULVINFZJSQ-UHFFFAOYSA-N 0.000 description 1
- GURWSPAJCGUOJP-BUHDBVOOSA-N CCCCCCCCCCCCCCCCCCOCCOP(=O)(COCCN1C=NC2=C1N=C(N)NC2=O)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(O)COCCN1C=NC2=C1N=C(N)NC2=O.N[2H]CF Chemical compound CCCCCCCCCCCCCCCCCCOCCOP(=O)(COCCN1C=NC2=C1N=C(N)NC2=O)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(O)COCCN1C=NC2=C1N=C(N)NC2=O.N[2H]CF GURWSPAJCGUOJP-BUHDBVOOSA-N 0.000 description 1
- YVHRUVUZUHRXJN-BUHDBVOOSA-N CCCCCCCCCCCCCCCCCCOCCOP(=O)(COCCN1C=NC2=C1N=CN=C2N)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(O)COCCN1C=NC2=C1N=CN=C2N.N[2H]CF Chemical compound CCCCCCCCCCCCCCCCCCOCCOP(=O)(COCCN1C=NC2=C1N=CN=C2N)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(O)COCCN1C=NC2=C1N=CN=C2N.N[2H]CF YVHRUVUZUHRXJN-BUHDBVOOSA-N 0.000 description 1
- RJALROBJHFRGSG-RNCFWYRHSA-N CCCCCCCCCCCCCCCCCCOCCOP(=O)(CO[C@H](C)CN1C=NC2=C1N=C(N)NC2=O)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(O)CO[C@H](C)CN1C=NC2=C1N=C(N)NC2=O Chemical compound CCCCCCCCCCCCCCCCCCOCCOP(=O)(CO[C@H](C)CN1C=NC2=C1N=C(N)NC2=O)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(O)CO[C@H](C)CN1C=NC2=C1N=C(N)NC2=O RJALROBJHFRGSG-RNCFWYRHSA-N 0.000 description 1
- OFJBUNPOFJJKRO-YBFWDBBESA-N CCCCCCCCCCCCCCCCCCOCCOP(=O)(CO[C@H](C)CN1C=NC2=C1N=CN=C2N)OC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(O)CO[C@H](C)CN1C=NC2=C1N=CN=C2N Chemical compound CCCCCCCCCCCCCCCCCCOCCOP(=O)(CO[C@H](C)CN1C=NC2=C1N=CN=C2N)OC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(O)CO[C@H](C)CN1C=NC2=C1N=CN=C2N OFJBUNPOFJJKRO-YBFWDBBESA-N 0.000 description 1
- YELLZAVEGCAUPX-RRLITVNESA-N CCCCCCCCCCCCCCCCCCOCCOP(=O)(CO[C@H](C)CN1C=NC2=C1N=CN=C2N)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(O)CO[C@H](C)CN1C=NC2=C1N=CN=C2N Chemical compound CCCCCCCCCCCCCCCCCCOCCOP(=O)(CO[C@H](C)CN1C=NC2=C1N=CN=C2N)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(O)CO[C@H](C)CN1C=NC2=C1N=CN=C2N YELLZAVEGCAUPX-RRLITVNESA-N 0.000 description 1
- LTKPAIOQAUWLCS-KQBCPHARSA-N CCCCCCCCCCCCCCCCCCOCCOP(=O)(CO[C@H](CF)CN1C=NC2=C1N=C(N)NC2=O)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(O)CO[C@H](CF)CN1C=NC2=C1N=C(N)NC2=O Chemical compound CCCCCCCCCCCCCCCCCCOCCOP(=O)(CO[C@H](CF)CN1C=NC2=C1N=C(N)NC2=O)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(O)CO[C@H](CF)CN1C=NC2=C1N=C(N)NC2=O LTKPAIOQAUWLCS-KQBCPHARSA-N 0.000 description 1
- RZRAPGBXQRKVSW-DHJSJYETSA-N CCCCCCCCCCCCCCCCCCOCCOP(=O)(CO[C@H](CO)CN1C=CC(=O)NC1=O)OCC1=CC=CC=C1.COC[C@H](CN1C=CC(OC)=NC1=O)OCP(=O)(O)OCC1=CC=CC=C1 Chemical compound CCCCCCCCCCCCCCCCCCOCCOP(=O)(CO[C@H](CO)CN1C=CC(=O)NC1=O)OCC1=CC=CC=C1.COC[C@H](CN1C=CC(OC)=NC1=O)OCP(=O)(O)OCC1=CC=CC=C1 RZRAPGBXQRKVSW-DHJSJYETSA-N 0.000 description 1
- IVGNQBHFFVFCMB-PSCZILRDSA-N CCCCCCCCCCCCCCCCCCOCCOP(=O)(CO[C@H](CO)CN1C=NC2=C1N=CN=C2N)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(CO[C@H](COC)CN1C=NC2=C1N=CN=C2NC)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(O)CO[C@H](COC)CN1C=NC2=C1N=CN=C2NC.N[2H]CF Chemical compound CCCCCCCCCCCCCCCCCCOCCOP(=O)(CO[C@H](CO)CN1C=NC2=C1N=CN=C2N)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(CO[C@H](COC)CN1C=NC2=C1N=CN=C2NC)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(O)CO[C@H](COC)CN1C=NC2=C1N=CN=C2NC.N[2H]CF IVGNQBHFFVFCMB-PSCZILRDSA-N 0.000 description 1
- GIAWKEWMRUKQTP-ZBQWRHTBSA-N CCCCCCCCCCCCCCCCCCOCCOP(=O)(CO[C@H](COC)CN1C=NC2=C1N=C(N)N=C2N)OC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(O)CO[C@H](COC)CN1C=NC2=C1N=C(N)N=C2N Chemical compound CCCCCCCCCCCCCCCCCCOCCOP(=O)(CO[C@H](COC)CN1C=NC2=C1N=C(N)N=C2N)OC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(O)CO[C@H](COC)CN1C=NC2=C1N=C(N)N=C2N GIAWKEWMRUKQTP-ZBQWRHTBSA-N 0.000 description 1
- BKPHVGRGTRWJCU-PBQNDGBSSA-N CCCCCCCCCCCCCCCCCCOCCOP(=O)(CO[C@H](COC)CN1C=NC2=C1N=CN=C2N)OC1=CC=CC2=C1C=CC=C2.CCCCCCCCCCCCCCCCCCOCCOP(=O)(O)CO[C@H](COC)CN1C=NC2=C1N=CN=C2N Chemical compound CCCCCCCCCCCCCCCCCCOCCOP(=O)(CO[C@H](COC)CN1C=NC2=C1N=CN=C2N)OC1=CC=CC2=C1C=CC=C2.CCCCCCCCCCCCCCCCCCOCCOP(=O)(O)CO[C@H](COC)CN1C=NC2=C1N=CN=C2N BKPHVGRGTRWJCU-PBQNDGBSSA-N 0.000 description 1
- FOIVLIPTXRTMDU-DPYWJHSCSA-N CCCCCCCCCCCCCCCCCCOCCOP(=O)(CO[C@H](COC)CN1C=NC2=C1N=CN=C2N)OC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(O)CO[C@H](COC)CN1C=NC2=C1N=CN=C2N Chemical compound CCCCCCCCCCCCCCCCCCOCCOP(=O)(CO[C@H](COC)CN1C=NC2=C1N=CN=C2N)OC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(O)CO[C@H](COC)CN1C=NC2=C1N=CN=C2N FOIVLIPTXRTMDU-DPYWJHSCSA-N 0.000 description 1
- DPGPZWIQIUJWKL-GGSCSLNDSA-N CCCCCCCCCCCCCCCCCCOCCOP(=O)(CO[C@H](COC)CN1C=NC2=C1N=CN=C2N)OCC.CCCCCCCCCCCCCCCCCCOCCOP(=O)(O)CO[C@H](COC)CN1C=NC2=C1N=CN=C2N Chemical compound CCCCCCCCCCCCCCCCCCOCCOP(=O)(CO[C@H](COC)CN1C=NC2=C1N=CN=C2N)OCC.CCCCCCCCCCCCCCCCCCOCCOP(=O)(O)CO[C@H](COC)CN1C=NC2=C1N=CN=C2N DPGPZWIQIUJWKL-GGSCSLNDSA-N 0.000 description 1
- LVLRTSLIESLGMQ-BZJPVRGISA-N CCCCCCCCCCCCCCCCCCOCCOP(=O)(CO[C@H](COC)CN1C=NC2=C1N=CN=C2N)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(O)CO[C@H](COC)CN1C=NC2=C1N=CN=C2N Chemical compound CCCCCCCCCCCCCCCCCCOCCOP(=O)(CO[C@H](COC)CN1C=NC2=C1N=CN=C2N)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOCCOP(=O)(O)CO[C@H](COC)CN1C=NC2=C1N=CN=C2N LVLRTSLIESLGMQ-BZJPVRGISA-N 0.000 description 1
- JDDGBSLSUUJAOS-UHFFFAOYSA-N CCCCCCCCCCCCCCCCOCCCOP(=O)(COCCN1C=NC2=C1N=C(N)NC2=O)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCOCCCOP(=O)(O)COCCN1C=NC2=C1N=C(N)NC2=O Chemical compound CCCCCCCCCCCCCCCCOCCCOP(=O)(COCCN1C=NC2=C1N=C(N)NC2=O)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCOCCCOP(=O)(O)COCCN1C=NC2=C1N=C(N)NC2=O JDDGBSLSUUJAOS-UHFFFAOYSA-N 0.000 description 1
- XSCSPGSOLBXFKI-UHFFFAOYSA-N CCCOCP(=O)(OC)OC.CCCOCP(=O)(OC)OC Chemical compound CCCOCP(=O)(OC)OC.CCCOCP(=O)(OC)OC XSCSPGSOLBXFKI-UHFFFAOYSA-N 0.000 description 1
- YKMYKBCSQZTESD-HFEGYEGKSA-N CC[C@@H](C)OCP(=O)(OC)OC.CC[C@@H](C)OCP(=O)(OC)OC Chemical compound CC[C@@H](C)OCP(=O)(OC)OC.CC[C@@H](C)OCP(=O)(OC)OC YKMYKBCSQZTESD-HFEGYEGKSA-N 0.000 description 1
- AMWMUBCYQBCFMQ-GRHHLOCNSA-N CC[C@@H](COC)OCP(=O)(OC)OC.CC[C@@H](COC)OCP(=O)(OC)OC Chemical compound CC[C@@H](COC)OCP(=O)(OC)OC.CC[C@@H](COC)OCP(=O)(OC)OC AMWMUBCYQBCFMQ-GRHHLOCNSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000018663 Central Nervous System Viral disease Diseases 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101001014059 Homo sapiens Metallothionein-2 Proteins 0.000 description 1
- 101000622322 Human papillomavirus type 16 Regulatory protein E2 Proteins 0.000 description 1
- 101000954454 Human papillomavirus type 16 Replication protein E1 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-O Imidazolium Chemical compound C1=C[NH+]=CN1 RAXXELZNTBOGNW-UHFFFAOYSA-O 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 101710125507 Integrase/recombinase Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 101000713102 Mus musculus C-C motif chemokine 1 Proteins 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- LIMFPAAAIVQRRD-BCGVJQADSA-N N-[2-[(3S,4R)-3-fluoro-4-methoxypiperidin-1-yl]pyrimidin-4-yl]-8-[(2R,3S)-2-methyl-3-(methylsulfonylmethyl)azetidin-1-yl]-5-propan-2-ylisoquinolin-3-amine Chemical compound F[C@H]1CN(CC[C@H]1OC)C1=NC=CC(=N1)NC=1N=CC2=C(C=CC(=C2C=1)C(C)C)N1[C@@H]([C@H](C1)CS(=O)(=O)C)C LIMFPAAAIVQRRD-BCGVJQADSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- QWZRZYWLWTWVLF-UHFFFAOYSA-N O.OP(O)=O Chemical compound O.OP(O)=O QWZRZYWLWTWVLF-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 206010034325 Penile wart Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 229910007161 Si(CH3)3 Inorganic materials 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 206010046905 Vaginal dysplasia Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 206010065173 Viral skin infection Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- CZOAPWVEZIGNTO-JGCGQSQUSA-N [(2S)-1-[2-[benzyl(2-octadecoxyethyl)amino]-6-oxo-1H-purin-9-yl]-3-fluoropropan-2-yl]oxymethylphosphonic acid Chemical compound N=1C=2N(C[C@@H](CF)OCP(O)(O)=O)C=NC=2C(=O)NC=1N(CCOCCCCCCCCCCCCCCCCCC)CC1=CC=CC=C1 CZOAPWVEZIGNTO-JGCGQSQUSA-N 0.000 description 1
- ZJHROJVIOHDKIZ-GXWBPOGOSA-N [1-[(1S)-1-[[(5-benzyl-2-oxo-1H-pyrimidin-6-yl)-methoxyamino]-diphenylmethyl]cyclohexa-2,4-dien-1-yl]-3-trityloxypropan-2-yl]oxymethylphosphonic acid Chemical compound C(C1=CC=CC=C1)C=1C(=NC(NC=1)=O)N(OC)C([C@@]1(CC=CC=C1)CC(COC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)OCP(=O)(O)O)(C1=CC=CC=C1)C1=CC=CC=C1 ZJHROJVIOHDKIZ-GXWBPOGOSA-N 0.000 description 1
- XSRZGKMZQPFLTP-UHFFFAOYSA-N [1-[2,6-diamino-8-(2-octadecoxy-3-phenylpropyl)purin-9-yl]-3-methoxypropan-2-yl]oxymethylphosphonic acid Chemical compound C(C1=CC=CC=C1)C(CC=1N(C2=NC(=NC(=C2N=1)N)N)CC(COC)OCP(=O)(O)O)OCCCCCCCCCCCCCCCCCC XSRZGKMZQPFLTP-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 102000010126 acid sphingomyelin phosphodiesterase activity proteins Human genes 0.000 description 1
- SUPKOOSCJHTBAH-UHFFFAOYSA-N adefovir Chemical compound NC1=NC=NC2=C1N=CN2CCOCP(O)(O)=O SUPKOOSCJHTBAH-UHFFFAOYSA-N 0.000 description 1
- 229960001997 adefovir Drugs 0.000 description 1
- 229960003205 adefovir dipivoxil Drugs 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000005237 alkyleneamino group Chemical group 0.000 description 1
- 125000005238 alkylenediamino group Chemical group 0.000 description 1
- 125000005530 alkylenedioxy group Chemical group 0.000 description 1
- 125000005529 alkyleneoxy group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 125000005165 aryl thioxy group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 239000013584 assay control Substances 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- WHHGLZMJPXIBIX-UHFFFAOYSA-N decabromodiphenyl ether Chemical compound BrC1=C(Br)C(Br)=C(Br)C(Br)=C1OC1=C(Br)C(Br)=C(Br)C(Br)=C1Br WHHGLZMJPXIBIX-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- UOEFFQWLRUBDME-UHFFFAOYSA-N diethoxyphosphorylmethyl 4-methylbenzenesulfonate Chemical compound CCOP(=O)(OCC)COS(=O)(=O)C1=CC=C(C)C=C1 UOEFFQWLRUBDME-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229960000366 emtricitabine Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000003020 exocrine pancreas Anatomy 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- ZCYVEMRRCGMTRW-YPZZEJLDSA-N iodine-125 Chemical compound [125I] ZCYVEMRRCGMTRW-YPZZEJLDSA-N 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000010829 isocratic elution Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000006682 monohaloalkyl group Chemical group 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- BLYNHZVAZVOTGV-SANMLTNESA-N ode-cdv Chemical compound CCCCCCCCCCCCCCCCCCOCCOP(O)(=O)CO[C@H](CO)CN1C=CC(N)=NC1=O BLYNHZVAZVOTGV-SANMLTNESA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical class OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 125000006684 polyhaloalkyl group Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229940101142 prefilled applicator Drugs 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002212 purine nucleoside Substances 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- 239000002718 pyrimidine nucleoside Substances 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- JJICLMJFIKGAAU-UHFFFAOYSA-M sodium;2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)purin-6-olate Chemical compound [Na+].NC1=NC([O-])=C2N=CN(COC(CO)CO)C2=N1 JJICLMJFIKGAAU-UHFFFAOYSA-M 0.000 description 1
- RMLUKZWYIKEASN-UHFFFAOYSA-M sodium;2-amino-9-(2-hydroxyethoxymethyl)purin-6-olate Chemical compound [Na+].O=C1[N-]C(N)=NC2=C1N=CN2COCCO RMLUKZWYIKEASN-UHFFFAOYSA-M 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 125000005717 substituted cycloalkylene group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 229960004556 tenofovir Drugs 0.000 description 1
- 229960004693 tenofovir disoproxil fumarate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000005309 thioalkoxy group Chemical group 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 125000005500 uronium group Chemical group 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000007442 viral DNA synthesis Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present disclosure relates, inter alia, to compositions and methods for treating viral diseases and cancer.
- it relates to lipophilic antiviral and anticancer acyclic nucleoside phosphonate diesters, preparation thereof, and methods of using the compounds to treat viral diseases and cancer.
- Viruses are infectious particles that can replicate their DNA and RNA only within host cells. Viral infections may lead to mild or severe illnesses in humans and mammals. Examples of viral infections include hepatitis B and C, smallpox, herpes simplex, cytomegalovirus, human immunodeficiency virus (HIV), influenza, adenovirus, chickenpox, BK virus, JC virus and precancerous lesions caused by infections with the human papillomavirus (cervical intraepithelial neoplasia, vaginal and anal intraepithelial neoplasia). Viral infection may also lead to cancer in humans and other species.
- Viruses known to cause cancer include but are not limited to human papilloma virus (HPV), hepatitis B virus (HBV), hepatitis C virus (HCV), HIV and Epstein Barr virus (EBV).
- HPV human papilloma virus
- HBV hepatitis B virus
- HCV hepatitis C virus
- HIV Epstein Barr virus
- Vaccination has been successful in preventing infection from many viruses.
- Antiviral agents are known that interfere with viral DNA or RNA synthesis and viral replication and are used to prevent or treat viral infections in mammals and humans.
- combinations of antiviral drugs are used to treat AIDS, hepatitis B, hepatitis C, herpes simplex viruses, cytomegalovirus and influenza.
- viral diseases remain an important public health problem and improved antiviral agents and anticancer agents are needed. For example, there is presently no approved antiviral treatment for human papillomavirus infections.
- antiviral drugs are nucleoside or nucleotide analogs.
- antiviral nucleoside analogs include azidothymidine, acyclovir, ganciclovir, lamivudine and emtricitabine.
- Acyclic nucleoside phosphonates are a class of nucleotide analogs and are effective antiviral agents.
- Adefovir, tenofovir and cidofovir (CDV) are ANPs that have been approved for clinical use against human infections with HBV, HIV and CMV, respectively.
- ANPs are known in the art not to be absorbed readily from the gastrointestinal tract of mammals because of their molecular weight and the presence of the double negative charge on the phosphonate. Because of their poor oral pharmacokinetic properties, ANPs are usually converted to prodrugs to produce clinically useful therapeutic agents. It has been demonstrated that masking one or both negative charges with promoieties improves the uptake and transport into the small intestinal enterocytes where the promoiety is cleaved, releasing the ANP into the circulation; examples include tenofovir disoproxil fumarate and adefovir dipivoxil. Another approach is to prepare alkoxyalkyl or alkyl monoesters of ANPs to increase oral bioavailability of the drug.
- alkoxyalkyl ANP monoester side effects may occur when non-targeted tissues such as the small intestine are overexposed.
- enzymatic cleavage of the promoiety by a phospholipase C or an acid sphingomyelinase to the ANP may result in local toxicity because of further anabolic phosphorylation to the ANP diphosphate which may inhibit enterocyte DNA synthesis.
- Lipophilic ANP diester compounds are anticipated to undergo less cleavage from intact prodrug to ANP in the small intestine enterocytes following oral administration reducing GI side effects and releasing more drug substance into the circulation and producing higher levels of the drug substance in the blood.
- ANPs or their alkyl or alkoxyalkyl monoesters may exhibit limited uptake in certain target tissues such as the central nervous system.
- An additional advantage of nucleoside phosphonate diesters is the masking of the remaining negative charge on the phosphonate oxygen with a second masking group which can increase penetration of the drug substance into the central nervous system (CNS) for treatment of CNS viral infections (for example, HIV or JC virus) or for treatment of brain cancers such as glioblastoma. Cancer cells rapidly synthesize DNA and undergo uncontrolled cell division.
- CNS viral infections for example, HIV or JC virus
- brain cancers such as glioblastoma.
- the lipophilic acyclic nucleoside phosphonate (ANP) diester compositions described herein can be metabolized to their diphosphates which inhibit or block DNA synthesis and cell division in target cancer cells, leading to cell death while having substantially lesser effects on non-malignant cells. Exposure of various types of cancer cells to acyclic nucleoside phosphonates diesters may result in much greater cytotoxicity than that observed in normal non-malignant cells. For example, leukemias, lymphomas, brain neoplasms such as glioblastoma and cervical cancer cells may be more susceptible to the cytotoxic effects when exposed to lipophilic ANP diesters than the corresponding non-malignant cell lines.
- Lipophilic acyclic nucleoside phosphonate diesters exhibit more selective toxicity, improved access to the central nervous system and effective topical uptake for treatment of skin cancers, viral skin infections, cervical intraepithelial neoplasia (CIN), vaginal and anal intraepithelial dysplasia, venereal warts and related infections caused by the human papillomavirus when compared to acyclic nucleoside phosphonate monoester compositions.
- compounds disclosed herein having both ANP phosphonate negative charges masked with functional groups provide for more effective use as topical agents for treatment of skin cancers and viral infections.
- compounds disclosed herein provide for efficacious treatment for infections of the cervical, vaginal, rectal and penile epithelium with the human papilloma virus including the high risk subtypes such as 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82 which are associated with cervical, rectal, penile and vaginal cancer and venereal warts.
- L is a lipophilic promoiety, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, or O-substituted glyceryl having the formula —CH 2 CH(OR 1 )—CH 2 (OR 2 ) (II), wherein R 1 and R 2 are independently substituted or unsubstituted alkyl or substituted or unsubstituted aryl.
- R is substituted or unsubstituted lower alkyl, substituted or unsubstituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, substituted or unsubstituted lower heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted lower heteroaryl.
- X is hydrogen, substituted or unsubstituted lower alkyl, or substituted or unsubstituted lower heteroalkyl.
- a method of treating a viral disease in a subject including administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I).
- a method for treating cancer in a subject including administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I).
- a method for killing or inhibiting the growth of a transformed cell including contacting a transformed cell with a therapeutically effective amount of a compound of Formula (I).
- a method for treating a proliferative disorder in a subject including administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I).
- a pharmaceutical composition which includes a compound according to Formula (I), and a pharmaceutically acceptable excipient.
- a method for synthesis of a compound with structure of Formula (I) according to Scheme 2 disclosed herein.
- the method includes contacting a protected nucleoside B Nuc with structure of Formula (2-1) with an ester with structure of Formula (2-2) in the presence of a strong base under conditions suitable to afford a monoester with structure of Formula (2-3); and reacting the afforded monoester with L-OH in the presence of a coupling agent, thereby synthesizing a compound with structure of Formula (I).
- B Nuc(a) can be a naturally occurring purine, a naturally occurring pyrimidine, a non-naturally occurring purine or a non-naturally occurring pyrimidine;
- L a can be an unsubstituted C 12-24 alkyl, an unsubstituted C 13-29 heteroalkyl or a substituted glyceryl moiety, wherein the glyceryl moiety can be substituted with one or more groups selected from an unsubstituted C 13-29 alkyl, an unsubstituted C 13-29 heteroalkyl, a substituted or unsubstituted aryl(C 1-6 alkyl), a substituted or unsubstituted heteroaryl(C 1-6 alkyl) and a substituted or unsubstituted heterocycloalkyl(C 1-6 alkyl);
- R a can be selected from an unsubstituted C 1-6 alkyl, a substituted or unsubstituted ary
- a pharmaceutical composition that can include an effective amount of a compound as disclosed herein (for example, a compound of Formula (Ia)), or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof, and a pharmaceutically acceptable excipient.
- a compound as disclosed herein for example, a compound of Formula (Ia)
- a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof for use in treating a viral disease in a subject
- the viral disease can be selected from human papilloma virus, HIV, hepatitis B virus, hepatitis C virus, variola virus, vaccinia virus, an adenovirus, a cytomegalovirus, herpes simplex virus 1, herpes simplex virus 2, Epstein Barr virus, BK virus, JC virus, feline leukemia virus and feline immunodeficiency virus.
- a compound as disclosed herein for example, a compound of Formula (Ia)
- a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof for use in treating cancer of the cervix in a subject.
- a compound as disclosed herein, or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof, for use in inhibiting growth of a cell transformed by a virus wherein the virus can be selected from human papilloma virus, HIV, hepatitis B virus, hepatitis C virus, variola virus, vaccinia virus, an adenovirus, a cytomegalovirus, herpes simplex virus 1, herpes simplex virus 2, Epstein Barr virus, BK virus, JC virus, feline leukemia virus and feline immunodeficiency virus.
- a compound as disclosed herein for example, a compound of Formula (Ia)
- a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof in the preparation of a medicament for treating a viral disease in a subject
- the viral disease can be selected from human papilloma virus, HIV, hepatitis B virus, hepatitis C virus, variola virus, vaccinia virus, an adenovirus, a cytomegalovirus, herpes simplex virus 1, herpes simplex virus 2, Epstein Barr virus, BK virus, JC virus, feline leukemia virus and feline immunodeficiency virus.
- a compound as disclosed herein for example, a compound of Formula (Ia)
- a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof in the preparation of a medicament for treating cancer of the cervix in a subject.
- a compound as disclosed herein for example, a compound of Formula (Ia)
- a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof in the preparation of a medicament for inhibiting growth of a cell transformed by a virus
- the virus can be selected from human papilloma virus, HIV, hepatitis B virus, hepatitis C virus, variola virus, vaccinia virus, an adenovirus, a cytomegalovirus, herpes simplex virus 1, herpes simplex virus 2, Epstein Barr virus, BK virus, JC virus, feline leukemia virus and feline immunodeficiency virus.
- the FIGURE provides a chromatogram of compound 1a (fast-eluting) and compound 1b (slow eluting), as described in Example 2.
- X-axis time (min); Y-axis (milli-absorption units, mAu).
- Solvent 50:50:0.1 Water:Acetonitrile:TFA.
- substituent groups are specified by their conventional chemical formulae, written from left to right, they equally encompass the chemically identical substituents that would result from writing the structure from right to left, e.g., —CH 2 O— is equivalent to —OCH 2 —.
- alkyl by itself or as part of another substituent, means, unless otherwise stated, and includes a straight (i.e., unbranched) or branched chain, or combination thereof, which may be fully saturated, mono- or polyunsaturated and can include di- and multivalent radicals, having the number of carbon atoms designated (i.e., C 1 -C 10 means one to ten carbons). Alkyl is an uncyclized chain.
- saturated hydrocarbon radicals include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, (cyclohexyl)methyl, homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like.
- An unsaturated alkyl group is one having one or more double bonds (an “alkenyl group”) or triple bonds (an “alkynyl group”).
- unsaturated alkyl groups include, but are not limited to, the alkenyl groups vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), and the alkynyl groups ethynyl, 1- and 3-propynyl, 3-butynyl, and the higher homologs and isomers.
- alkoxy is an alkyl attached to the remainder of the molecule via an oxygen linker (—O—).
- alkylene by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkyl, as exemplified, but not limited by, —CH 2 CH 2 CH 2 CH 2 —.
- an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, or 10 or fewer carbon atoms.
- a “lower alkyl” or “lower alkylene” is a shorter chain alkyl or alkylene group, generally having eight or fewer carbon atoms.
- heteroalkyl by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or combinations thereof, consisting of at least one carbon atom and at least one heteroatom selected from the group consisting of O, N, P, Si, and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized.
- the heteroatom(s) O, N, P, S, and Si may be placed at any interior position of the heteroalkyl group or at the position at which the alkyl group is attached to the remainder of the molecule.
- Heteroalkyl is an uncyclized chain.
- Examples include, but are not limited to: —CH 2 —CH 2 —O—CH 3 , —CH 2 —CH 2 —NH—CH 3 , —CH 2 —CH 2 —N(CH 3 )—CH 3 , —CH 2 —S—CH 2 —CH 3 , —CH 2 —CH 2 , —S(O)—CH 3 , —CH 2 —CH 2 —S(O) 2 —CH 3 , —CH ⁇ CH—O—CH 3 , —Si(CH 3 ) 3 , —CH 2 —CH ⁇ N—OCH 3 , —CH ⁇ CH—N(CH 3 )—CH 3 , —O—CH 3 , —O—CH 2 —CH 3 , and —CN.
- Up to two heteroatoms may be consecutive, such as, for example, —CH 2 —NH—OCH 3 .
- heteroalkylene by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from heteroalkyl, as exemplified, but not limited by, —CH 2 —CH 2 —S—CH 2 —CH 2 — and —CH 2 —S—CH 2 —CH 2 —NH—CH 2 —.
- heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, and the like).
- heteroalkyl groups include those groups that are attached to the remainder of the molecule through a heteroatom, such as —NR′R′′, —OR′, —SR′, and/or —SO 2 R′.
- heteroalkyl is recited, followed by recitations of specific heteroalkyl groups, such as —NR′R′′ or the like, it will be understood that the terms heteroalkyl and —NR′R′′ are not redundant or mutually exclusive. Rather, the specific heteroalkyl groups are recited to add clarity. Thus, the term “heteroalkyl” should not be interpreted herein as excluding specific heteroalkyl groups, such as —NR′R′′ or the like.
- cycloalkyl and heterocycloalkyl mean, unless otherwise stated, cyclic versions of “alkyl” and “heteroalkyl,” respectively. Cycloalkyl and heteroalkyl are not aromatic. Additionally, for heterocycloalkyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like.
- heterocycloalkyl examples include, but are not limited to, 1-(1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl, and the like.
- a “cycloalkylene” and a “heterocycloalkylene,” alone or as part of another substituent, means a divalent radical derived from a cycloalkyl and heterocycloalkyl, respectively.
- halo or “halogen,” by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom. Additionally, terms such as “haloalkyl” are meant to include monohaloalkyl and polyhaloalkyl.
- halo(C 1 -C 4 )alkyl includes, but is not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.
- acyl means, unless otherwise stated, —C(O)R* where R* is a substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
- aryl means, unless otherwise stated, a polyunsaturated, aromatic, hydrocarbon substituent, which can be a single ring or multiple rings (preferably from 1 to 3 rings) that are fused together (i.e., a fused ring aryl) or linked covalently.
- a fused ring aryl refers to multiple rings fused together wherein at least one of the fused rings is an aryl ring.
- heteroaryl refers to aryl groups (or rings) that contain from one to four heteroatoms selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized.
- heteroaryl includes fused ring heteroaryl groups (i.e., multiple rings fused together wherein at least one of the fused rings is a heteroaromatic ring).
- a 5,6-fused ring heteroarylene refers to two rings fused together, wherein one ring has 5 members and the other ring has 6 members, and wherein at least one ring is a heteroaryl ring.
- a 6,6-fused ring heteroarylene refers to two rings fused together, wherein one ring has 6 members and the other ring has 6 members, and wherein at least one ring is a heteroaryl ring.
- a 6,5-fused ring heteroarylene refers to two rings fused together, wherein one ring has 6 members and the other ring has 5 members, and wherein at least one ring is a heteroaryl ring.
- a heteroaryl group can be attached to the remainder of the molecule through a carbon or heteroatom.
- Non-limiting examples of aryl and heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinoly
- arylene and heteroarylene are selected from the group of acceptable substituents described below.
- aryl when used in combination with other terms (e.g., aryloxy, arylthioxy, arylalkyl) includes both aryl and heteroaryl rings as defined above.
- arylalkyl e.g., aryl(C 1-6 alkyl)
- alkyl group e.g., benzyl (Bn), phenethyl, pyridylmethyl, and the like
- alkyl group e.g., benzyl (Bn), phenethyl, pyridylmethyl, and the like
- an oxygen atom e.g., phenoxymethyl, 2-pyridyloxymethyl, 3-(1-naphthyloxy)propyl, and the like.
- heteroarylalkyl refers to those radicals in which a heteroaryl group is attached to an alkyl group.
- heterocycloalkylalkyl refers to those radicals in which a heterocycloalkyl is attached to an alkyl group.
- oxo means an oxygen that is double bonded to a carbon atom.
- alkylsulfonyl means a moiety having the formula —S(O 2 )—R′, where R′ is an alkyl group as defined above. R′ may have a specified number of carbons (e.g., “C 1 -C 4 alkylsulfonyl”).
- Substituents for the alkyl and heteroalkyl radicals can be one or more of a variety of groups selected from, but not limited to, —OR′, ⁇ O, ⁇ NR′, ⁇ N—OR′, —NR′R′′, —SR′, -halogen, —SiR′R′′R′′′, —OC(O)R′, —C(O)R′, —CO 2 R′, —CONR′R′′, —OC(O)NR′R′′, —NR′′C(O)R′, —NR′—C(O)NR′′R′′′, —NR′′C(O) 2 R′, —NR—C(NR′R′′R′′′) ⁇ NR′′′′, —NR—C(NR′R′′R′′′) ⁇ NR′′′′,
- R′, R′′, R′′′, and R′′′′ each preferably independently refer to hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl (e.g., aryl substituted with 1-3 halogens), substituted or unsubstituted alkyl, alkoxy, or thioalkoxy groups, or arylalkyl groups.
- each of the R groups is independently selected as are each R′, R′′, R′′′, and R′′′′ group when more than one of these groups is present.
- R′ and R′′ When R′ and R′′ are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 4-, 5-, 6-, or 7-membered ring.
- —NR′R′′ includes, but is not limited to, 1-pyrrolidinyl and 4-morpholinyl.
- substituted alkyl is meant to include groups including carbon atoms bound to groups other than hydrogen groups, such as haloalkyl (e.g., —CF 3 and —CH 2 CF 3 ) and acyl (e.g., —C(O)CH 3 , —C(O)CF 3 , —C(O)CH 2 OCH 3 , and the like).
- haloalkyl e.g., —CF 3 and —CH 2 CF 3
- acyl e.g., —C(O)CH 3 , —C(O)CF 3 , —C(O)CH 2 OCH 3 , and the like.
- substituents for the aryl and heteroaryl groups are varied and are selected from, for example: —OR′, —NR′R′′, —SR′, -halogen, —SiR′R′′R′′′, —OC(O)R′, —C(O)R′, —CO 2 R′, —CONR′R′′, —OC(O)NR′R′′, —NR′′C(O)R′, —NR′—C(O)NR′′R′′′, —NR′′C(O) 2 R′, —NR—C(NR′R′′R′′′) ⁇ NR′′′′, —NR—C(NR′R′′) ⁇ NR′′′, —S(O)R′, —S(O) 2 R′, —S(O) 2 NR′R′′, —NRSO 2 R′, —CN, —NO 2 , —R′, —N 3 , —CH(Ph
- Two or more substituents may optionally be joined to form aryl, heteroaryl, cycloalkyl, or heterocycloalkyl groups.
- Such so-called ring-forming substituents are typically, though not necessarily, found attached to a cyclic base structure.
- the ring-forming substituents are attached to adjacent members of the base structure.
- two ring-forming substituents attached to adjacent members of a cyclic base structure create a fused ring structure.
- the ring-forming substituents are attached to a single member of the base structure.
- two ring-forming substituents attached to a single member of a cyclic base structure create a spirocyclic structure.
- the ring-forming substituents are attached to non-adjacent members of the base structure.
- Two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally form a ring of the formula -T-C(O)—(CRR′) q —U—, wherein T and U are independently —NR—, —O—, —CRR′—, or a single bond, and q is an integer of from 0 to 3.
- two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -A-(CH 2 ) r -B—, wherein A and B are independently —CRR′—, —O—, —NR—, —S—, —S(O)—, —S(O) 2 —, —S(O) 2 NR′—, or a single bond, and r is an integer of from 1 to 4.
- One of the single bonds of the new ring so formed may optionally be replaced with a double bond.
- two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula —(CRR′) s —X′— (C′′R′′′) d —, where s and d are independently integers of from 0 to 3, and X′ is —O—, —NR′—, —S—, —S(O)—, —S(O) 2 —, or —S(O) 2 NR′—.
- R, R′, R′′, and R′′′ are preferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
- heteroatom or “ring heteroatom” are meant to include oxygen (O), nitrogen (N), sulfur (S), phosphorus (P), and silicon (Si).
- a “substituent group,” as used herein, means a group selected from the following moieties:
- a “size-limited substituent” or “size-limited substituent group,” as used herein, means a group selected from all of the substituents described above for a “substituent group,” wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted C 1 -C 29 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 30 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C 3 -C 8 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 8 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted C 6 -C 10 aryl, and each substituted or unsubstituted heteroaryl is
- a “lower substituent” or “lower substituent group,” as used herein, means a group selected from all of the substituents described above for a “substituent group,” wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted C 1 -C 8 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 8 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C 3 -C 7 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 7 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted C 6 -C 10 aryl, and each substituted or unsubstituted heteroaryl is a substitute
- each substituted group described in the compounds herein is substituted with at least one substituent group. More specifically, in embodiments, each substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene described in the compounds herein are substituted with at least one substituent group. In embodiments, at least one or all of these groups are substituted with at least one size-limited substituent group. In embodiments, at least one or all of these groups are substituted with at least one lower substituent group.
- each substituted or unsubstituted alkyl may be a substituted or unsubstituted C 1 -C 30 alkyl
- each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 30 membered heteroalkyl
- each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C 3 -C 8 cycloalkyl
- each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 8 membered heterocycloalkyl
- each substituted or unsubstituted aryl is a substituted or unsubstituted C 6 -C 10 aryl
- each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 10 membered heteroaryl.
- each substituted or unsubstituted alkylene is a substituted or unsubstituted C 1 -C 30 alkylene
- each substituted or unsubstituted heteroalkylene is a substituted or unsubstituted 2 to 30 membered heteroalkylene
- each substituted or unsubstituted cycloalkylene is a substituted or unsubstituted C 3 -C 8 cycloalkylene
- each substituted or unsubstituted heterocycloalkylene is a substituted or unsubstituted 3 to 8 membered heterocycloalkylene
- each substituted or unsubstituted arylene is a substituted or unsubstituted C 6 -C 10 arylene
- each substituted or unsubstituted heteroarylene is a substituted or unsubstituted 5 to 10 membered heteroarylene.
- each substituted or unsubstituted alkyl is a substituted or unsubstituted C 1 -C 8 alkyl
- each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 8 membered heteroalkyl
- each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C 3 -C 7 cycloalkyl
- each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 7 membered heterocycloalkyl
- each substituted or unsubstituted aryl is a substituted or unsubstituted C 6 -C 10 aryl
- each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 9 membered heteroaryl.
- each substituted or unsubstituted alkylene is a substituted or unsubstituted C 1 -C 8 alkylene
- each substituted or unsubstituted heteroalkylene is a substituted or unsubstituted 2 to 8 membered heteroalkylene
- each substituted or unsubstituted cycloalkylene is a substituted or unsubstituted C 3 -C 7 cycloalkylene
- each substituted or unsubstituted heterocycloalkylene is a substituted or unsubstituted 3 to 7 membered heterocycloalkylene
- each substituted or unsubstituted arylene is a substituted or unsubstituted C 6 -C 10 arylene
- each substituted or unsubstituted heteroarylene is a substituted or unsubstituted 5 to 9 membered heteroarylene.
- pharmaceutically acceptable salts is meant to include salts of the active compounds that are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein.
- base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent.
- pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt.
- acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent.
- Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, oxalic, methanesulfonic, and the like.
- inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic,
- salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge et al., “Pharmaceutical Salts”, Journal of Pharmaceutical Science, 1977, 66:1-19).
- Certain specific compounds described herein contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.
- the compounds described herein may exist as salts, such as with pharmaceutically acceptable acids.
- salts include hydrochlorides, hydrobromides, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, tartrates (e.g., (+)-tartrates, ( ⁇ )-tartrates, or mixtures thereof including racemic mixtures), succinates, benzoates, and salts with amino acids such as glutamic acid.
- salts may be prepared by methods known to those skilled in the art.
- the neutral forms of the compounds can be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner.
- the parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents.
- compounds described herein can be in a prodrug form.
- Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide a compound described herein.
- prodrugs can be converted to a compounds described herein by chemical or biochemical methods in an ex vivo environment.
- prodrugs can be slowly converted to a compounds described herein when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.
- promoiety is meant to refer to a chemical entity reversibly attached to the drug that improves an aspect of drug performance by masking a problematic functional group.
- Certain compounds described herein can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are encompassed. Certain compounds described herein [for example, a compound of Formula (I) and/or a compound of Formula (Ia)] may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated and are intended.
- Certain compounds described herein [for example, a compound of Formula (I) and/or a compound of Formula (Ia)] can possess asymmetric atoms (optical centers) or double bonds; the racemates, diastereomers, tautomers, geometric isomers, and individual isomers are encompassed.
- the compounds described herein [for example, a compound of Formula (I) and/or a compound of Formula (Ia)] do not include those that are known in the art to be too unstable to synthesize and/or isolate.
- the compounds described herein may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds.
- the compounds may be radiolabeled with radioactive isotopes, such as for example tritium ( 3 H), iodine-125 ( 125 I), or carbon-14 ( 14 C). All isotopic variations of the compounds, whether radioactive or not, are encompassed.
- B Nuc is a naturally occurring purine or pyrimidine base, or analog thereof;
- L is a lipophilic promoiety, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, or O-substituted glyceryl having the formula —CH 2 CH(OR 1 )—CH 2 (OR 2 ) (II), wherein R 1 and R 2 are independently substituted or unsubstituted alkyl, or substituted or unsubstituted aryl;
- R is substituted or unsubstituted lower alkyl, substituted or unsubstituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, substituted or unsubstituted lower heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted lower heteroaryl
- the compound is a stereoisomer with the structure of Formula (I). In embodiments, the compound is a salt of a compound with the structure of Formula (I). In embodiments, the compound is a solvate of a compound with the structure of Formula (I). In embodiments, the compound is a crystalline form of a compound with the structure of Formula (I).
- naturally occurring purine or pyrimidine base refers, in the usual and customary sense as employed in the art, to purine or pyrimidine bases, e.g., guanine, adenine, cytosine, thymine, uracil, or 2,6-diaminopurine. Attachment of the naturally occurring purine or pyrimidine base can be at any available site, e.g., guanin-9-yl, adenine-9-yl, cytosine-1-yl, thymin-1-yl, uracil-1-yl, 2,6-diaminopurin-9-yl, and the like. When attached to the remainder of the compounds described herein, the naturally occurring purine or pyrimidine base is in monovalent from (the form of a chemical moiety or substituent as known in the art).
- analog of naturally occurring purine or pyrimidine base refers, in the usual and customary sense, to a chemical analog of a naturally occurring purine or pyrimidine base, as known in the art.
- analog of naturally occurring purine or pyrimidine base is in monovalent from (the form of a chemical moiety or substituent as known in the art).
- B Nuc is a naturally occurring purine or pyrimidine base.
- B Nuc is a naturally occurring purine base.
- B Nuc is a naturally occurring pyrimidine base.
- B Nuc is an analog of a naturally occurring purine or pyrimidine base.
- B Nuc is an analog of a naturally occurring base.
- B Nuc is an analog of a naturally occurring pyrimidine base.
- lipophilic promoiety refers to a chemical moiety which imparts increased lipophilicity when incorporated into a compound with structure of Formula (I).
- the lipophilic promoiety is a substituted or unsubstituted C 8-24 alkyl.
- the lipophilic promoiety is a substituted or unsubstituted C 8-24 heteroalkyl.
- the lipophilic promoiety is a substituted or unsubstituted C 8-24 alkoxyalkyl.
- Exemplary lipophilic promoieties include glyceryl moieties having substituted or unsubstituted alkyl, and/or substituted or unsubstituted aryl substituents.
- substitution at a glyceryl moiety is via O-substitution with a substituted or unsubstituted alkyl, and/or via 0-substitution with a substituted or unsubstituted aryl.
- the lipophilic promoiety, L imparts lipophilicity and therefore may include glyceryl ether linked compounds (e.g., 1-O-octadecyl-2-O-benzyl) wherein the hydrogens of the glyceryl hydroxyls are replaced with substituted or unsubstituted alkyl or substituted or unsubstituted aryl groups that do not impart hydrophilicity, and the carbons atoms of the glyceryl are not further substituted.
- L is an O-substituted glyceryl having the formula —CH 2 CH(OR 1 )—CH 2 (OR 2 ) (II), wherein R 1 and R 2 are independently a substituted or unsubstituted alkyl or a substituted or unsubstituted aryl.
- L is a substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, or an O-substituted glyceryl having the formula —CH 2 CH(OR 1 )—CH 2 (OR 2 ) (II), wherein R 1 and R 2 are independently a substituted or unsubstituted alkyl or a substituted or unsubstituted aryl.
- L is an O-substituted glyceryl.
- L is 1-O-alkyl-2-O-benzyl-sn-glyceryl.
- L is 1-O-octadecyl-2-O-benzyl-sn-glyceryl.
- L is an unsubstituted alkyl.
- L is a size-limited unsubstituted alkyl.
- L is C 8-24 alkyl.
- L is an unsubstituted heteroalkyl.
- L is a size-limited unsubstituted heteroalkyl.
- L is C 8-24 heteroalkyl.
- L is an unsubstituted alkoxyoalkyl.
- L is a size-limited unsubstituted alkoxyalkyl.
- L is C 8-24 alkoxyalkyl.
- R is a substituted or unsubstituted lower alkyl, a substituted or unsubstituted lower heteroalkyl, a substituted or unsubstituted lower cycloalkyl, a substituted or unsubstituted lower heterocycloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted lower heteroaryl.
- R is a substituted or unsubstituted lower alkyl.
- R is a substituted or unsubstituted lower heteroalkyl.
- R is an O-substituted glyceryl having the formula —CH 2 CH(OR 3 )—CH 2 (OR 4 ) (III), wherein R 3 and R 4 are independently a substituted or unsubstituted alkyl or a substituted or unsubstituted aryl.
- R is a substituted or unsubstituted lower cycloalkyl.
- R is a substituted or unsubstituted lower heterocycloalkyl.
- R is a substituted or unsubstituted hexopyranosyl.
- R is an unsubstituted hexopyranosyl.
- R is a substituted or unsubstituted aryl. In embodiments, R is a substituted or unsubstituted lower heteroaryl. In embodiments, R is an unsubstituted lower alkyl. In embodiments, R is an unsubstituted lower heteroalkyl. In embodiments, R is an unsubstituted lower cycloalkyl. In embodiments, R is an unsubstituted lower heterocycloalkyl. In embodiments, R is an unsubstituted aryl. In embodiments, R is an unsubstituted lower heteroaryl. In embodiments, R is a size-limited substituted or unsubstituted lower cycloalkyl.
- R is a size-limited substituted or unsubstituted lower heterocycloalkyl. In embodiments, R is a size-limited substituted or unsubstituted aryl. In embodiments, R is a size-limited substituted or unsubstituted lower heteroaryl. In embodiments, R is C 1 -s substituted or unsubstituted alkyl. In embodiments, R is C 1-8 s substituted or unsubstituted heteroalkyl. In embodiments, R is C 4 -8 substituted or unsubstituted cycloalkyl. In embodiments, R is C 4 -8 substituted or unsubstituted heterocycloalkyl.
- R is C 6 -10 substituted or unsubstituted aryl. In embodiments, R is C 6-10 substituted or unsubstituted heteroaryl. In embodiments, R is C 1-8 unsubstituted alkyl. In embodiments, R is C 2-8 unsubstituted heteroalkyl. In embodiments, R is C 4-8 unsubstituted cycloalkyl. In embodiments, R is C 4-8 unsubstituted heterocycloalkyl. In embodiments, R is C 6-10 unsubstituted aryl. In embodiments, R is C 6-10 unsubstituted heteroaryl.
- R is a substituted or unsubstituted phenyl, a substituted or unsubstituted naphthyl, a substituted or unsubstituted benzyl, a substituted or unsubstituted glyceryl, or a substituted or unsubstituted hexopyranosyl.
- R is a substituted phenyl.
- R is a substituted naphthyl.
- R is a substituted benzyl.
- R is a substituted glyceryl.
- R is a substituted hexopyranosyl.
- R is an unsubstituted phenyl. In embodiments, R is an unsubstituted naphthyl. In embodiments, R is an unsubstituted benzyl. In embodiments, R is an unsubstituted glyceryl. In embodiments, R is an unsubstituted hexopyranosyl.
- X is hydrogen, a substituted or unsubstituted lower alkyl, or a substituted or unsubstituted lower heteroalkyl. In embodiments, X is hydrogen. In embodiments, X is a substituted or unsubstituted lower alkyl. In embodiments, X is a substituted or unsubstituted lower heteroalkyl. In embodiments, X is an unsubstituted lower alkyl. In embodiments, X is an unsubstituted lower heteroalkyl. In embodiments, X is a size-limited substituted or unsubstituted alkyl. In embodiments, X is a size-limited substituted or unsubstituted heteroalkyl.
- X is a size-limited unsubstituted alkyl. In embodiments, X is a size-limited unsubstituted heteroalkyl. In embodiments, X is methyl. In embodiments, X is methoxymethyl. In embodiments, X is hydroxymethyl. In embodiments, X is fluoromethyl.
- the compound with structure of Formula (I) has the structure of Formula (I-1):
- B Nuc is as described for any of the embodiments of the compound of Formula (I) disclosed herein.
- L is as described for any of the embodiments of the compound of Formula (I) described herein.
- L is octadecyloxyethyl, hexadecyloxypropyl, or 1-O-octadecyl-2-O-benzyl-sn-glyceryl.
- L is octadecyloxyethyl.
- L is hexadecyloxypropyl.
- L is 1-O-octadecyl-2-O-benzyl-sn-glyceryl.
- R is as described for any of the embodiments of the compound of Formula (I) described herein.
- R is a substituted or unsubstituted phenyl, a substituted or unsubstituted naphthyl, a substituted or unsubstituted benzyl, a substituted or unsubstituted glyceryl, or a substituted or unsubstituted hexopyranosyl.
- R is a substituted phenyl.
- R is a substituted naphthyl.
- R is a substituted benzyl.
- R is a substituted glyceryl.
- R is a substituted hexopyranosyl. In embodiments, R is an unsubstituted phenyl. In embodiments, R is an unsubstituted naphthyl. In embodiments, R is an unsubstituted benzyl. In embodiments, R is an unsubstituted glyceryl. In embodiments, R is an unsubstituted hexopyranosyl.
- the compound with structure of Formula (I) has the structure of Formula (I-2):
- B Nuc is as described for any of the embodiments of the compound of Formulae (I)-(I-1) disclosed herein.
- L is as described for any of the embodiments of the compound of Formulae (I)-(I-1) described herein.
- R is as described for any of the embodiments of the compound of Formulae (I)-(I-1) described herein.
- the compound with structure of Formula (I) has the structure of Formula (I-3):
- B Nuc is as described for any of the embodiments of the compound of Formulae (I)-(I-2) disclosed herein.
- L is as described for any of the embodiments of the compound of Formulae (I)-(I-2) described herein.
- R is as described for any of the embodiments of the compound of Formulae (I)-(I-2) described herein.
- the compound with structure of Formula (I) has the structure of Formula (I-4):
- B Nuc is as described for any of the embodiments of the compound of Formulae (I)-(I-3) disclosed herein.
- L is as described for any of the embodiments of the compound of Formulae (I)-(I-3) described herein.
- R is as described for any of the embodiments of the compound of Formulae (I)-(I-3) described herein.
- the compound with structure of Formula (I) has the structure of Formula (I-5):
- B Nuc is as described for any of the embodiments of the compound of Formulae (I)-(I-4) disclosed herein.
- L is as described for any of the embodiments of the compound of Formulae (I)-(I-4) described herein.
- R is as described for any of the embodiments of the compound of Formulae (I)-(I-4) described herein.
- B Nuc(a) can be a naturally occurring purine, a naturally occurring pyrimidine, a non-naturally occurring purine or a non-naturally occurring pyrimidine.
- L a can be an unsubstituted C 12-24 alkyl, an unsubstituted C 13-29 heteroalkyl or a substituted glyceryl moiety.
- the glyceryl moiety may be substituted with one or more groups selected from an unsubstituted C 13-29 alkyl, an unsubstituted C 13-29 heteroalkyl, a substituted or unsubstituted aryl(C 1-6 alkyl), a substituted or unsubstituted heteroaryl(C 1-6 alkyl) and a substituted or unsubstituted heterocycloalkyl(C 1-6 alkyl).
- R a can be selected from an unsubstituted C 1-6 alkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aryl(C 1-6 alkyl), a substituted or unsubstituted heteroaryl(C 1-6 alkyl) and a substituted or unsubstituted heterocycloalkyl(C 1-6 alkyl).
- X a can be hydrogen, an unsubstituted C 1-6 alkyl, a halogen substituted C 1-6 alkyl, a hydroxy substituted C 1-6 alkyl or an unsubstituted C 1-6 alkoxy.
- X a can be hydrogen, an unsubstituted C 1-6 alkyl, a halogen substituted C 1-6 alkyl, a hydroxy substituted C 1-6 alkyl or an unsubstituted C 1-6 alkoxy. In embodiments, X a can be hydrogen. In embodiments, X a can be an unsubstituted C 1-6 alkyl. In embodiments, X a can be methyl. In embodiments, X a can be a hydroxy substituted C 1-6 alkyl. In embodiments, X a can be —CH 2 OH. In embodiments, X can be an unsubstituted C 1-6 alkoxy. In embodiments, X a can be methoxy.
- X a can be a halogen substituted C 1-6 alkyl. In embodiments, X a can be a fluoro substituted C 1-6 alkyl. In embodiments, X a can be —CH 2 F.
- L a can be an unsubstituted C 13-29 heteroalkyl.
- L a can have the structure —(CH 2 ) 1-6 —O—(CH 2 ) 11-21 —CH 3 .
- L a can have the structure —(CH 2 ) 2 —O—(CH 2 ) 17 —CH 3 .
- L a can have the structure —(CH 2 ) 3 —O—(CH 2 ) 15 —CH 3 .
- L a can have the structure —(CH 2 ) 1-6 —O—(CH 2 ) 10-20 —(CHCH 3 )—CH 3 .
- L a can be a substituted glyceryl moiety.
- L a can have the structure —(CH 2 )—CH(OR a1 )—(CH 2 )—O(CH 2 ) 11-21 —CH 3 , wherein R a1 can be a substituted or unsubstituted aryl(C 1-6 alkyl), a substituted or unsubstituted heteroaryl(C 1-6 alkyl) or a substituted or unsubstituted heterocycloalkyl(C 1-6 alkyl).
- R a1 can be a substituted aryl(C 1-6 alkyl).
- R a1 can be an unsubstituted aryl(C 1-6 alkyl). In embodiment, R a1 can be a substituted heteroaryl(C 1-6 alkyl). In embodiment, R a1 can be an unsubstituted heteroaryl(C 1-6 alkyl)). In embodiment, R a1 can be a substituted heterocycloalkyl(C 1-6 alkyl). In embodiment, R a1 can be an unsubstituted heterocycloalkyl(C 1-6 alkyl).
- L a can have the structure
- R a can be a substituted or unsubstituted aryl.
- the substituted aryl can be a substituted phenyl.
- the unsubstituted aryl can be an unsubstituted phenyl.
- the substituted aryl can be a substituted naphthyl.
- the unsubstituted aryl can be an unsubstituted naphthyl.
- R a can be a substituted or unsubstituted aryl(C 1-6 alkyl).
- the substituted aryl(C 1-6 alkyl) can be a substituted benzyl.
- the unsubstituted aryl(C 1-6 alkyl) can be an unsubstituted benzyl.
- R a can be a substituted or unsubstituted heterocycloalkyl(C 1-6 alkyl).
- the substituted or unsubstituted heterocycloalkyl(C 1-6 alkyl) is a substituted or unsubstituted galactosyl.
- B Nuc(a) can be a naturally occurring purine.
- B Nuc(a) can be a naturally occurring pyrimidine.
- B Nuc(a) can be a non-naturally occurring purine.
- B Nuc(a) can be a non-naturally occurring pyrimidine.
- non-naturally occurring and the like, in the context of purine or pyrimidine nucleoside B Nuc(a) groups, refers to moieties having a purine or pyrimidine core and additional chemical modifications not found in naturally occurring systems.
- purines examples include adenine, guanine, hypoxanthine, xanthine, theobromine, caffeine, uric acid, isoguanine, 2,6-diaminopurine.
- pyrimidines examples include cytosine, thymine, and uracil.
- B Nuc(a) can be selected from:
- a compound of Formula (Ia) can have the structure:
- a compound of Formula (Ia) can have the structure:
- a compound of Formula (Ia) can have the structure:
- a compound of Formula (Ia) can have the structure:
- a compound of Formula (Ia) can have the structure:
- a compound of Formula (Ia) can have the structure:
- the compound can be selected from:
- Tables 1-10 following disclose structures contemplated herein. The structures of Tables 1-10 and are not intended to be limiting on the full breadth of the contemplated compounds represented by the structure of Formulae (I), (I-1), (I-2), (I-3), (I-4), (I-5) and (Ia).
- any one of the contemplated acyclic nucleoside phosphonate (ANP) scaffolds PME-, (R)-PMP-, (S)-MPMP-, (S)-HPMP- and (S)-FPMP-) or their stereoisomers, can be used in combination with any of the contemplated combinations of naturally occurring or modified purine or pyrimidine base (B Nuc /B Nuc(a) ), L/L a and R/R a .
- Phosphonomethoxyethyl (PME) diester compounds Cmpd No. B Nuc /B Nuc(a) L/L a R/R a Name 1-(Rp, guanin-9-yl octadecyloxyethyl benzyl benzyl octadecyloxyethyl 9-(2- sp) phosphonomethoxyethyl)guanine 1a guanin-9-yl octadecyloxyethyl benzyl benzyl octadecyloxyethyl 9-(2- (fast) phosphonomethoxyethyl)guanine 1b guanin-9-yl octadecyloxyethyl benzyl benzyl octadecyloxyethyl 9-(2- (slow) phosphonomethoxyethyl)guanine 2
- Phosphonomethoxyethyl (PME) diester compounds Cmpd No. B Nuc /B Nuc(a) L/L a R/R a Name 361 guanin-9-yl octadecyloxyethyl naphthyl naphthyl octadecyloxyethyl 9-(2- phosphonomethoxyethyl)guanine 362 adenine-9-yl octadecyloxyethyl naphthyl naphthyl octadecyloxyethyl 9-(2- phosphonomethoxyethyl)adenine 363 cytosine-1-yl octadecyloxyethyl naphthyl naphthyl octadecyloxyethyl 1-(2- phosphonomethoxyethyl)cytosine 364 thymin-1-yl
- a method for treating a viral disease in a subject includes administering to a subject in need thereof a therapeutically effective amount of a compound with structure of any of Formulae (I), (I-1), (I-2), (I-3), (I-4), (I-5) and/or (Ia).
- L/L a of any of Formulae (I), (I-1), (I-2), (I-3), (I-4), (I-5) and/or (Ia) is a lipophilic promoiety.
- Exemplary viral diseases include human papilloma virus, HIV, hepatitis B virus, hepatitis C virus, variola virus (smallpox), vaccinia virus, adenovirus, cytomegalovirus (CMV), herpes simplex viruses, Epstein Barr virus, BK virus, JC virus, any double stranded DNA virus, feline leukemia virus, feline immunodeficiency virus, and the like.
- a therapeutically effective amount of a compound of Formula (I) can be administered to a human or mammal in need of treatment of a viral disease.
- the compound is administered by a route (topical, intravitreal, oral, intravenous etc.) which results in delivery of an amount sufficient to inhibit replication of the virus.
- the compound can be administered topically.
- the compound can be administered topically in the form of a cream, a gel or an ointment
- a method for treating a disease or disorder in a subject in need thereof including administering to a subject in need thereof a therapeutically effective amount of a compound with structure of any of Formulae (I), (I-1), (I-2), (I-3), (I-4), (I-5) and/or (Ia).
- a compound with structure of any of Formulae (I), (I-1), (I-2), (I-3), (I-4), (I-5) and/or (Ia) are based on the surprising discovery that compounds of Formulae (I) and/or (Ia) are effective in killing or inhibiting growth of cells that are transformed by human papillomavirus (HPV), for example cervical cancer cells and cervical intraepithelial neoplasia (CIN) lesions.
- HPV human papillomavirus
- CIN cervical intraepithelial neoplasia
- a therapeutically effective amount of a compound of Formula (I), (I-1), (I-2), (I-3), (I-4), (I-5) and/or (Ia) can be administered by an appropriate route (topical, orally, intravenous etc.) to kill or inhibit growth of infected/transformed cells.
- Cells that are transformed by other types of viruses, such as herpes simplex virus-2 (HSV-2) also may be treated with a compound of Formula (I), (I-1), (I-2), (I-3), (I-4), (I-5) and/or (Ia).
- HSV-2 herpes simplex virus-2
- a method for treating cancer in a subject includes administering to a subject in need thereof a therapeutically effective amount of a compound with the structure of any of Formulae (I), (I-1), (I-2), (I-3), (I-4), (I-5) and/or (Ia).
- L/L a of any of Formulae (I), (I-1), (I-2), (I-3), (I-4), (I-5) and/or (Ia) is a lipophilic promoiety.
- the cancer is leukemia, carcinoma and/or sarcoma, such as cancer of the brain, breast, cervix, colon, pancreas, head and neck, liver, kidney, lung, non-small cell lung, prostate, melanoma, mesothelioma, ovary, sarcoma, stomach, uterus and/or medulloblastoma.
- leukemia carcinoma and/or sarcoma
- carcinoma and/or sarcoma such as cancer of the brain, breast, cervix, colon, pancreas, head and neck, liver, kidney, lung, non-small cell lung, prostate, melanoma, mesothelioma, ovary, sarcoma, stomach, uterus and/or medulloblastoma.
- Additional examples include, Hodgkin's Disease, Non-Hodgkin's Lymphoma, multiple myeloma, neuroblastoma, ovarian cancer, rhabdomyosarcoma, primary thrombocytosis, primary macroglobulinemia, primary brain tumors, malignant pancreatic insulanoma, malignant carcinoid, urinary bladder cancer, premalignant skin lesions, testicular cancer, lymphomas, thyroid cancer, neuroblastoma, esophageal cancer, genitourinary tract cancer, malignant hypercalcemia, endometrial cancer, adrenal cortical cancer, and neoplasms of the endocrine and exocrine pancreas.
- the cancer is liver cancer, colon cancer, breast cancer, melanoma, acute myelogenous leukemia, chronic myelogenous leukemia, and/or non-small-cell lung cancer.
- a method for treating a proliferative disorder in a subject includes administering to a subject in need thereof a therapeutically effective amount of a compound with the structure of any of Formulae (I), (I-1), (I-2), (I-3), (I-4), (I-5) and/or (Ia).
- the proliferative disorder may be caused by the human papilloma virus.
- Exemplary proliferative disorders include, e.g., cervical intraepithelial neoplasia (CIN), vulvar intraepithelial neoplasia (VIN), anal intraepithelial neoplasia (AIN), or penile and venereal warts.
- L/L a of any of Formulae (I), (I-1), (I-2), (I-3), (I-4), (I-5) and/or (Ia) is a lipophilic promoiety.
- a method for killing or inhibiting the growth of a transformed cell includes contacting a transformed cell with a therapeutically effective amount of a compound of any one of Formulae (I), (I-1), (I-2), (I-3), (I-4), (I-5) and/or (Ia).
- a compound of Formula (Ia) or embodiment thereof, or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof, for use in treating a viral disease in a subject wherein the viral disease can be selected from human papilloma virus (HPV), HIV, hepatitis B virus, hepatitis C virus, variola virus, vaccinia virus, an adenovirus, a cytomegalovirus, herpes simplex virus 1, herpes simplex virus 2, Epstein Barr virus, BK virus, JC virus, feline leukemia virus and feline immunodeficiency virus.
- HPV human papilloma virus
- HIV hepatitis B virus
- hepatitis C virus variola virus
- vaccinia virus an adenovirus
- a cytomegalovirus herpes simplex virus 1
- herpes simplex virus 2 Epstein Barr virus
- BK virus Epstein Barr virus
- JC virus feline leukemia virus and fel
- the virus can be human papilloma virus.
- HPV is the most common sexually transmitted infection (STI).
- HPV viruses can be classified into mucosal and cutaneous HPVs. Within each of these groups, the individual viruses are designated high risk or low risk. More than 40 types of HPV's can infect the genital areas of women and men, and several HPV types can infect the mouth and throat. Additionally, HPV is the most common cause of cervical cancer. Type 16 is one of the most prominent strains of HPV and can cause cervical cancer.
- HPVs include, but are not limited to, 2, 3, 4, 5, 6, 8, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 63, 66, 68, 69 and 82.
- the use is for treating a plurality of types of human papilloma virus, for example, types described herein.
- the use is for more than 2 types of HPV, more than 5 types of HPV or more than 10 types of HPV.
- the human papilloma virus can be selected from human papilloma virus type 11, type 16 and type 18.
- a compound of Formula (Ia) or embodiment thereof, or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof in the preparation of a medicament for treating a viral disease in a subject, wherein the viral disease can be selected from human papilloma virus, HIV, hepatitis B virus, hepatitis C virus, variola virus, vaccinia virus, an adenovirus, a cytomegalovirus, herpes simplex virus 1, herpes simplex virus 2, Epstein Barr virus, BK virus, JC virus, feline leukemia virus and feline immunodeficiency virus.
- the viral disease can be selected from human papilloma virus, HIV, hepatitis B virus, hepatitis C virus, variola virus, vaccinia virus, an adenovirus, a cytomegalovirus, herpes simplex virus 1, herpes simplex virus 2, Epstein Barr virus, BK virus, JC virus, feline leukemia virus and fel
- the virus can be human papilloma virus.
- the use is for treating a plurality of types of human papilloma virus, for example, types described herein. In embodiments, the use is for more than 2 types of HPV, more than 5 types of HPV or more than 10 types of HPV.
- the human papilloma virus can be selected from human papilloma virus type 11, type 16 and type 18.
- a method of treating a subject having a viral disease include administering to the subject having a viral disease in need thereof an effective amount of a compound of Formula (Ia) or embodiment thereof, or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof, wherein the viral disease can be selected from human papilloma virus, HIV, hepatitis B virus, hepatitis C virus, variola virus, vaccinia virus, an adenovirus, a cytomegalovirus, herpes simplex virus 1, herpes simplex virus 2, Epstein Barr virus, BK virus, JC virus, feline leukemia virus and feline immunodeficiency virus, thereby treating the viral disease.
- the viral disease can be selected from human papilloma virus, HIV, hepatitis B virus, hepatitis C virus, variola virus, vaccinia virus, an adenovirus, a cytomegalovirus, herpes simplex virus 1, herpes simplex virus 2,
- the cancer of the cervix can be caused by a HPV infection, for example, a HPV infection of type 16.
- a compound of Formula (Ia) or embodiment thereof, or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof in the preparation of a medicament for treating cancer of the cervix in a subject.
- the cancer of the cervix can be caused by a HPV infection, for example, a HPV infection of type 16.
- a method of treating a subject having cancer of the cervix includes administering an effective amount of a compound of Formula (Ia) or embodiment thereof, or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof, to a subject having cancer of the cervix in need thereof, thereby treating the subject having cancer of the cervix.
- the cancer of the cervix can be caused by a HPV infection, for example, a HPV infection of type 16.
- the virus can be selected from human papilloma virus, HIV, hepatitis B virus, hepatitis C virus, variola virus, vaccinia virus, an adenovirus, a cytomegalovirus, herpes simplex virus 1, herpes simplex virus 2, Epstein Barr virus, BK virus, JC virus, feline leukemia virus and feline immunodeficiency virus.
- a compound of Formula (Ia) or embodiment thereof, or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof in the preparation of a medicament for inhibiting growth of a cell transformed by a virus
- the virus can be selected from human papilloma virus, HIV, hepatitis B virus, hepatitis C virus, variola virus, vaccinia virus, an adenovirus, a cytomegalovirus, herpes simplex virus 1, herpes simplex virus 2, Epstein Barr virus, BK virus, JC virus, feline leukemia virus and feline immunodeficiency virus.
- a method of inhibiting growth of a cell transformed by a virus includes contacting a compound of Formula (Ia) or embodiment thereof, or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof, with a cell transformed by a virus, wherein the virus can be selected from human papilloma virus, HIV, hepatitis B virus, hepatitis C virus, variola virus, vaccinia virus, an adenovirus, a cytomegalovirus, herpes simplex virus 1, herpes simplex virus 2, Epstein Barr virus, BK virus, JC virus, feline leukemia virus and feline immunodeficiency virus, thereby inhibiting growth of the cell transformed by a virus.
- the virus can be selected from human papilloma virus, HIV, hepatitis B virus, hepatitis C virus, variola virus, vaccinia virus, an adenovirus, a cytomegalovirus, herpes simplex virus 1, herpes simple
- the method includes reacting a suitably substituted ANP monoester with R—OH or R a —OH in the presence of a coupling agent such as (benzotriazol-1-yloxy)-tripyrrolidinophosphonium hexafluorophosphate (PYBOP®) to give a diester.
- a coupling agent such as (benzotriazol-1-yloxy)-tripyrrolidinophosphonium hexafluorophosphate (PYBOP®)
- PYBOP® benzotriazol-1-yloxy
- Methods for preparing the ANP monoesters are well known. For examples, see Beadle, J. R et al. Journal of Medicinal Chemistry, 2006, 49:2010-2015, and Valiaeva, N. et al. Antiviral Research, 2006, 72:10-19. The use of PYBOP® for synthesis of phosphonate diesters was first described in Campagne, J-M. et al
- B Nuc is a naturally occurring purine or pyrimidine base, or analog thereof;
- L is a lipophilic promoiety, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, or O-substituted glyceryl having the formula —CH 2 CH(OR 1 )—CH 2 (OR 2 ) (II), wherein R 1 and R 2 are independently substituted or unsubstituted alkyl or substituted or unsubstituted aryl;
- R is substituted or unsubstituted lower alkyl, substituted or unsubstituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, substituted or unsubstituted lower heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted lower heteroaryl;
- X is hydrogen, substituted or unsubstituted lower alkyl, or substituted or un
- the method includes: 1) contacting a protected nucleoside B Nuc with structure of Formula (2-1) with an ester with structure of Formula (2-2) in the presence of a strong base under conditions suitable to afford a monoester with structure of Formula (2-3); and 2) reacting the monoester so formed with structure of Formula (2-3) with L-OH in the presence of a coupling agent as known in the art, thereby synthesizing a compound with structure of Formula (I).
- a method for synthesis of compounds of Formula (Ia) includes the following as provided in Scheme 2a.
- substituents B Nuc(a) , X a , R a and L a are as described for Formula (Ia) herein, and Y a can be a leaving group.
- the method includes: 1) contacting a protected nucleoside B Nuc(a) with structure of Formula (2-1a) with an ester with structure of Formula (2-2a) in the presence of a strong base under conditions suitable to afford a monoester with structure of Formula (2-3a); and 2) reacting the monoester so formed with structure of Formula (2-3a) with L a -OH in the presence of a coupling agent as known in the art, thereby synthesizing a compound with structure of Formula (Ia).
- the method includes the steps provided in Scheme 2-1 following, specifically, contacting a suitably protected nucleoside (general structure 2-1 where B Nuc is a naturally occurring or modified purine or pyrimidine base, with an ester of general structure 2-2 (where Y is a leaving group such as p-toluenesulfonyl, methanesulfonyl, trifluoromethanesulfonyl, bromo, iodo, or the like) in the presence of a strong base and suitable solvent to yield ANP monoesters of Formula 2-3, and secondly, reacting ANP monoester 2-3 with L-OH (i.e., hydroxy form of L) in the presence of a coupling agent such as PYBOP® to give a diester of Formula (I).
- a suitably protected nucleoside generally structure 2-1 where B Nuc is a naturally occurring or modified purine or pyrimidine base
- an ester of general structure 2-2 where Y is a leaving group such as
- B Nuc , X, R and L are as described for Formula (I) herein, and Y can be a leaving group; said method comprising: contacting a compound of Formula (2-1) that has a protected B Nuc with a compound of Formula (2-2) in the presence of a strong base to form a compound of Formula (2-3); and reacting the compound of Formula (2-3) with L-OH in the presence of a coupling agent to form the compound of Formula (I).
- B Nuc(a) can be a naturally occurring purine, a naturally occurring pyrimidine, a non-naturally occurring purine or a non-naturally occurring pyrimidine;
- L a can be an unsubstituted C 12-24 alkyl, an unsubstituted C 13-29 heteroalkyl or a substituted glyceryl moiety, wherein the glyceryl moiety can be substituted with one or more groups selected from an unsubstituted C 13-29 alkyl, an unsubstituted C 13-29 heteroalkyl, a substituted or unsubstituted aryl(C 1-6 alkyl), a substituted or unsubstituted heteroaryl(C 1-6 alkyl) and a substituted or unsubstituted heterocycloalkyl(C 1-6 alkyl);
- R a can be selected
- the method includes contacting a suitably protected nucleoside (general structure 3-1 where B Nuc is a naturally occurring or modified purine or pyrimidine base), with a diester of general structure 3-2 (where Y is a leaving group such as p-toluenesulfonyl, methanesulfonyl, trifluoromethanesulfonyl, bromo, iodo, or the like) in the presence of a strong base and suitable solvent to yield a compound of Formula (I).
- a suitably protected nucleoside generally 3-1 where B Nuc is a naturally occurring or modified purine or pyrimidine base
- a diester of general structure 3-2 where Y is a leaving group such as p-toluenesulfonyl, methanesulfonyl, trifluoromethanesulfonyl, bromo, iodo, or the like
- the method includes contacting a suitably protected nucleoside (3-1a), with a diester 3-2 (where Y a is a leaving group such as p-toluenesulfonyl, methanesulfonyl, trifluoromethanesulfonyl, bromo, iodo, or the like) in the presence of a strong base and suitable solvent to yield a compound of Formula (Ia).
- a diester 3-2 where Y a is a leaving group such as p-toluenesulfonyl, methanesulfonyl, trifluoromethanesulfonyl, bromo, iodo, or the like
- compositions including a compound of Formula (I) and/or a compound of Formula (Ia) in combination with a pharmaceutically acceptable excipient (e.g., carrier).
- a pharmaceutically acceptable excipient e.g., carrier
- pharmaceutically acceptable carrier refers to pharmaceutical excipients, for example, pharmaceutically, physiologically, acceptable organic or inorganic carrier substances suitable for enteral or parenteral application that do not deleteriously react with the active agent.
- suitable pharmaceutically acceptable carriers include water, salt solutions (such as Ringer's solution), alcohols, oils, gelatins, and carbohydrates such as lactose, amylose or starch, fatty acid esters, hydroxymethycellulose, and polyvinyl pyrrolidine.
- Such preparations can be sterilized and, if desired, mixed with auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like that do not deleteriously react with the compounds described herein.
- auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like that do not deleteriously react with the compounds described herein.
- the compounds described herein can be administered alone or can be coadministered to the subject. Coadministration is meant to include simultaneous or sequential administration of the compounds individually or in combination (more than one compound).
- the preparations can also be combined, when desired, with other active substances (e.g., to reduce metabolic degradation).
- the compounds described herein can be prepared and administered in a wide variety of oral, parenteral, and topical dosage forms.
- the compounds described herein can be administered by injection (e.g. intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally).
- the compounds described herein can be administered by inhalation, for example, intranasally.
- the compounds described herein can be administered transdermally. It is also envisioned that multiple routes of administration (e.g., intramuscular, oral, transdermal) can be used to administer the compounds described herein.
- pharmaceutical compositions comprising a pharmaceutically acceptable carrier or excipient and one or more compounds are contemplated.
- pharmaceutically acceptable carriers can be either solid or liquid.
- Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
- a solid carrier can be one or more substances that may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
- the carrier is a finely divided solid in a mixture with the finely divided active component.
- the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
- the powders and tablets preferably contain from 5% to 70% of the active compound.
- Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like.
- the term “preparation” is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it.
- cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.
- a low melting wax such as a mixture of fatty acid glycerides or cocoa butter
- the active component is dispersed homogeneously therein, as by stirring.
- the molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.
- Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water/propylene glycol solutions.
- liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.
- admixtures are injectable, sterile solutions, preferably oily or aqueous solutions, as well as suspensions, emulsions, or implants, including suppositories.
- carriers for parenteral administration include aqueous solutions of dextrose, cyclodextrins, saline, pure water, ethanol, glycerol, propylene glycol, peanut oil, sesame oil, polyoxyethylene-block polymers, and the like. Ampoules are convenient unit dosages.
- the compounds described herein can also be incorporated into liposomes or administered via transdermal pumps or patches.
- compositions suitable for use include those described, for example, in PHARMACEUTICAL SCIENCES (17th Ed., Mack Pub. Co., Easton, Pa.) and WO 96/05309, the teachings of both of which are hereby incorporated by reference.
- Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizers, and/or thickening agents as desired.
- Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.
- solid form preparations that are intended to be converted, shortly before use, to liquid form preparations for oral administration.
- liquid forms include solutions, suspensions, and emulsions.
- These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
- the pharmaceutical preparation is preferably in unit dosage form.
- the preparation is subdivided into unit doses containing appropriate quantities of the active component.
- the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules.
- the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
- the unit dosage form can be in the form of an applicator pre-filled with a pharmaceutical composition described herein (for example, a pharmaceutical composition that contains an effective amount of a compound of Formula (I) and/or a compound of Formula (Ia)).
- the pre-filled applicator can be filled with a pharmaceutical composition in the form of a cream, a gel or an ointment that contains a compound described herein (for example, a compound of Formula (I) and/or a compound of Formula (Ia)).
- a pharmaceutical composition in the form of a cream, a gel or an ointment that contains a compound described herein (for example, a compound of Formula (I) and/or a compound of Formula (Ia)).
- the quantity of active component in a unit dose preparation may be varied or adjusted from 0.1 mg to 10000 mg, more typically 1.0 mg to 1000 mg, most typically 10 mg to 500 mg, according to the particular application and the potency of the active component.
- the composition can, if desired, also contain other compatible therapeutic agents.
- co-solvents include: Polysorbate 20, 60, and 80; PLURONIC® F-68, F-84, and P-103; cyclodextrin; and polyoxyl 35 castor oil. Such co-solvents are typically employed at a level between about 0.01% and about 2% by weight.
- Viscosity greater than that of simple aqueous solutions may be desirable to decrease variability in dispensing the formulations, to decrease physical separation of components of a suspension or emulsion of formulation, and/or otherwise to improve the formulation.
- Such viscosity building agents include, for example, polyvinyl alcohol, polyvinyl pyrrolidone, methyl cellulose, hydroxy propyl methylcellulose, hydroxyethyl cellulose, carboxymethyl cellulose, hydroxy propyl cellulose, chondroitin sulfate and salts thereof, hyaluronic acid and salts thereof, and combinations of the foregoing.
- Such agents are typically employed at a level between about 0.01% and about 2% by weight.
- compositions may additionally include components to provide sustained release and/or comfort.
- components include high molecular weight, anionic mucomimetic polymers, gelling polysaccharides, and finely-divided drug carrier substrates. These components are discussed in greater detail in U.S. Pat. Nos. 4,911,920; 5,403,841; 5,212,162; and 4,861,760. The entire contents of these patents are incorporated herein by reference in their entirety for all purposes.
- compositions include compositions wherein the active ingredient is contained in a therapeutically effective amount, i.e., in an amount effective to achieve its intended purpose.
- a therapeutically effective amount i.e., in an amount effective to achieve its intended purpose.
- the actual amount effective for a particular application will depend, inter alia, on the condition being treated.
- such compositions when administered in methods to treat cancer, such compositions will contain an amount of active ingredient effective to achieve the desired result (e.g., decreasing the number of cancer cells in a subject).
- the dosage and frequency (single or multiple doses) of compound administered can vary depending upon a variety of factors, including route of administration; size, age, sex, health, body weight, body mass index, and diet of the recipient; nature and extent of symptoms of the disease being treated; presence of other diseases or other health-related problems; kind of concurrent treatment; and complications from any disease or treatment regimen.
- Other therapeutic regimens or agents can be used in conjunction with the methods and compounds described herein.
- the therapeutically effective amount can be initially determined from cell culture assays. Therapeutically effective amounts for use in humans may subsequently be estimated from animal models using conventional techniques that are confirmed or refined in actual clinical trials.
- Dosages may be varied depending upon the requirements of the patient and the compound being employed.
- the dose administered to a patient should be sufficient to effect a beneficial therapeutic response in the patient over time.
- the size of the dose also will be determined by the existence, nature, and extent of any adverse side effects.
- treatment is initiated with smaller dosages, which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under circumstances is reached.
- the dosage range is 0.001% to 10% w/v. In another embodiment, the dosage range is 0.1% to 5% w/v.
- Dosage amounts and intervals can be adjusted individually to provide levels of the administered compound effective for the particular clinical indication being treated. This will provide a therapeutic regimen that is commensurate with the severity of the individual's disease state.
- an effective prophylactic or therapeutic treatment regimen can be planned that does not cause substantial toxicity and yet is entirely effective to treat the clinical symptoms demonstrated by the particular patient.
- This planning should involve the careful choice of active compound by considering factors such as compound potency, relative bioavailability, patient body weight, presence and severity of adverse side effects, preferred mode of administration, and the toxicity profile of the selected agent.
- the ratio between toxicity and therapeutic effect for a particular compound is its therapeutic index and can be expressed as the ratio between LD 50 (the amount of compound lethal in 50% of the population) and ED 50 (the amount of compound effective in 50% of the population).
- LD 50 the amount of compound lethal in 50% of the population
- ED 50 the amount of compound effective in 50% of the population.
- Compounds that exhibit high therapeutic indices are preferred.
- Therapeutic index data obtained from cell culture assays and/or animal studies can be used in formulating a range of dosages for use in humans.
- the dosage of such compounds preferably lies within a range of plasma concentrations that include the ED 50 with little or no toxicity.
- the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. See, e.g.
- Purity of the target compounds was characterized by high performance liquid chromatography (HPLC) using a Beckman Coulter SYSTEM GOLD® chromatography system.
- the analytical column was PHENOMENEX® SYNERGITM Polar-RP (4.6 ⁇ 150 mm) equipped with a SECURITYGUARDTM protection column.
- Mobile phase A was 95% water/5% methanol and mobile phase B was 95% methanol/5% water.
- flow rate 0.8 mL/min, isocratic elution was used.
- Compounds were detected by ultraviolet light (UV) absorption at 274 nm.
- TLC thin layer chromatography
- ODE-PMEG octadecyloxyethyl 9-[2-(phosphonomethoxy)ethyl]guanine
- Bn-ODE-PMEG of Example 1 was obtained as a mixture of enantiomers because of the chirality at phosphorus.
- the enantiomers were separated on a LuxTM Cellulose-1 column (Phenomenex®, Torrance, Calif. USA) using reverse phase conditions (mobile phase of 50:50:0.1 20 mM AmmAc:AcN:TFA). The absolute stereochemistry of the P-chiral enantiomers was not determined.
- the preparative chromatographic resolution of the material obtained in Example 1 provided two enantiomers that are characterized as 1a (fast eluting enantiomer) and 1b (slow eluting enantiomer). An example chromatogram is provided in the FIGURE.
- Example 2 preparation of the racemic mixture is described, however, the method of Example 2, or modifications thereof known in the art, can be used to resolve each into optically active enantiomers or diastereomers as needed.
- ODE PMEA octadecyloxyethyl 9-[2-(phosphonomethoxy)ethyl]adenine
- the protected compound (0.15 g, 0.13 mmol) was treated with 80% aq acetic acid (10 ml) at 30° C. for 3 h. The solvents were evaporated, and then the residue was purified by column chromatography on silica gel to give compound 218 (0.06 g, 68%).
- ODE PMEG octadecyloxyethyl 9-[2-(phosphonomethoxy)ethyl]guanine
- Diethyl p-toluenesulfonyloxymethyl phosphonate (3.2 g, 9.9 mmol) was dissolved in N,N-DMF (10 ml) and then bromotrimethylsilane (10 ml) was added. The mixture was stirred at room temperature overnight. The solvent was evaporated, and co-evaporated with toluene (2 ⁇ 10 ml). An ethanol/water mixture (10 ml) was added, and then mixture was stirred for 30 min at room temperature. The solvents were evaporated and co-evaporated with toluene (2 ⁇ 10 ml).
- the protected compound (0.33 g, 0.13 mmol) was treated with 80% aq acetic acid (20 ml) at 30° C. for 3 h. The solvents were then evaporated and the residue was purified by column chromatography on silica gel to give compound 230 (0.13 g, 65%).
- the protected compound (0.44 g, 0.37 mmol) was treated with 80% acetic acid (20 ml) at 30° C. for 3 h. The solvents were evaporated, and the residue was purified by column chromatography to give compound 219 (0.16 g, 64%).
- Example 20 Preparation of benzyl octadecyloxyethyl 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]uracil (Cmpd 221, Bn-ODE-(S)-HPMPU)
- Example 21 Preparation of ethyl octadecyloxyethyl 9-(S)-[3-methoxy-2-(phosphonomethoxy)propyl]adenine (Cmpd 182, Et-ODE-(S)-MPMPA)
- Example 22 Preparation of benzyl octadecyloxyethyl 9-[3-methoxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine (Cmpd 150, Bn-ODE(S)-MPMPDAP)
- Example 23 Antiproliferative Activity of Nucleoside Phosphonates Diesters in Normal Human Fibroblasts and in Human Cervical Cancer Lines In Vitro
- MT-2 cells were incubated with drug for 72 hrs and harvested.
- Flow count beads (Beckman Coulter, Miami, Fla.) were added to the cell suspension followed by propidium iodide staining and analysis using flow cytometer and the 50% cytotoxic concentration (CC 50 ) was calculated from the cell counts and viability.
- Compounds disclosed herein are effective antiproliferative agents in human T cell leukemia (MT-2) cells (Table 12).
- MT-2 cells were maintained in RPMI 1640 supplemented with 10% FBS, 10 mM HEPES buffer, 50 IU of penicillin/ml, and 50 ⁇ g of streptomycin/ml.
- the antiviral activity of each compound was determined by inoculating MT-2 cells with HIV-1 LAI at a multiplicity of infection (MOI) of 0.001 TCID 50 /cell, followed by incubation in the presence of threefold serial drug dilutions (three wells per dilution).
- MOI multiplicity of infection
- culture supernatants were harvested, lysed with 0.5% Triton X-100, and assayed for p24 antigen concentration using a commercial ELISA assay (Perkin Elmer Life Sciences, Boston, Mass.).
- the antiviral activity of each compound is expressed as the EC 50 , which is the concentration required to inhibit p24 antigen production by 50%.
- MT-2 cells were incubated with drug for 72 hrs and harvested.
- Flow count beads (Beckman Coulter, Miami, Fla.) were added to the cell suspension followed by propidium iodide staining and analysis using flow cytometer and the 50% cytotoxic concentration (CC 50 ) was calculated from the cell counts and viability.
- Table 13 shows that compounds disclosed herein have considerable antiviral activity against HIV-1 and exhibit selectivity.
- HFF human foreskin fibroblast
- Compounds were administered at the indicated doses by oral gavage daily for 5 days. Weights measured before and on day 6 after 5 doses.
- HFF human foreskin fibroblast
- HFF human foreskin fibroblast
- HFF human foreskin fibroblast
- HFF human foreskin fibroblast
- An origin-containing plasmid was co-transfected with HPV-11 E1 and E2 protein expression vectors into HEK 293 cells. At 4 hr post-transfection, cells were treated with compound dilutions and the cells were incubated for 48 hr. Replication of the virus origin was detected with DpnI and exonuclease III to remove unreplicated input bacterial plasmid DNA. Remaining replicated DNA was quantified by qPCR. Toxicity was determined by trypan blue exclusion.
- An origin-containing plasmid was co-transfected with HPV-16 E1 and E2 protein expression vectors into HEK 293 cells. At 4 hr post-transfection, cells were treated with compound dilutions and the cells were incubated for 48 hr. Replication of the virus origin was detected with DpnI and exonuclease III to remove unreplicated input bacterial plasmid DNA. Remaining replicated DNA was quantified by qPCR. Toxicity was determined by trypan blue exclusion.
- PHKs Primary human keratinocytes
- HPV-18 genomic plasmid containing G418 resistance gene which was generated by Cre-loxP-mediated excision recombination.
- the surviving cells were cultured for 2-3 day and used to develop into raft cultures where the PHK cells stratify and differentiate into a squamous epithelium in 10 or more days.
- HPV-18 viral DNA usually amplifies between 10-14 days after the raft cultures are lifted to the air-medium interface.
- Efficacy and toxicity of the test compounds were determined at three concentrations added to the media from day 6 or 8 until day 14. Medium is changed every other day.
- BrdU is added to the medium at 100 ⁇ g/ml to document host cell DNA replication.
- One set of raft cultures (with or without test compounds) is harvested for quantitative real time PCR (qPCR) to determine the copy number of HPV-18 DNA/cell.
- Another set of the raft cultures are fixed in formalin, embedded in paraffin and toxicity is determined by histology. Additional sections are subjected to in situ hybridization to localize viral DNA amplification and BrdU incorporation which denotes host DNA replication in basal and suprabasal strata.
- COS7 cells in 96-well plates were infected at an MOI of 0.01 PFU/cell with the MAD-1 strain of JC virus and incubated for 7 days. Media was then aspirated and total DNA was isolated and genome copy number was quantified by qPCR using primers 5′-CTG GTC ATG TGG ATG CTG TCA-3′ (SEQ ID NO:4) and 5′-GCC AGC AGG CTG TTG ATA CTG-3′ (SEQ ID NO:5) and probe 5′-6-FAM-CCC TTT GTT TGG CTG CT-TAMRA-3 (SEQ ID NO:6) together with the plasmid pMP508 to provide a standard curve for quantitation. In a parallel experiment in uninfected cells, cytotoxicity was determined by CELLTITER-GLO® to find the concentration that reduced cell number by 50% (CC 50 ).
- PBMC Human peripheral blood monocyte
- HBV antiviral assays (Korba & Gerin, Antivir. Res., 1992, 19:55 and Iyer, et al., Antivir Agents Chem Chemother., 2004, 48:2199) are conducted using confluent cultures of 2.2.15 cells (genotype ayw; parental cell HepG2) maintained on 96-well flat-bottomed tissue culture plates. Confluence in this culture system is required for active, high levels of HBV replication equivalent to that observed in chronically-infected individuals (Sells, et al., J. Virol., 1988, 62:2836; Korba & Gerin, Antivir. Res., 1992, 19:55). Cultures are treated for 7 days.
- HBV DNA levels in the culture medium are assessed by quantitative blot hybridization 24 hrs. after the last treatment. Cytotoxicity is assessed (A 510 ) by uptake of neutral red dye 24 hr. following the last treatment.
- Lamivudine (LMV) is used as the standard assay control.
- EC 50 , EC 90 and CC 50 values are calculated by linear regression analysis (MS EXCEL®, QUATTROPRO®) using data combined from all treated cultures (Korba & Gerin, 1992, Id.; Okuse, et al., Antivir. Res., 2005, 65:23). Standard deviations for EC 50 and EC 90 values are calculated from the standard errors generated by the regression analyses.
- EC 50 and EC 90 are drug concentrations at which a 2-fold, or a 10-fold depression of HBV DNA (relative to the average levels in untreated cultures), respectively, is observed.
- CC 50 is the drug concentration at which a 2-fold lower level of neutral red dye uptake (relative to the average levels in untreated cultures) is observed.
- a first set of embodiments P1-P7 follows.
- B Nuc is a naturally occurring purine or pyrimidine base, or analog thereof;
- L is a lipophilic promoiety, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, or O-substituted glyceryl having the formula —CH 2 CH(OR 1 )—CH 2 (OR 2 ) (II), wherein R 1 and R 2 are independently substituted or unsubstituted alkyl, or substituted or unsubstituted aryl;
- R is substituted or unsubstituted lower alkyl, substituted or unsubstituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, substituted or unsubstituted lower heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted lower heteroaryl;
- X is hydrogen, substituted or unsubstituted lower alkyl, substituted or un
- a method of treating a viral disease in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a compound of embodiment P1.
- a method for treating cancer in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a compound of embodiment P1.
- a method of killing or inhibiting the growth of a transformed cell comprising contacting a transformed cell with a therapeutically effective amount of a compound of embodiment P1.
- a method for treating a proliferative disorder in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a compound of embodiment P1.
- a pharmaceutical composition comprising a compound according to embodiment P1, and pharmaceutically acceptable excipient.
- B Nuc is a naturally occurring purine or pyrimidine base, or analog thereof;
- L is a lipophilic promoiety, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, or O-substituted glyceryl having the formula —CH 2 CH(OR 1 )—CH 2 (OR 2 ) (II), wherein R 1 and R 2 are independently substituted or unsubstituted alkyl, or substituted or unsubstituted aryl;
- R is substituted or unsubstituted lower alkyl, substituted or unsubstituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, substituted or unsubstituted lower heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted lower heteroaryl;
- X is hydrogen, substituted or unsubstituted lower alkyl, or substituted or
- B Nuc(a) is a naturally occurring purine, a naturally occurring pyrimidine, a non-naturally occurring purine or a non-naturally occurring pyrimidine
- L a is an unsubstituted C 12-24 alkyl, an unsubstituted C 13-29 heteroalkyl or a substituted glyceryl moiety, wherein the glyceryl moiety is substituted with one or more groups selected from an unsubstituted C 13-29 alkyl, an unsubstituted C 13-29 heteroalkyl, a substituted or unsubstituted aryl(C 1-6 alkyl), a substituted or unsubstituted heteroaryl(C 1-6 alkyl) and a substituted or unsubstituted heterocycloalkyl(C 1-6 alkyl);
- R a is selected from the group consisting of an unsubstituted C 1-6 alkyl, a substituted or unsubstituted aryl
- L a has the structure —(CH 2 )—CH(OR a1 )—(CH 2 )—O(CH 2 ) 11-21 —CH 3 , wherein R a1 is a substituted or unsubstituted aryl(C 1-6 alkyl), a substituted or unsubstituted heteroaryl(C 1-6 alkyl) and a substituted or unsubstituted heterocycloalkyl(C 1-6 alkyl).
- R a is a substituted or unsubstituted aryl(C 1-6 alkyl).
- R a is a substituted or unsubstituted heterocycloalkyl(C 1-6 alkyl).
- a pharmaceutical composition including an effective amount of a compound of any one of embodiments 1-32, or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof, and a pharmaceutically acceptable excipient.
- composition of embodiment 33 wherein the pharmaceutical composition is in the form of a cream, a gel or an ointment.
- composition of embodiment 33 or 34, wherein the pharmaceutical composition is a topical formulation.
- a compound of any one of embodiments 1-32, or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof, in the preparation of a medicament for treating a viral disease in a subject wherein the viral disease is selected from the group consisting of human papilloma virus, HIV, hepatitis B virus, hepatitis C virus, variola virus, vaccinia virus, an adenovirus, a cytomegalovirus, herpes simplex virus 1, herpes simplex virus 2, Epstein Barr virus, BK virus, JC virus, feline leukemia virus and feline immunodeficiency virus.
- embodiment 36 wherein said virus is human papilloma virus.
- embodiment 37 said compound, or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof, for use in treating a plurality of types of human papilloma virus.
- embodiment 37 wherein the human papilloma virus is selected from the group consisting human papilloma virus type 11, type 16 and type 18.
- a compound of any one of embodiments 1-32, or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof, in the preparation of a medicament for inhibiting growth of a cell transformed by a virus wherein the virus is selected from the group consisting of human papilloma virus, HIV, hepatitis B virus, hepatitis C virus, variola virus, vaccinia virus, an adenovirus, a cytomegalovirus, herpes simplex virus 1, herpes simplex virus 2, Epstein Barr virus, BK virus, JC virus, feline leukemia virus and feline immunodeficiency virus.
- the compound of embodiment 43 or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof, for use in treating a plurality of types of human papilloma virus.
- the compound of embodiment 43, wherein the human papilloma virus is selected from the group consisting human papilloma virus type 11, type 16 and type 18.
- the virus is selected from the group consisting of human papilloma virus, HIV, hepatitis B virus, hepatitis C virus, variola virus, vaccinia virus, an adenovirus, a cytomegalovirus, herpes simplex virus 1, herpes simplex virus 2, Epstein Barr virus, BK virus, JC virus, feline leukemia virus
- B Nuc(a) is a naturally occurring purine, a naturally occurring pyrimidine, a non-naturally occurring purine or a non-naturally occurring pyrimidine
- L a is an unsubstituted C 12-24 alkyl, an unsubstituted C 13-29 heteroalkyl or a substituted glyceryl moiety, wherein the glyceryl moiety is substituted with one or more groups selected from an unsubstituted C 13-29 alkyl, an unsubstituted C 13-29 heteroalkyl, a substituted or unsubstituted aryl(C 1-6 alkyl), a substituted or unsubstituted heteroaryl(C 1-6 alkyl) and a substituted or unsubstituted heterocycloalkyl(C 1-6 alkyl);
- R a is selected from the group consisting of an unsubstituted C 1-6 alkyl, a substituted or unsubstituted aryl
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present disclosure relates, inter alia, to compositions and methods for treating viral diseases and cancer. There are disclosed lipophilic antiviral and anticancer acyclic nucleoside phosphonate diesters, preparation thereof, and methods of using the compounds to treat viral diseases and cancer.
Description
- This application is continuation of U.S. application Ser. No. 16/111,378 filed Aug. 24, 2018, which is a continuation of U.S. application Ser. No. 15/809,400 filed Nov. 10, 2017, Issued as U.S. Pat. No. 10,076,533, which is a continuation of U.S. application Ser. No. 15/617,841 filed Jun. 8, 2017, issued as U.S. Pat. No. 10,076,532, which is a continuation of U.S. application Ser. No. 15/179,209 filed Jun. 10, 2016, issued as U.S. Pat. No. 9,775,852, which is a continuation of U.S. application Ser. No. 14/874,027 filed Oct. 2, 2015, issued as U.S. Pat. No. 9,387,217, which is a continuation of U.S. application Ser. No. 14/463,908 filed Aug. 20, 2014, issued as U.S. Pat. No. 9,156,867, which is a continuation of U.S. application Ser. No. 14/211,235 filed Mar. 14, 2014, issued as U.S. Pat. No. 8,835,630, which claims the benefit of priority to U.S. Application No. 61/793,993 filed Mar. 15, 2013, the content of each of which is incorporated herein by reference in its entirety and for all purposes.
- This invention was made with government support under grant numbers AI071803, AI074057 and EY07366 awarded by the National Institutes of Health. The government has certain rights in the invention.
- The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Sep. 6, 2019, is named 24978_0517_SL.txt and is 2,042 bytes in size.
- The present disclosure relates, inter alia, to compositions and methods for treating viral diseases and cancer. In one aspect it relates to lipophilic antiviral and anticancer acyclic nucleoside phosphonate diesters, preparation thereof, and methods of using the compounds to treat viral diseases and cancer.
- Viruses are infectious particles that can replicate their DNA and RNA only within host cells. Viral infections may lead to mild or severe illnesses in humans and mammals. Examples of viral infections include hepatitis B and C, smallpox, herpes simplex, cytomegalovirus, human immunodeficiency virus (HIV), influenza, adenovirus, chickenpox, BK virus, JC virus and precancerous lesions caused by infections with the human papillomavirus (cervical intraepithelial neoplasia, vaginal and anal intraepithelial neoplasia). Viral infection may also lead to cancer in humans and other species. Viruses known to cause cancer include but are not limited to human papilloma virus (HPV), hepatitis B virus (HBV), hepatitis C virus (HCV), HIV and Epstein Barr virus (EBV). Vaccination has been successful in preventing infection from many viruses. Antiviral agents are known that interfere with viral DNA or RNA synthesis and viral replication and are used to prevent or treat viral infections in mammals and humans. For example, combinations of antiviral drugs are used to treat AIDS, hepatitis B, hepatitis C, herpes simplex viruses, cytomegalovirus and influenza. Despite these successes, viral diseases remain an important public health problem and improved antiviral agents and anticancer agents are needed. For example, there is presently no approved antiviral treatment for human papillomavirus infections.
- Many antiviral drugs are nucleoside or nucleotide analogs. Examples of antiviral nucleoside analogs include azidothymidine, acyclovir, ganciclovir, lamivudine and emtricitabine. Acyclic nucleoside phosphonates (ANPs) are a class of nucleotide analogs and are effective antiviral agents. Adefovir, tenofovir and cidofovir (CDV) are ANPs that have been approved for clinical use against human infections with HBV, HIV and CMV, respectively.
- ANPs are known in the art not to be absorbed readily from the gastrointestinal tract of mammals because of their molecular weight and the presence of the double negative charge on the phosphonate. Because of their poor oral pharmacokinetic properties, ANPs are usually converted to prodrugs to produce clinically useful therapeutic agents. It has been demonstrated that masking one or both negative charges with promoieties improves the uptake and transport into the small intestinal enterocytes where the promoiety is cleaved, releasing the ANP into the circulation; examples include tenofovir disoproxil fumarate and adefovir dipivoxil. Another approach is to prepare alkoxyalkyl or alkyl monoesters of ANPs to increase oral bioavailability of the drug. With the alkoxyalkyl ANP monoester approach, side effects may occur when non-targeted tissues such as the small intestine are overexposed. For example, in enterocytes, enzymatic cleavage of the promoiety by a phospholipase C or an acid sphingomyelinase to the ANP may result in local toxicity because of further anabolic phosphorylation to the ANP diphosphate which may inhibit enterocyte DNA synthesis. Lipophilic ANP diester compounds are anticipated to undergo less cleavage from intact prodrug to ANP in the small intestine enterocytes following oral administration reducing GI side effects and releasing more drug substance into the circulation and producing higher levels of the drug substance in the blood.
- ANPs or their alkyl or alkoxyalkyl monoesters may exhibit limited uptake in certain target tissues such as the central nervous system. An additional advantage of nucleoside phosphonate diesters is the masking of the remaining negative charge on the phosphonate oxygen with a second masking group which can increase penetration of the drug substance into the central nervous system (CNS) for treatment of CNS viral infections (for example, HIV or JC virus) or for treatment of brain cancers such as glioblastoma. Cancer cells rapidly synthesize DNA and undergo uncontrolled cell division. The lipophilic acyclic nucleoside phosphonate (ANP) diester compositions described herein can be metabolized to their diphosphates which inhibit or block DNA synthesis and cell division in target cancer cells, leading to cell death while having substantially lesser effects on non-malignant cells. Exposure of various types of cancer cells to acyclic nucleoside phosphonates diesters may result in much greater cytotoxicity than that observed in normal non-malignant cells. For example, leukemias, lymphomas, brain neoplasms such as glioblastoma and cervical cancer cells may be more susceptible to the cytotoxic effects when exposed to lipophilic ANP diesters than the corresponding non-malignant cell lines. Lipophilic acyclic nucleoside phosphonate diesters exhibit more selective toxicity, improved access to the central nervous system and effective topical uptake for treatment of skin cancers, viral skin infections, cervical intraepithelial neoplasia (CIN), vaginal and anal intraepithelial dysplasia, venereal warts and related infections caused by the human papillomavirus when compared to acyclic nucleoside phosphonate monoester compositions.
- Compounds disclosed herein having both ANP phosphonate negative charges masked with functional groups provide for more effective use as topical agents for treatment of skin cancers and viral infections. In particular, compounds disclosed herein provide for efficacious treatment for infections of the cervical, vaginal, rectal and penile epithelium with the human papilloma virus including the high risk subtypes such as 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82 which are associated with cervical, rectal, penile and vaginal cancer and venereal warts.
- In a first aspect, there is provided a compound with structure of Formula (I),
- or stereoisomer, salt, hydrate, solvate, or crystalline form thereof. Regarding Formula (I), L is a lipophilic promoiety, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, or O-substituted glyceryl having the formula —CH2CH(OR1)—CH2(OR2) (II), wherein R1 and R2 are independently substituted or unsubstituted alkyl or substituted or unsubstituted aryl. R is substituted or unsubstituted lower alkyl, substituted or unsubstituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, substituted or unsubstituted lower heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted lower heteroaryl. X is hydrogen, substituted or unsubstituted lower alkyl, or substituted or unsubstituted lower heteroalkyl.
- In another aspect, there is provided a method of treating a viral disease in a subject, including administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I).
- In another aspect, there is provided a method for treating cancer in a subject, including administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I).
- In another aspect, there is provided a method for killing or inhibiting the growth of a transformed cell, including contacting a transformed cell with a therapeutically effective amount of a compound of Formula (I).
- In another aspect, there is provided a method for treating a proliferative disorder in a subject, including administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I).
- In another aspect, there is provided a pharmaceutical composition which includes a compound according to Formula (I), and a pharmaceutically acceptable excipient.
- In another aspect, there is provided a method for synthesis of a compound with structure of Formula (I) according to Scheme 2 disclosed herein. The method includes contacting a protected nucleoside BNuc with structure of Formula (2-1) with an ester with structure of Formula (2-2) in the presence of a strong base under conditions suitable to afford a monoester with structure of Formula (2-3); and reacting the afforded monoester with L-OH in the presence of a coupling agent, thereby synthesizing a compound with structure of Formula (I).
- In another aspect, there is provided a compound of Formula (Ia), or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof:
- For Formula (Ia), BNuc(a) can be a naturally occurring purine, a naturally occurring pyrimidine, a non-naturally occurring purine or a non-naturally occurring pyrimidine; La can be an unsubstituted C12-24 alkyl, an unsubstituted C13-29 heteroalkyl or a substituted glyceryl moiety, wherein the glyceryl moiety can be substituted with one or more groups selected from an unsubstituted C13-29 alkyl, an unsubstituted C13-29 heteroalkyl, a substituted or unsubstituted aryl(C1-6 alkyl), a substituted or unsubstituted heteroaryl(C1-6 alkyl) and a substituted or unsubstituted heterocycloalkyl(C1-6 alkyl); Ra can be selected from an unsubstituted C1-6 alkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aryl(C1-6 alkyl), a substituted or unsubstituted heteroaryl(C1-6 alkyl) and a substituted or unsubstituted heterocycloalkyl(C1-6 alkyl); and Xa can be hydrogen, an unsubstituted C1-6 alkyl, a halogen substituted C1-6 alkyl, a hydroxy substituted C1-6 alkyl or an unsubstituted C1-6 alkoxy.
- In another aspect, there is provided a pharmaceutical composition that can include an effective amount of a compound as disclosed herein (for example, a compound of Formula (Ia)), or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof, and a pharmaceutically acceptable excipient.
- In another aspect, there is provided a compound as disclosed herein (for example, a compound of Formula (Ia)), or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof, for use in treating a viral disease in a subject, wherein the viral disease can be selected from human papilloma virus, HIV, hepatitis B virus, hepatitis C virus, variola virus, vaccinia virus, an adenovirus, a cytomegalovirus, herpes simplex virus 1, herpes simplex virus 2, Epstein Barr virus, BK virus, JC virus, feline leukemia virus and feline immunodeficiency virus.
- In another aspect, there is provided a compound as disclosed herein (for example, a compound of Formula (Ia)), or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof, for use in treating cancer of the cervix in a subject.
- In another aspect, there is provided a compound as disclosed herein, or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof, for use in inhibiting growth of a cell transformed by a virus, wherein the virus can be selected from human papilloma virus, HIV, hepatitis B virus, hepatitis C virus, variola virus, vaccinia virus, an adenovirus, a cytomegalovirus, herpes simplex virus 1, herpes simplex virus 2, Epstein Barr virus, BK virus, JC virus, feline leukemia virus and feline immunodeficiency virus.
- In another aspect, there is provided a compound as disclosed herein (for example, a compound of Formula (Ia)), or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof, in the preparation of a medicament for treating a viral disease in a subject, wherein the viral disease can be selected from human papilloma virus, HIV, hepatitis B virus, hepatitis C virus, variola virus, vaccinia virus, an adenovirus, a cytomegalovirus, herpes simplex virus 1, herpes simplex virus 2, Epstein Barr virus, BK virus, JC virus, feline leukemia virus and feline immunodeficiency virus.
- In another aspect, there is provided use of a compound as disclosed herein (for example, a compound of Formula (Ia)), or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof, in the preparation of a medicament for treating cancer of the cervix in a subject.
- In another aspect, there is provided use of a compound as disclosed herein (for example, a compound of Formula (Ia)), or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof, in the preparation of a medicament for inhibiting growth of a cell transformed by a virus, wherein the virus can be selected from human papilloma virus, HIV, hepatitis B virus, hepatitis C virus, variola virus, vaccinia virus, an adenovirus, a cytomegalovirus, herpes simplex virus 1, herpes simplex virus 2, Epstein Barr virus, BK virus, JC virus, feline leukemia virus and feline immunodeficiency virus.
- In another aspect, there is provided a method of synthesis of a compound with structure of Formula (Ia).
- The FIGURE provides a chromatogram of compound 1a (fast-eluting) and compound 1b (slow eluting), as described in Example 2. X-axis: time (min); Y-axis (milli-absorption units, mAu). Solvent: 50:50:0.1 Water:Acetonitrile:TFA.
- The abbreviations used herein have their conventional meaning within the chemical and biological arts. The chemical structures and formulae set forth herein are constructed according to the standard rules of chemical valency known in the chemical arts.
- Where substituent groups are specified by their conventional chemical formulae, written from left to right, they equally encompass the chemically identical substituents that would result from writing the structure from right to left, e.g., —CH2O— is equivalent to —OCH2—.
- As used herein, the term “alkyl,” by itself or as part of another substituent, means, unless otherwise stated, and includes a straight (i.e., unbranched) or branched chain, or combination thereof, which may be fully saturated, mono- or polyunsaturated and can include di- and multivalent radicals, having the number of carbon atoms designated (i.e., C1-C10 means one to ten carbons). Alkyl is an uncyclized chain. Examples of saturated hydrocarbon radicals include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, (cyclohexyl)methyl, homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like.
- An unsaturated alkyl group is one having one or more double bonds (an “alkenyl group”) or triple bonds (an “alkynyl group”). Examples of unsaturated alkyl groups include, but are not limited to, the alkenyl groups vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), and the alkynyl groups ethynyl, 1- and 3-propynyl, 3-butynyl, and the higher homologs and isomers.
- An alkoxy is an alkyl attached to the remainder of the molecule via an oxygen linker (—O—).
- The term “alkylene,” by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkyl, as exemplified, but not limited by, —CH2CH2CH2CH2—. Typically, an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, or 10 or fewer carbon atoms. A “lower alkyl” or “lower alkylene” is a shorter chain alkyl or alkylene group, generally having eight or fewer carbon atoms.
- The term “heteroalkyl,” by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or combinations thereof, consisting of at least one carbon atom and at least one heteroatom selected from the group consisting of O, N, P, Si, and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized. The heteroatom(s) O, N, P, S, and Si may be placed at any interior position of the heteroalkyl group or at the position at which the alkyl group is attached to the remainder of the molecule. Heteroalkyl is an uncyclized chain. Examples include, but are not limited to: —CH2—CH2—O—CH3, —CH2—CH2—NH—CH3, —CH2—CH2—N(CH3)—CH3, —CH2—S—CH2—CH3, —CH2—CH2, —S(O)—CH3, —CH2—CH2—S(O)2—CH3, —CH═CH—O—CH3, —Si(CH3)3, —CH2—CH═N—OCH3, —CH═CH—N(CH3)—CH3, —O—CH3, —O—CH2—CH3, and —CN. Up to two heteroatoms may be consecutive, such as, for example, —CH2—NH—OCH3.
- Similarly, the term “heteroalkylene,” by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from heteroalkyl, as exemplified, but not limited by, —CH2—CH2—S—CH2—CH2— and —CH2—S—CH2—CH2—NH—CH2—. For heteroalkylene groups, heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, and the like). Still further, for alkylene and heteroalkylene linking groups, no orientation of the linking group is implied by the direction in which the formula of the linking group is written. For example, the formula —C(O)2R′— represents both —C(O)2R′— and —R′C(O)2—.
- As described above, heteroalkyl groups, as used herein, include those groups that are attached to the remainder of the molecule through a heteroatom, such as —NR′R″, —OR′, —SR′, and/or —SO2R′. Where “heteroalkyl” is recited, followed by recitations of specific heteroalkyl groups, such as —NR′R″ or the like, it will be understood that the terms heteroalkyl and —NR′R″ are not redundant or mutually exclusive. Rather, the specific heteroalkyl groups are recited to add clarity. Thus, the term “heteroalkyl” should not be interpreted herein as excluding specific heteroalkyl groups, such as —NR′R″ or the like.
- The terms “cycloalkyl” and “heterocycloalkyl,” by themselves or in combination with other terms, mean, unless otherwise stated, cyclic versions of “alkyl” and “heteroalkyl,” respectively. Cycloalkyl and heteroalkyl are not aromatic. Additionally, for heterocycloalkyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like. Examples of heterocycloalkyl include, but are not limited to, 1-(1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl, and the like.
- A “cycloalkylene” and a “heterocycloalkylene,” alone or as part of another substituent, means a divalent radical derived from a cycloalkyl and heterocycloalkyl, respectively.
- The terms “halo” or “halogen,” by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom. Additionally, terms such as “haloalkyl” are meant to include monohaloalkyl and polyhaloalkyl. For example, the term “halo(C1-C4)alkyl” includes, but is not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.
- The term “acyl” means, unless otherwise stated, —C(O)R* where R* is a substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
- The term “aryl” means, unless otherwise stated, a polyunsaturated, aromatic, hydrocarbon substituent, which can be a single ring or multiple rings (preferably from 1 to 3 rings) that are fused together (i.e., a fused ring aryl) or linked covalently. A fused ring aryl refers to multiple rings fused together wherein at least one of the fused rings is an aryl ring.
- The term “heteroaryl” refers to aryl groups (or rings) that contain from one to four heteroatoms selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized. Thus, the term “heteroaryl” includes fused ring heteroaryl groups (i.e., multiple rings fused together wherein at least one of the fused rings is a heteroaromatic ring). A 5,6-fused ring heteroarylene refers to two rings fused together, wherein one ring has 5 members and the other ring has 6 members, and wherein at least one ring is a heteroaryl ring. Likewise, a 6,6-fused ring heteroarylene refers to two rings fused together, wherein one ring has 6 members and the other ring has 6 members, and wherein at least one ring is a heteroaryl ring. And a 6,5-fused ring heteroarylene refers to two rings fused together, wherein one ring has 6 members and the other ring has 5 members, and wherein at least one ring is a heteroaryl ring. A heteroaryl group can be attached to the remainder of the molecule through a carbon or heteroatom. Non-limiting examples of aryl and heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinolyl, 5-isoquinolyl, 2-quinoxalinyl, 5-quinoxalinyl, 3-quinolyl, and 6-quinolyl. Substituents for each of the above noted aryl and heteroaryl ring systems are selected from the group of acceptable substituents described below. An “arylene” and a “heteroarylene,” alone or as part of another substituent, mean a divalent radical derived from an aryl and heteroaryl, respectively.
- For brevity, the term “aryl” when used in combination with other terms (e.g., aryloxy, arylthioxy, arylalkyl) includes both aryl and heteroaryl rings as defined above. Thus, the term “arylalkyl” [e.g., aryl(C1-6 alkyl)] is meant to include those radicals in which an aryl group is attached to an alkyl group (e.g., benzyl (Bn), phenethyl, pyridylmethyl, and the like) including those alkyl groups in which a carbon atom (e.g., a methylene group) has been replaced by, for example, an oxygen atom (e.g., phenoxymethyl, 2-pyridyloxymethyl, 3-(1-naphthyloxy)propyl, and the like). Thus, the term “heteroarylalkyl” [e.g., heteroaryl(C1-6 alkyl)] refers to those radicals in which a heteroaryl group is attached to an alkyl group. The term “heterocycloalkylalkyl” [e.g., heterocycloalkyl(C1-6 alkyl)] refers to those radicals in which a heterocycloalkyl is attached to an alkyl group.
- The term “oxo,” as used herein, means an oxygen that is double bonded to a carbon atom.
- The term “alkylsulfonyl,” as used herein, means a moiety having the formula —S(O2)—R′, where R′ is an alkyl group as defined above. R′ may have a specified number of carbons (e.g., “C1-C4 alkylsulfonyl”).
- Each of the above terms (e.g., “alkyl,” “heteroalkyl,” “aryl,” and “heteroaryl”) includes both substituted and unsubstituted forms of the indicated radical. Preferred substituents for each type of radical are provided below.
- Substituents for the alkyl and heteroalkyl radicals (including those groups often referred to as alkylene, alkenyl, heteroalkylene, heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl) can be one or more of a variety of groups selected from, but not limited to, —OR′, ═O, ═NR′, ═N—OR′, —NR′R″, —SR′, -halogen, —SiR′R″R′″, —OC(O)R′, —C(O)R′, —CO2R′, —CONR′R″, —OC(O)NR′R″, —NR″C(O)R′, —NR′—C(O)NR″R′″, —NR″C(O)2R′, —NR—C(NR′R″R′″)═NR″″, —NR—C(NR′R″)═NR′″, —S(O)R′, —S(O)2R′, —S(O)2NR′R″, —NRSO2R′, —CN, and —NO2 in a number ranging from zero to (2m′+1), where m′ is the total number of carbon atoms in such radical. R′, R″, R′″, and R″″ each preferably independently refer to hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl (e.g., aryl substituted with 1-3 halogens), substituted or unsubstituted alkyl, alkoxy, or thioalkoxy groups, or arylalkyl groups. When a compound includes more than one R group, for example, each of the R groups is independently selected as are each R′, R″, R′″, and R″″ group when more than one of these groups is present. When R′ and R″ are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 4-, 5-, 6-, or 7-membered ring. For example, —NR′R″ includes, but is not limited to, 1-pyrrolidinyl and 4-morpholinyl. From the above discussion of substituents, one of skill in the art will understand that the term “substituted alkyl” is meant to include groups including carbon atoms bound to groups other than hydrogen groups, such as haloalkyl (e.g., —CF3 and —CH2CF3) and acyl (e.g., —C(O)CH3, —C(O)CF3, —C(O)CH2OCH3, and the like).
- Similar to the substituents described for the alkyl radical, substituents for the aryl and heteroaryl groups are varied and are selected from, for example: —OR′, —NR′R″, —SR′, -halogen, —SiR′R″R′″, —OC(O)R′, —C(O)R′, —CO2R′, —CONR′R″, —OC(O)NR′R″, —NR″C(O)R′, —NR′—C(O)NR″R′″, —NR″C(O)2R′, —NR—C(NR′R″R′″)═NR″″, —NR—C(NR′R″)═NR′″, —S(O)R′, —S(O)2R′, —S(O)2NR′R″, —NRSO2R′, —CN, —NO2, —R′, —N3, —CH(Ph)2, fluoro(C1-C4)alkoxy, and fluoro(C1-C4)alkyl, in a number ranging from zero to the total number of open valences on the aromatic ring system; and where R′, R″, R′″, and R″″ are preferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. When a compound includes more than one R group, for example, each of the R groups is independently selected as are each R′, R″, R′″, and R″″ groups when more than one of these groups is present.
- Two or more substituents may optionally be joined to form aryl, heteroaryl, cycloalkyl, or heterocycloalkyl groups. Such so-called ring-forming substituents are typically, though not necessarily, found attached to a cyclic base structure. In embodiments, the ring-forming substituents are attached to adjacent members of the base structure. For example, two ring-forming substituents attached to adjacent members of a cyclic base structure create a fused ring structure. In another embodiment, the ring-forming substituents are attached to a single member of the base structure. For example, two ring-forming substituents attached to a single member of a cyclic base structure create a spirocyclic structure. In yet another embodiment, the ring-forming substituents are attached to non-adjacent members of the base structure.
- Two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally form a ring of the formula -T-C(O)—(CRR′)q—U—, wherein T and U are independently —NR—, —O—, —CRR′—, or a single bond, and q is an integer of from 0 to 3. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -A-(CH2)r-B—, wherein A and B are independently —CRR′—, —O—, —NR—, —S—, —S(O)—, —S(O)2—, —S(O)2NR′—, or a single bond, and r is an integer of from 1 to 4. One of the single bonds of the new ring so formed may optionally be replaced with a double bond. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula —(CRR′)s—X′— (C″R′″)d—, where s and d are independently integers of from 0 to 3, and X′ is —O—, —NR′—, —S—, —S(O)—, —S(O)2—, or —S(O)2NR′—. The substituents R, R′, R″, and R′″ are preferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
- As used herein, the terms “heteroatom” or “ring heteroatom” are meant to include oxygen (O), nitrogen (N), sulfur (S), phosphorus (P), and silicon (Si).
- A “substituent group,” as used herein, means a group selected from the following moieties:
-
- (A) —OH, —NH2, —SH, —CN, —CF3, —NO2, oxo, halogen, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, and
- (B) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, substituted with at least one substituent selected from:
- (i) oxo, —OH, —NH2, —SH, —CN, —CF3, —NO2, halogen, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, and
- (ii) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, substituted with at least one substituent selected from:
- (a) oxo, —OH, —NH2, —SH, —CN, —CF3, —NO2, halogen, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, and
- (b) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, substituted with at least one substituent selected from: oxo, —OH, —NH2, —SH, —CN, —CF3, —NO2, halogen, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, and unsubstituted heteroaryl.
- A “size-limited substituent” or “size-limited substituent group,” as used herein, means a group selected from all of the substituents described above for a “substituent group,” wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted C1-C29 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 30 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C3-C8 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 8 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted C6-C10 aryl, and each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 10 membered heteroaryl.
- A “lower substituent” or “lower substituent group,” as used herein, means a group selected from all of the substituents described above for a “substituent group,” wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted C1-C8 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 8 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C3-C7 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 7 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted C6-C10 aryl, and each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 9 membered heteroaryl.
- In embodiments, each substituted group described in the compounds herein is substituted with at least one substituent group. More specifically, in embodiments, each substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene described in the compounds herein are substituted with at least one substituent group. In embodiments, at least one or all of these groups are substituted with at least one size-limited substituent group. In embodiments, at least one or all of these groups are substituted with at least one lower substituent group.
- In embodiments of the compounds herein, each substituted or unsubstituted alkyl may be a substituted or unsubstituted C1-C30 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 30 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C3-C8 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 8 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted C6-C10 aryl, and/or each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 10 membered heteroaryl. In embodiments of the compounds herein, each substituted or unsubstituted alkylene is a substituted or unsubstituted C1-C30 alkylene, each substituted or unsubstituted heteroalkylene is a substituted or unsubstituted 2 to 30 membered heteroalkylene, each substituted or unsubstituted cycloalkylene is a substituted or unsubstituted C3-C8 cycloalkylene, each substituted or unsubstituted heterocycloalkylene is a substituted or unsubstituted 3 to 8 membered heterocycloalkylene, each substituted or unsubstituted arylene is a substituted or unsubstituted C6-C10 arylene, and/or each substituted or unsubstituted heteroarylene is a substituted or unsubstituted 5 to 10 membered heteroarylene.
- In embodiments, each substituted or unsubstituted alkyl is a substituted or unsubstituted C1-C8 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 8 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C3-C7 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 7 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted C6-C10 aryl, and/or each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 9 membered heteroaryl. In some embodiments, each substituted or unsubstituted alkylene is a substituted or unsubstituted C1-C8 alkylene, each substituted or unsubstituted heteroalkylene is a substituted or unsubstituted 2 to 8 membered heteroalkylene, each substituted or unsubstituted cycloalkylene is a substituted or unsubstituted C3-C7 cycloalkylene, each substituted or unsubstituted heterocycloalkylene is a substituted or unsubstituted 3 to 7 membered heterocycloalkylene, each substituted or unsubstituted arylene is a substituted or unsubstituted C6-C10 arylene, and/or each substituted or unsubstituted heteroarylene is a substituted or unsubstituted 5 to 9 membered heteroarylene.
- The term “pharmaceutically acceptable salts” is meant to include salts of the active compounds that are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein. When compounds described herein contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt. When compounds described herein contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, oxalic, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge et al., “Pharmaceutical Salts”, Journal of Pharmaceutical Science, 1977, 66:1-19). Certain specific compounds described herein contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.
- Thus, the compounds described herein [for example, a compound of Formula (I) and/or a compound of Formula (Ia)] may exist as salts, such as with pharmaceutically acceptable acids. Examples of such salts include hydrochlorides, hydrobromides, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, tartrates (e.g., (+)-tartrates, (−)-tartrates, or mixtures thereof including racemic mixtures), succinates, benzoates, and salts with amino acids such as glutamic acid. These salts may be prepared by methods known to those skilled in the art.
- The neutral forms of the compounds can be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents.
- In addition to salt forms, compounds described herein [for example, a compound of Formula (I) and/or a compound of Formula (Ia)] can be in a prodrug form. Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide a compound described herein. Additionally, prodrugs can be converted to a compounds described herein by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to a compounds described herein when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent. The term “promoiety” is meant to refer to a chemical entity reversibly attached to the drug that improves an aspect of drug performance by masking a problematic functional group.
- Certain compounds described herein [for example, a compound of Formula (I) and/or a compound of Formula (Ia)] can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are encompassed. Certain compounds described herein [for example, a compound of Formula (I) and/or a compound of Formula (Ia)] may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated and are intended.
- Certain compounds described herein [for example, a compound of Formula (I) and/or a compound of Formula (Ia)] can possess asymmetric atoms (optical centers) or double bonds; the racemates, diastereomers, tautomers, geometric isomers, and individual isomers are encompassed. The compounds described herein [for example, a compound of Formula (I) and/or a compound of Formula (Ia)] do not include those that are known in the art to be too unstable to synthesize and/or isolate.
- The compounds described herein [for example, a compound of Formula (I) and/or a compound of Formula (Ia)] may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the compounds may be radiolabeled with radioactive isotopes, such as for example tritium (3H), iodine-125 (125I), or carbon-14 (14C). All isotopic variations of the compounds, whether radioactive or not, are encompassed.
-
- Compounds
- In a first aspect, there is provided a compound with structure of Formula (I):
- or stereoisomer, salt, hydrate, solvate, or crystalline form thereof. For the compound with structure of Formula (I), BNuc is a naturally occurring purine or pyrimidine base, or analog thereof; L is a lipophilic promoiety, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, or O-substituted glyceryl having the formula —CH2CH(OR1)—CH2(OR2) (II), wherein R1 and R2 are independently substituted or unsubstituted alkyl, or substituted or unsubstituted aryl; R is substituted or unsubstituted lower alkyl, substituted or unsubstituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, substituted or unsubstituted lower heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted lower heteroaryl; and X is hydrogen, substituted or unsubstituted lower alkyl, or substituted or unsubstituted lower heteroalkyl.
- In embodiments, the compound is a stereoisomer with the structure of Formula (I). In embodiments, the compound is a salt of a compound with the structure of Formula (I). In embodiments, the compound is a solvate of a compound with the structure of Formula (I). In embodiments, the compound is a crystalline form of a compound with the structure of Formula (I).
- The terms “naturally occurring purine or pyrimidine base” and the like refer, in the usual and customary sense as employed in the art, to purine or pyrimidine bases, e.g., guanine, adenine, cytosine, thymine, uracil, or 2,6-diaminopurine. Attachment of the naturally occurring purine or pyrimidine base can be at any available site, e.g., guanin-9-yl, adenine-9-yl, cytosine-1-yl, thymin-1-yl, uracil-1-yl, 2,6-diaminopurin-9-yl, and the like. When attached to the remainder of the compounds described herein, the naturally occurring purine or pyrimidine base is in monovalent from (the form of a chemical moiety or substituent as known in the art).
- The terms “analog of naturally occurring purine or pyrimidine base” and the like refer, in the usual and customary sense, to a chemical analog of a naturally occurring purine or pyrimidine base, as known in the art. When attached to the remainder of the compounds described herein, the analog of naturally occurring purine or pyrimidine base is in monovalent from (the form of a chemical moiety or substituent as known in the art).
- Accordingly, in embodiments, BNuc is a naturally occurring purine or pyrimidine base. In embodiments, BNuc is a naturally occurring purine base. In embodiments, BNuc is a naturally occurring pyrimidine base. In embodiments, BNuc is an analog of a naturally occurring purine or pyrimidine base. In embodiments, BNuc is an analog of a naturally occurring base. In embodiments, BNuc is an analog of a naturally occurring pyrimidine base.
- The terms “lipophilic promoiety” and the like refer to a chemical moiety which imparts increased lipophilicity when incorporated into a compound with structure of Formula (I). In embodiments, the lipophilic promoiety is a substituted or unsubstituted C8-24 alkyl. In embodiments, the lipophilic promoiety is a substituted or unsubstituted C8-24 heteroalkyl. In embodiments, the lipophilic promoiety is a substituted or unsubstituted C8-24 alkoxyalkyl. Exemplary lipophilic promoieties include glyceryl moieties having substituted or unsubstituted alkyl, and/or substituted or unsubstituted aryl substituents. In embodiments, substitution at a glyceryl moiety is via O-substitution with a substituted or unsubstituted alkyl, and/or via 0-substitution with a substituted or unsubstituted aryl. Thus, the lipophilic promoiety, L, imparts lipophilicity and therefore may include glyceryl ether linked compounds (e.g., 1-O-octadecyl-2-O-benzyl) wherein the hydrogens of the glyceryl hydroxyls are replaced with substituted or unsubstituted alkyl or substituted or unsubstituted aryl groups that do not impart hydrophilicity, and the carbons atoms of the glyceryl are not further substituted. In some embodiments, L is an O-substituted glyceryl having the formula —CH2CH(OR1)—CH2(OR2) (II), wherein R1 and R2 are independently a substituted or unsubstituted alkyl or a substituted or unsubstituted aryl.
- In some embodiments, L is a substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, or an O-substituted glyceryl having the formula —CH2CH(OR1)—CH2(OR2) (II), wherein R1 and R2 are independently a substituted or unsubstituted alkyl or a substituted or unsubstituted aryl. In embodiments, L is an O-substituted glyceryl. In one embodiment L is 1-O-alkyl-2-O-benzyl-sn-glyceryl. In embodiments, L is 1-O-octadecyl-2-O-benzyl-sn-glyceryl. In embodiments, L is an unsubstituted alkyl. In embodiments, L is a size-limited unsubstituted alkyl. In embodiments, L is C8-24 alkyl. In embodiments, L is an unsubstituted heteroalkyl. In embodiments, L is a size-limited unsubstituted heteroalkyl. In embodiments, L is C8-24 heteroalkyl. In embodiments, L is an unsubstituted alkoxyoalkyl. In embodiments, L is a size-limited unsubstituted alkoxyalkyl. In embodiments, L is C8-24 alkoxyalkyl.
- In embodiments, R is a substituted or unsubstituted lower alkyl, a substituted or unsubstituted lower heteroalkyl, a substituted or unsubstituted lower cycloalkyl, a substituted or unsubstituted lower heterocycloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted lower heteroaryl. In embodiments, R is a substituted or unsubstituted lower alkyl. In embodiments, R is a substituted or unsubstituted lower heteroalkyl. In embodiments, R is an O-substituted glyceryl having the formula —CH2CH(OR3)—CH2(OR4) (III), wherein R3 and R4 are independently a substituted or unsubstituted alkyl or a substituted or unsubstituted aryl. In embodiments, R is a substituted or unsubstituted lower cycloalkyl. In embodiments, R is a substituted or unsubstituted lower heterocycloalkyl. In embodiments, R is a substituted or unsubstituted hexopyranosyl. In embodiments, R is an unsubstituted hexopyranosyl. In embodiments, R is a substituted or unsubstituted aryl. In embodiments, R is a substituted or unsubstituted lower heteroaryl. In embodiments, R is an unsubstituted lower alkyl. In embodiments, R is an unsubstituted lower heteroalkyl. In embodiments, R is an unsubstituted lower cycloalkyl. In embodiments, R is an unsubstituted lower heterocycloalkyl. In embodiments, R is an unsubstituted aryl. In embodiments, R is an unsubstituted lower heteroaryl. In embodiments, R is a size-limited substituted or unsubstituted lower cycloalkyl. In embodiments, R is a size-limited substituted or unsubstituted lower heterocycloalkyl. In embodiments, R is a size-limited substituted or unsubstituted aryl. In embodiments, R is a size-limited substituted or unsubstituted lower heteroaryl. In embodiments, R is C1-s substituted or unsubstituted alkyl. In embodiments, R is C1-8s substituted or unsubstituted heteroalkyl. In embodiments, R is C4-8 substituted or unsubstituted cycloalkyl. In embodiments, R is C4-8 substituted or unsubstituted heterocycloalkyl. In embodiments, R is C6-10 substituted or unsubstituted aryl. In embodiments, R is C6-10 substituted or unsubstituted heteroaryl. In embodiments, R is C1-8 unsubstituted alkyl. In embodiments, R is C2-8 unsubstituted heteroalkyl. In embodiments, R is C4-8 unsubstituted cycloalkyl. In embodiments, R is C4-8 unsubstituted heterocycloalkyl. In embodiments, R is C6-10 unsubstituted aryl. In embodiments, R is C6-10 unsubstituted heteroaryl.
- In embodiments, R is a substituted or unsubstituted phenyl, a substituted or unsubstituted naphthyl, a substituted or unsubstituted benzyl, a substituted or unsubstituted glyceryl, or a substituted or unsubstituted hexopyranosyl. In embodiments, R is a substituted phenyl. In embodiments, R is a substituted naphthyl. In embodiments, R is a substituted benzyl. In embodiments, R is a substituted glyceryl. In embodiments, R is a substituted hexopyranosyl. In embodiments, R is an unsubstituted phenyl. In embodiments, R is an unsubstituted naphthyl. In embodiments, R is an unsubstituted benzyl. In embodiments, R is an unsubstituted glyceryl. In embodiments, R is an unsubstituted hexopyranosyl.
- In embodiments, X is hydrogen, a substituted or unsubstituted lower alkyl, or a substituted or unsubstituted lower heteroalkyl. In embodiments, X is hydrogen. In embodiments, X is a substituted or unsubstituted lower alkyl. In embodiments, X is a substituted or unsubstituted lower heteroalkyl. In embodiments, X is an unsubstituted lower alkyl. In embodiments, X is an unsubstituted lower heteroalkyl. In embodiments, X is a size-limited substituted or unsubstituted alkyl. In embodiments, X is a size-limited substituted or unsubstituted heteroalkyl. In embodiments, X is a size-limited unsubstituted alkyl. In embodiments, X is a size-limited unsubstituted heteroalkyl. In embodiments, X is methyl. In embodiments, X is methoxymethyl. In embodiments, X is hydroxymethyl. In embodiments, X is fluoromethyl.
- In embodiments, the compound with structure of Formula (I) has the structure of Formula (I-1):
- For the compound with structure of Formula (I-1), BNuc is as described for any of the embodiments of the compound of Formula (I) disclosed herein.
- In embodiments, L is as described for any of the embodiments of the compound of Formula (I) described herein. In embodiments, L is octadecyloxyethyl, hexadecyloxypropyl, or 1-O-octadecyl-2-O-benzyl-sn-glyceryl. In embodiments, L is octadecyloxyethyl. In embodiments, L is hexadecyloxypropyl. In embodiments, L is 1-O-octadecyl-2-O-benzyl-sn-glyceryl.
- In embodiments, R is as described for any of the embodiments of the compound of Formula (I) described herein. In embodiments, R is a substituted or unsubstituted phenyl, a substituted or unsubstituted naphthyl, a substituted or unsubstituted benzyl, a substituted or unsubstituted glyceryl, or a substituted or unsubstituted hexopyranosyl. In embodiments, R is a substituted phenyl. In embodiments, R is a substituted naphthyl. In embodiments, R is a substituted benzyl. In embodiments, R is a substituted glyceryl. In embodiments, R is a substituted hexopyranosyl. In embodiments, R is an unsubstituted phenyl. In embodiments, R is an unsubstituted naphthyl. In embodiments, R is an unsubstituted benzyl. In embodiments, R is an unsubstituted glyceryl. In embodiments, R is an unsubstituted hexopyranosyl.
- In embodiments, the compound with structure of Formula (I) has the structure of Formula (I-2):
- For the compound with structure of Formula (I-2), in one embodiment BNuc is as described for any of the embodiments of the compound of Formulae (I)-(I-1) disclosed herein.
- In embodiments, L is as described for any of the embodiments of the compound of Formulae (I)-(I-1) described herein.
- In embodiments, R is as described for any of the embodiments of the compound of Formulae (I)-(I-1) described herein.
- In embodiments, the compound with structure of Formula (I) has the structure of Formula (I-3):
- For the compound with structure of Formula (I-3), in one embodiment BNuc is as described for any of the embodiments of the compound of Formulae (I)-(I-2) disclosed herein.
- In embodiments, L is as described for any of the embodiments of the compound of Formulae (I)-(I-2) described herein.
- In embodiments, R is as described for any of the embodiments of the compound of Formulae (I)-(I-2) described herein.
- In embodiments, the compound with structure of Formula (I) has the structure of Formula (I-4):
- For the compound with structure of Formula (I-4), in one embodiment BNuc is as described for any of the embodiments of the compound of Formulae (I)-(I-3) disclosed herein.
- In embodiments, L is as described for any of the embodiments of the compound of Formulae (I)-(I-3) described herein.
- In embodiments, R is as described for any of the embodiments of the compound of Formulae (I)-(I-3) described herein.
- In embodiments, the compound with structure of Formula (I) has the structure of Formula (I-5):
- For the compound with structure of Formula (I-5), in one embodiment BNuc is as described for any of the embodiments of the compound of Formulae (I)-(I-4) disclosed herein.
- In embodiments, L is as described for any of the embodiments of the compound of Formulae (I)-(I-4) described herein.
- In embodiments, R is as described for any of the embodiments of the compound of Formulae (I)-(I-4) described herein.
- In another aspect, there is provided a compound of Formula (Ia), or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof:
- For this aspect, BNuc(a) can be a naturally occurring purine, a naturally occurring pyrimidine, a non-naturally occurring purine or a non-naturally occurring pyrimidine. La can be an unsubstituted C12-24 alkyl, an unsubstituted C13-29 heteroalkyl or a substituted glyceryl moiety. The glyceryl moiety may be substituted with one or more groups selected from an unsubstituted C13-29 alkyl, an unsubstituted C13-29 heteroalkyl, a substituted or unsubstituted aryl(C1-6 alkyl), a substituted or unsubstituted heteroaryl(C1-6 alkyl) and a substituted or unsubstituted heterocycloalkyl(C1-6 alkyl). Ra can be selected from an unsubstituted C1-6 alkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aryl(C1-6 alkyl), a substituted or unsubstituted heteroaryl(C1-6 alkyl) and a substituted or unsubstituted heterocycloalkyl(C1-6 alkyl). Xa can be hydrogen, an unsubstituted C1-6 alkyl, a halogen substituted C1-6 alkyl, a hydroxy substituted C1-6 alkyl or an unsubstituted C1-6 alkoxy.
- In embodiments, Xa can be hydrogen, an unsubstituted C1-6 alkyl, a halogen substituted C1-6 alkyl, a hydroxy substituted C1-6 alkyl or an unsubstituted C1-6 alkoxy. In embodiments, Xa can be hydrogen. In embodiments, Xa can be an unsubstituted C1-6 alkyl. In embodiments, Xa can be methyl. In embodiments, Xa can be a hydroxy substituted C1-6 alkyl. In embodiments, Xa can be —CH2OH. In embodiments, X can be an unsubstituted C1-6 alkoxy. In embodiments, Xa can be methoxy. In embodiments, Xa can be a halogen substituted C1-6 alkyl. In embodiments, Xa can be a fluoro substituted C1-6 alkyl. In embodiments, Xa can be —CH2F.
- Further to any embodiment above, in embodiments La can be an unsubstituted C13-29 heteroalkyl. In embodiments, La can have the structure —(CH2)1-6—O—(CH2)11-21—CH3. In embodiments, La can have the structure —(CH2)2—O—(CH2)17—CH3. In embodiments, La can have the structure —(CH2)3—O—(CH2)15—CH3. In embodiments, La can have the structure —(CH2)1-6—O—(CH2)10-20—(CHCH3)—CH3.
- Further to any embodiment above, in embodiments La can be a substituted glyceryl moiety. In embodiments, La can have the structure —(CH2)—CH(ORa1)—(CH2)—O(CH2)11-21—CH3, wherein Ra1 can be a substituted or unsubstituted aryl(C1-6 alkyl), a substituted or unsubstituted heteroaryl(C1-6 alkyl) or a substituted or unsubstituted heterocycloalkyl(C1-6 alkyl). In embodiment, Ra1 can be a substituted aryl(C1-6 alkyl). In embodiment, Ra1 can be an unsubstituted aryl(C1-6 alkyl). In embodiment, Ra1 can be a substituted heteroaryl(C1-6 alkyl). In embodiment, Ra1 can be an unsubstituted heteroaryl(C1-6 alkyl)). In embodiment, Ra1 can be a substituted heterocycloalkyl(C1-6 alkyl). In embodiment, Ra1 can be an unsubstituted heterocycloalkyl(C1-6 alkyl).
- In embodiments, La can have the structure
- Further to any embodiment of the compound of Formula (Ia), in embodiments Ra can be a substituted or unsubstituted aryl. In embodiments, the substituted aryl can be a substituted phenyl. In embodiments, the unsubstituted aryl can be an unsubstituted phenyl. In embodiments, the substituted aryl can be a substituted naphthyl. In embodiments, the unsubstituted aryl can be an unsubstituted naphthyl.
- Further to any embodiment of the compound of Formula (Ia), in embodiments Ra can be a substituted or unsubstituted aryl(C1-6 alkyl). In embodiments, the substituted aryl(C1-6 alkyl) can be a substituted benzyl. In embodiments, the unsubstituted aryl(C1-6 alkyl) can be an unsubstituted benzyl.
- Further to any embodiment of the compound of Formula (Ia), in embodiments Ra can be a substituted or unsubstituted heterocycloalkyl(C1-6 alkyl). In embodiments, the substituted or unsubstituted heterocycloalkyl(C1-6 alkyl) is a substituted or unsubstituted galactosyl.
- Further to any embodiment of the compound of Formula (Ia), in embodiments BNuc(a) can be a naturally occurring purine. In embodiments, BNuc(a) can be a naturally occurring pyrimidine. In embodiments, BNuc(a) can be a non-naturally occurring purine. In embodiments, BNuc(a) can be a non-naturally occurring pyrimidine. The term “non-naturally occurring” and the like, in the context of purine or pyrimidine nucleoside BNuc(a) groups, refers to moieties having a purine or pyrimidine core and additional chemical modifications not found in naturally occurring systems. Examples of purines include adenine, guanine, hypoxanthine, xanthine, theobromine, caffeine, uric acid, isoguanine, 2,6-diaminopurine. Examples of pyrimidines include cytosine, thymine, and uracil.
- In embodiments, BNuc(a) can be selected from:
- In embodiments, a compound of Formula (Ia) can have the structure:
- In embodiments, a compound of Formula (Ia) can have the structure:
- In embodiments, a compound of Formula (Ia) can have the structure:
- In embodiments, a compound of Formula (Ia) can have the structure:
- In embodiments, a compound of Formula (Ia) can have the structure:
- In embodiments, a compound of Formula (Ia) can have the structure:
- In embodiments, the compound can be selected from:
- or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form of any of the foregoing.
- As can be seen from Formulae (I) and (Ia), there are many embodiments. For example, there are disclosed embodiments directed to a compound of Formula (I) and a compound of Formula (Ia) based on the identity of the acyclic nucleoside phosphonate scaffold. This is not intended to be an explicit or implicit admission that the embodiments are independent or distinct nor should it be interpreted as such. Rather, it is intended to convey information so that the full breadth of Formulae (I) and (Ia) can be understood. Furthermore, the following embodiments, and aspects thereof, are not meant to be limiting on the full breadth of the structure of Formula (I) and/or the structure of Formula (Ia).
- Tables 1-10 following disclose structures contemplated herein. The structures of Tables 1-10 and are not intended to be limiting on the full breadth of the contemplated compounds represented by the structure of Formulae (I), (I-1), (I-2), (I-3), (I-4), (I-5) and (Ia). Moreover, it is contemplated that any one of the contemplated acyclic nucleoside phosphonate (ANP) scaffolds (PME-, (R)-PMP-, (S)-MPMP-, (S)-HPMP- and (S)-FPMP-) or their stereoisomers, can be used in combination with any of the contemplated combinations of naturally occurring or modified purine or pyrimidine base (BNuc/BNuc(a)), L/La and R/Ra. Additionally, as the phosphorus atom of the ANP diester is a potential chiral center, it is understood that Rp and Sp (i.e., Cahn-Ingold-Prelog nomenclature as known in the art) stereochemical configurations are possible. Therefore, the structures below include stereochemical configurations possible for phosphorus.
-
TABLE 1 Phosphonomethoxyethyl (PME) diester compounds Cmpd No. BNuc/BNuc(a) L/La R/Ra Name 1-(Rp, guanin-9-yl octadecyloxyethyl benzyl benzyl octadecyloxyethyl 9-(2- sp) phosphonomethoxyethyl)guanine 1a guanin-9-yl octadecyloxyethyl benzyl benzyl octadecyloxyethyl 9-(2- (fast) phosphonomethoxyethyl)guanine 1b guanin-9-yl octadecyloxyethyl benzyl benzyl octadecyloxyethyl 9-(2- (slow) phosphonomethoxyethyl)guanine 2 adenine-9-yl octadecyloxyethyl benzyl benzyl octadecyloxyethyl 9-(2- phosphonomethoxyethyl)adenine 3 cytosine-1-yl octadecyloxyethyl benzyl benzyl octadecyloxyethyl 1-(2- phosphonomethoxyethyl)cytosine 4 thymin-1-yl octadecyloxyethyl benzyl benzyl octadecyloxyethyl 1-(2- phosphonomethoxyethyl)thymine 5 uracil-1-yl octadecyloxyethyl benzyl benzyl octadecyloxyethyl 9-(2- phosphonomethoxyethyl)uracil 6 2,6- octadecyloxyethyl benzyl benzyl octadecyloxyethyl 9-(2- diaminopurin- phosphonomethoxyethyl)-2,6- 9-yl diaminopurine 7 guanin-7-yl hexadecyloxypropyl benzyl benzyl hexadecyloxypropyl 9-(2- phosphonomethoxyethyl)guanine 8 adenine-9-yl hexadecyloxypropyl benzyl benzyl hexadecyloxypropyl 9-(2- phosphonomethoxyethyl)adenine 9 cytosine-1-yl hexadecyloxypropyl benzyl benzyl hexadecyloxypropyl 1-(2- phosphonomethoxyethyl)cytosine 10 thymin-1-yl hexadecyloxypropyl benzyl benzyl hexadecyloxypropyl 1-(2- phosphonomethoxyethyl)thymine 11 uracil-1-yl hexadecyloxypropyl benzyl benzyl hexadecyloxypropyl 9-(2- phosphonomethoxyethyl)uracil 12 2,6- hexadecyloxypropyl benzyl benzyl hexadecyloxypropyl 9-(2- diaminopurin- phosphonomethoxyethyl)-2,6- 9-yl diaminopurine 13 guanin-9-yl 1-O-octadecyl-2-O- benzyl benzyl 1-O-octadecyl-2-O-benzyl- benzyl-sn glyceryl sn glyceryl 9-(2- phosphonomethoxyethyl)guanine 14 adenine-9-yl 1-O-octadecyl-2-O- benzyl benzyl 1-O-octadecyl-2-O-benzyl- benzyl-sn glyceryl sn glyceryl 9-(2- phosphonomethoxyethyl)adenine 15 cytosine-1-yl 1-O-octadecyl-2-O- benzyl benzyl 1-O-octadecyl-2-O-benzyl- benzyl-sn glyceryl sn glyceryl 1-(2- phosphonomethoxyethyl)cytosine 16 thymin-1-yl 1-O-octadecyl-2-O- benzyl benzyl 1-O-octadecyl-2-O-benzyl- benzyl-sn glyceryl sn glyceryl 1-(2-phosphonomethoxy- ethyl)thymine 17 uracil-1-yl 1-O-octadecyl-2-O- benzyl benzyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 9-(2-phosphonomethoxy- ethyl)uracil 18 2,6- 1-O-octadecyl-2-O- benzyl benzyl 1-O-octadecyl-2-O-benzyl-sn diaminopurin- benzyl-sn glyceryl glyceryl 9-(2-phosphonomethoxy- 9-yl ethyl)-2,6-diaminopurine 19 guanin-9-yl octadecyloxyethyl phenyl phenyl octadecyloxyethyl 9-(2- phosphonomethoxyethyl)guanine 20 adenine-9-yl octadecyloxyethyl phenyl phenyl octadecyloxyethyl 9-(2- phosphonomethoxyethyl)adenine 21 cytosine-1-yl octadecyloxyethyl phenyl phenyl octadecyloxyethyl 1-(2- phosphonomethoxyethyl)cytosine 22 thymin-1-yl octadecyloxyethyl phenyl phenyl octadecyloxyethyl 1-(2- phosphonomethoxyethyl)thymine 23 uracil-1-yl octadecyloxyethyl phenyl phenyl octadecyloxyethyl 9-(2- phosphonomethoxyethyl)uracil 24 2,6- octadecyloxyethyl phenyl phenyl octadecyloxyethyl 9-(2- diaminopurin- phosphonomethoxyethyl)-2,6- 9-yl diaminopurine 25 guanin-9-yl hexadecyloxypropyl phenyl phenyl hexadecyloxypropyl 9-(2- phosphonomethoxyethyl)guanine 26 adenine-9-yl hexadecyloxypropyl phenyl phenyl hexadecyloxypropyl 9-(2- phosphonomethoxyethyl)adenine 27 cytosine-1-yl hexadecyloxypropyl phenyl phenyl hexadecyloxypropyl 1-(2- phosphonomethoxyethyl)cytosine 28 thymin-1-yl hexadecyloxypropyl phenyl phenyl hexadecyloxypropyl 1-(2- phosphonomethoxyethyl)thymine 29 uracil-1-yl hexadecyloxypropyl phenyl phenyl hexadecyloxypropyl 9-(2- phosphonomethoxyethyl)uracil 30 2,6- hexadecyloxypropyl phenyl phenyl hexadecyloxypropyl 9-(2- diaminopurin- phosphonomethoxyethyl)-2,6- 9-yl diaminopurine 31 guanin-9-yl 1-O-octadecyl-2-O- phenyl phenyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 9-(2- phosphonomethoxyethyl)guanine 32 adenine-9-yl 1-O-octadecyl-2-O- phenyl phenyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 9-(2- phosphonomethoxyethyl)adenine 33 cytosine-1-yl 1-O-octadecyl-2-O- phenyl phenyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(2- phosphonomethoxyethyl)cytosine 34 thymin-1-yl 1-O-octadecyl-2-O- phenyl phenyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(2- phosphonomethoxyethyl)thymine 35 uracil-1-yl 1-O-octadecyl-2-O- phenyl phenyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 9-(2- phosphonomethoxyethyl)uracil 36 2,6- 1-O-octadecyl-2-O- phenyl phenyl 1-O-octadecyl-2-O-benzyl-sn diaminopurin- benzyl-sn glyceryl glyceryl 9-(2- 9-yl phosphonomethoxyethyl)-2,6- diaminopurine 37 guanin-9-yl octadecyloxyethyl ethyl ethyl octadecyloxyethyl 9-(2- phosphonomethoxyethyl)guanine 38 adenine-9-yl octadecyloxyethyl ethyl ethyl octadecyloxyethyl 9-(2- phosphonomethoxyethyl)adenine 39 cytosine-1-yl octadecyloxyethyl ethyl ethyl octadecyloxyethyl 1-(2- phosphonomethoxyethyl)cytosine 40 thymin-1-yl octadecyloxyethyl ethyl ethyl octadecyloxyethyl 1-(2- phosphonomethoxyethyl)thymine 41 uracil-1-yl octadecyloxyethyl ethyl ethyl octadecyloxyethyl 9-(2- phosphonomethoxyethyl)uracil 42 2,6- octadecyloxyethyl ethyl ethyl octadecyloxyethyl 9-(2- diaminopurin- phosphonomethoxyethyl)-2,6- 9-yl diaminopurine 43 guanin-9-yl hexadecyloxypropyl ethyl ethyl hexadecyloxypropyl 9-(2- phosphonomethoxyethyl)guanine 44 adenine-9-yl hexadecyloxypropyl ethyl ethyl hexadecyloxypropyl 9-(2- phosphonomethoxyethyl)adenine 45 cytosine-1-yl hexadecyloxypropyl ethyl ethyl hexadecyloxypropyl 1-(2- phosphonomethoxyethyl)cytosine 46 thymin-1-yl hexadecyloxypropyl ethyl ethyl hexadecyloxypropyl 1-(2- phosphonomethoxyethyl)thymine 47 uracil-1-yl hexadecyloxypropyl ethyl ethyl hexadecyloxypropyl 9-(2- phosphonomethoxyethyl)uracil 48 2,6- hexadecyloxypropyl ethyl ethyl hexadecyloxypropyl 9-(2- diaminopurin- phosphonomethoxyethyl)-2,6- 9-yl diaminopurine 49 guanin-9-yl 1-O-octadecyl-2-O- ethyl ethyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 9-(2- phosphonomethoxyethyl)guanine 50 adenine-9-yl 1-O-octadecyl-2-O- ethyl ethyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 9-(2- phosphonomethoxyethyl)adenine 51 cytosine-1-yl 1-O-octadecyl-2-O- ethyl ethyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(2- phosphonomethoxyethyl)cytosine 52 thymin-1-yl 1-O-octadecyl-2-O- ethyl ethyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(2- phosphonomethoxyethyl)thymine 53 uracil-1-yl 1-O-octadecyl-2-O- ethyl ethyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 9-(2- phosphonomethoxyethyl)uracil 54 2,6- 1-O-octadecyl-2-O- ethyl ethyl 1-O-octadecyl-2-O-benzyl-sn diaminopurin- benzyl-sn glyceryl glyceryl 9-(2- 9-yl phosphonomethoxyethyl)-2,6- diaminopurine 55 guanin-9-yl octadecyloxyethyl galactosyl galactosyl octadecyloxyethyl 9-(2- phosphonomethoxyethyl)guanine 56 adenine-9-yl octadecyloxyethyl galactosyl galactosyl octadecyloxyethyl 9-(2- phosphonomethoxyethyl)adenine 57 cytosine-1-yl octadecyloxyethyl galactosyl galactosyl octadecyloxyethyl 1-(2- phosphonomethoxyethyl)cytosine 58 thymin-1-yl octadecyloxyethyl galactosyl galactosyl octadecyloxyethyl 1-(2- phosphonomethoxyethyl)thymine 59 uracil-1-yl octadecyloxyethyl galactosyl galactosyl octadecyloxyethyl 9-(2- phosphonomethoxyethyl)uracil 60 2,6- octadecyloxyethyl galactosyl galactosyl octadecyloxyethyl 9-(2- diaminopurin- phosphonomethoxyethyl)-2,6- 9-yl diaminopurine 61 guanin-9-yl hexadecyloxypropyl galactosyl galactosyl hexadecyloxypropyl 9-(2- phosphonomethoxyethyl)guanine 62 adenine-9-yl hexadecyloxypropyl galactosyl galactosyl hexadecyloxypropyl 9-(2- phosphonomethoxyethyl)adenine 63 cytosine-1-yl hexadecyloxypropyl galactosyl galactosyl hexadecyloxypropyl 1-(2- phosphonomethoxyethyl)cytosine 64 thymin-1-yl hexadecyloxypropyl galactosyl galactosyl hexadecyloxypropyl 1-(2- phosphonomethoxyethyl)thymine 65 uracil-1-yl hexadecyloxypropyl galactosyl galactosyl hexadecyloxypropyl 9-(2- phosphonomethoxyethyl)uracil 66 2,6- hexadecyloxypropyl galactosyl galactosyl hexadecyloxypropyl 9-(2- diaminopurin- phosphonomethoxyethyl)-2,6- 9-yl diaminopurine 67 guanin-9-yl 1-O-octadecyl-2-O- galactosyl galactosyl 1-O-octadecyl-2-O-benzyl- benzyl-sn glyceryl sn glyceryl 9-(2- phosphonomethoxyethyl)guanine 68 adenine-9-yl 1-O-octadecyl-2-O- galactosyl galactosyl 1-O-octadecyl-2-O-benzyl- benzyl-sn glyceryl sn glyceryl 9-(2- phosphonomethoxyethyl)adenine 69 cytosine-1-yl 1-O-octadecyl-2-O- galactosyl galactosyl 1-O-octadecyl-2-O-benzyl- benzyl-sn glyceryl sn glyceryl 1-(2- phosphonomethoxyethyl)cytosine 70 thymin-1-yl 1-O-octadecyl-2-O- galactosyl galactosyl 1-O-octadecyl-2-O-benzyl- benzyl-sn glyceryl sn glyceryl 1-(2- phosphonomethoxyethyl)thymine 71 uracil-1-yl 1-O-octadecyl-2-O- galactosyl galactosyl 1-O-octadecyl-2-O-benzyl- benzyl-sn glyceryl sn glyceryl 9-(2- phosphonomethoxyethyl)uracil 72 2,6- 1-O-octadecyl-2-O- galactosyl galactosyl 1-O-octadecyl-2-O-benzyl- diaminopurin- benzyl-sn glyceryl sn glyceryl 9-(2- 9-yl phosphonomethoxyethyl)-2,6- diaminopurine -
TABLE 2 (R)-phosphonomethoxypropyl [(R)-PMP] diester compounds Cmpd No. BNuc/BNuc(a) L/La R/Ra Name 73 guanin-9-yl octadecyloxyethyl benzyl benzyl octadecyloxyethyl 9-(R)-[(2- phosphonomethoxy)propyl]guanine 74 adenine-9-yl octadecyloxyethyl benzyl benzyl octadecyloxyethyl 9-(R)-[(2- phosphonomethoxy)propyl]adenine 75 cytosine-1-yl octadecyloxyethyl benzyl benzyl octadecyloxyethyl 1-(R)-[(2- phosphonomethoxy)propyl]cytosine 76 thymin-1-yl octadecyloxyethyl benzyl benzyl octadecyloxyethyl 1-(R)-[(2- phosphonomethoxy)propyl]thymine 77 uracil-1-yl octadecyloxyethyl benzyl benzyl octadecyloxyethyl 1-(R)-[(2- phosphonomethoxy)propyl]uracil 78 2,6- octadecyloxyethyl benzyl benzyl octadecyloxyethyl 9-(R)-[(2- diaminopurin- phosphonomethoxy)propyl]2,6- 9-yl diaminopurine 79 guanin-9-yl hexadecyloxypropyl benzyl benzyl hexadecyloxypropyl 9-(R)-[(2- phosphonomethoxy)propyl]guanine 80 adenine-9-yl hexadecyloxypropyl benzyl benzyl hexadecyloxypropyl 9-(R)-[(2- phosphonomethoxy)propyl]adenine 81 cytosine-1-yl hexadecyloxypropyl benzyl benzyl hexadecyloxypropyl 1-(R)-[(2- phosphonomethoxy)propyl]cytosine 82 thymin-1-yl hexadecyloxypropyl benzyl benzyl hexadecyloxypropyl 1-(R)-[(2- phosphonomethoxy)propyl]thymine 83 uracil-1-yl hexadecyloxypropyl benzyl benzyl hexadecyloxypropyl 1-(R)-[(2- phosphonomethoxy)propyl]uracil 84 2,6- hexadecyloxypropyl benzyl benzyl hexadecyloxypropyl 9-(R)-[(2- diaminopurin- phosphonomethoxy)propyl]2,6- 9-yl diaminopurine 85 guanin-9-yl 1-O-octadecyl-2-O- benzyl benzyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 9-(R)-[(2- phosphonomethoxy)propyl]guanine 86 adenine-9-yl 1-O-octadecyl-2-O- benzyl benzyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 9-(R)-[(2- phosphonomethoxy)propyl]adenine 87 cytosine-1-yl 1-O-octadecyl-2-O- benzyl benzyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(R)-[(2- phosphonomethoxy)propyl]cytosine 88 thymin-1-yl 1-O-octadecyl-2-O- benzyl benzyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(R)-[(2- phosphonomethoxy)propyl]thymine 89 uracil-1-yl 1-O-octadecyl-2-O- benzyl benzyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(R)-[(2- phosphonomethoxy)propyl]uracil 90 2,6- 1-O-octadecyl-2-O- benzyl benzyl 1-O-octadecyl-2-O-benzyl-sn diaminopurin- benzyl-sn glyceryl glyceryl 9-(R)-[(2- 9-yl phosphonomethoxy)propyl]2,6- diaminopurine 91 guanin-9-yl octadecyloxyethyl phenyl phenyl octadecyloxyethyl 9-(R)-[(2- phosphonomethoxy)propyl]guanine 92 adenine-9-yl octadecyloxyethyl phenyl phenyl octadecyloxyethyl 9-(R)-[(2- phosphonomethoxy)propyl]adenine 93 cytosine-1-yl octadecyloxyethyl phenyl phenyl octadecyloxyethyl 1-(R)-[(2- phosphonomethoxy)propyl]cytosine 94 thymin-1-yl octadecyloxyethyl phenyl phenyl octadecyloxyethyl 1-(R)-[(2- phosphonomethoxy)propyl]thymine 95 uracil-1-yl octadecyloxyethyl phenyl phenyl octadecyloxyethyl 1-(R)-[(2- phosphonomethoxy)propyl]uracil 96 2,6- octadecyloxyethyl phenyl phenyl octadecyloxyethyl 9-(R)-[(2- diaminopurin- phosphonomethoxy)propyl]2,6- 9-yl diaminopurine 97 guanin-9-yl hexadecyloxypropyl phenyl phenyl hexadecyloxypropyl 9-(R)-[(2- phosphonomethoxy)propyl]guanine 98 adenine-9-yl hexadecyloxypropyl phenyl phenyl hexadecyloxypropyl 9-(R)-[(2- phosphonomethoxy)propyl]adenine 99 cytosine-1-yl hexadecyloxypropyl phenyl phenyl hexadecyloxypropyl 1-(R)-[(2- phosphonomethoxy)propyl]cytosine 100 thymin-1-yl hexadecyloxypropyl phenyl phenyl hexadecyloxypropyl 1-(R)-[(2- phosphonomethoxy)propyl]thymine 101 uracil-1-yl hexadecyloxypropyl phenyl phenyl hexadecyloxypropyl 1-(R)-[(2- phosphonomethoxy)propyl]uracil 102 2,6- hexadecyloxypropyl phenyl phenyl hexadecyloxypropyl 9-(R)-[(2- diaminopurin- phosphonomethoxy)propyl]2,6- 9-yl diaminopurine 103 guanin-9-yl 1-O-octadecyl-2-O- phenyl phenyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 9-(R)-[(2- phosphonomethoxy)propyl]guanine 104 adenine-9-yl 1-O-octadecyl-2-O- phenyl phenyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 9-(R)-[(2- phosphonomethoxy)propyl]adenine 105 cytosine-1-yl 1-O-octadecyl-2-O- phenyl phenyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(R)-[(2- phosphonomethoxy)propyl]cytosine 106 thymin-1-yl 1-O-octadecyl-2-O- phenyl phenyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(R)-[(2- phosphonomethoxy)propyl]thymine 107 uracil-1-yl 1-O-octadecyl-2-O- phenyl phenyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(R)-[(2- phosphonomethoxy)propyl]uracil 108 2,6- 1-O-octadecyl-2-O- phenyl phenyl 1-O-octadecyl-2-O-benzyl-sn diaminopurin- benzyl-sn glyceryl glyceryl 9-(R)-[(2- 9-yl phosphonomethoxy)propyl]2,6- diaminopurine 109 guanin-9-yl octadecyloxyethyl ethyl ethyl octadecyloxyethyl 9-(R)-[(2- phosphonomethoxy)propyl]guanine 110 adenine-9-yl octadecyloxyethyl ethyl ethyl octadecyloxyethyl 9-(R)-[(2- phosphonomethoxy)propyl]adenine 111 cytosine-1-yl octadecyloxyethyl ethyl ethyl octadecyloxyethyl 1-(R)-[(2- phosphonomethoxy)propyl]cytosine 112 thymin-1-yl octadecyloxyethyl ethyl ethyl octadecyloxyethyl 1-(R)-[(2- phosphonomethoxy)propyl]thymine 113 uracil-1-yl octadecyloxyethyl ethyl ethyl octadecyloxyethyl 1-(R)-[(2- phosphonomethoxy)propyl]uracil 114 2,6- octadecyloxyethyl ethyl ethyl octadecyloxyethyl 9-(R)-[(2- diaminopurin- phosphonomethoxy)propyl]2,6- 9-yl diaminopurine 115 guanin-9-yl hexadecyloxypropyl ethyl ethyl hexadecyloxypropyl 9-(R)-[(2- phosphonomethoxy)propyl]guanine 116 adenine-9-yl hexadecyloxypropyl ethyl ethyl hexadecyloxypropyl 9-(R)-[(2- phosphonomethoxy)propyl]adenine 117 cytosine-1-yl hexadecyloxypropyl ethyl ethyl hexadecyloxypropyl 1-(R)-[(2- phosphonomethoxy)propyl]cytosine 118 thymin-1-yl hexadecyloxypropyl ethyl ethyl hexadecyloxypropyl 1-(R)-[(2- phosphonomethoxy)propyl]thymine 119 uracil-1-yl hexadecyloxypropyl ethyl ethyl hexadecyloxypropyl 1-(R)-[(2- phosphonomethoxy)propyl]uracil 120 2,6- hexadecyloxypropyl ethyl ethyl hexadecyloxypropyl 9-(R)-[(2- diaminopurin- phosphonomethoxy)propyl]2,6- 9-yl diaminopurine 121 guanin-9-yl 1-O-octadecyl-2-O- ethyl ethyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 9-(R)-[(2- phosphonomethoxy)propyl]guanine 122 adenine-9-yl 1-O-octadecyl-2-O- ethyl ethyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 9-(R)-[(2- phosphonomethoxy)propyl]adenine 123 cytosine-1-yl 1-O-octadecyl-2-O- ethyl ethyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(R)-[(2- phosphonomethoxy)propyl]cytosine 124 thymin-1-yl 1-O-octadecyl-2-O- ethyl ethyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(R)-[(2- phosphonomethoxy)propyl]thymine 125 uracil-1-yl 1-O-octadecyl-2-O- ethyl ethyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(R)-[(2- phosphonomethoxy)propyl]uracil 126 2,6- 1-O-octadecyl-2-O- ethyl phenyl 1-O-octadecyl-2-O-benzyl-sn diaminopurin- benzyl-sn glyceryl glyceryl 9-(R)-[(2- 9-yl phosphonomethoxy)propyl]2,6- diaminopurine 127 guanin-9-yl octadecyloxyethyl galactosyl galactosyl octadecyloxyethyl 9-(R)-[(2- phosphonomethoxy)propyl]guanine 128 adenine-9-yl octadecyloxyethyl galactosyl galactosyl octadecyloxyethyl 9-(R)-[(2- phosphonomethoxy)propyl]adenine 129 cytosine-1-yl octadecyloxyethyl galactosyl galactosyl octadecyloxyethyl 1-(R)-[(2- phosphonomethoxy)propyl]cytosine 130 thymin-1-yl octadecyloxyethyl galactosyl galactosyl octadecyloxyethyl 1-(R)-[(2- phosphonomethoxy)propyl]thymine 131 uracil-1-yl octadecyloxyethyl galactosyl galactosyl octadecyloxyethyl 1-(R)-[(2- phosphonomethoxy)propyl]uracil 132 2,6- octadecyloxyethyl galactosyl galactosyl octadecyloxyethyl 9-(R)-[(2- diaminopurin- phosphonomethoxy)propyl]2,6- 9-yl diaminopurine 133 guanin-9-yl hexadecyloxypropyl galactosyl galactosyl hexadecyloxypropyl 9-(R)- [(2-phosphonomethoxy)propyl]guanine 134 adenine-9-yl hexadecyloxypropyl galactosyl galactosyl hexadecyloxypropyl 9-(R)- [(2-phosphonomethoxy)propyl]adenine 135 cytosine-1-yl hexadecyloxypropyl galactosyl galactosyl hexadecyloxypropyl 1-(R)- [(2-phosphonomethoxy)propyl]cytosine 136 thymin-1-yl hexadecyloxypropyl galactosyl galactosyl hexadecyloxypropyl 1-(R)- [(2-phosphonomethoxy)propyl]thymine 137 uracil-1-yl hexadecyloxypropyl galactosyl galactosyl hexadecyloxypropyl 1-(R)- [(2-phosphonomethoxy)propyl]uracil 138 2,6- hexadecyloxypropyl galactosyl galactosyl hexadecyloxypropyl 9-(R)- diaminopurin- [(2-phosphonomethoxy)propyl]2,6- 9-yl diaminopurine 139 guanin-9-yl 1-O-octadecyl-2-O- galactosyl galactosyl 1-O-octadecyl-2-O-benzyl- benzyl-sn glyceryl sn glyceryl 9-(R)-[(2- phosphonomethoxy)propyl]guanine 140 adenine-9-yl 1-O-octadecyl-2-O- galactosyl galactosyl 1-O-octadecyl-2-O-benzyl- benzyl-sn glyceryl sn glyceryl 9-(R)-[(2- phosphonomethoxy)propyl]adenine 141 cytosine-1-yl 1-O-octadecyl-2-O- galactosyl galactosyl 1-O-octadecyl-2-O-benzyl- benzyl-sn glyceryl sn glyceryl 1-(R)-[(2- phosphonomethoxy)propyl]cytosine 142 thymin-1-yl 1-O-octadecyl-2-O- galactosyl galactosyl 1-O-octadecyl-2-O-benzyl- benzyl-sn glyceryl sn glyceryl 1-(R)-[(2- phosphonomethoxy)propyl]thymine 143 uracil-1-yl 1-O-octadecyl-2-O- galactosyl galactosyl 1-O-octadecyl-2-O-benzyl- benzyl-sn glyceryl sn glyceryl 1-(R)-[(2- phosphonomethoxy)propyl]uracil 144 2,6- 1-O-octadecyl-2-O- galactosyl galactosyl 1-O-octadecyl-2-O-benzyl- diaminopurin- benzyl-sn glyceryl sn glyceryl 9-(R)-[(2- 9-yl phosphonomethoxy)propyl]2,6- diaminopurine -
TABLE 3 (S)-3-methoxy-2-phosphonmethoxypropyl [(S)-MPMP] diester compounds Cmpd No. BNuc/BNuc(a) L/La R/Ra Name 145 guanin-9-yl octadecyloxyethyl benzyl benzyl octadecyloxyethyl 9-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]guanine 146 adenine-9-yl octadecyloxyethyl benzyl benzyl octadecyloxyethyl 9-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]adenine 147 cytosine-1-yl octadecyloxyethyl benzyl benzyl octadecyloxyethyl 1-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]cytosine 148 thymin-1-yl octadecyloxyethyl benzyl benzyl octadecyloxyethyl 1-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]thymine 149 uracil-1-yl octadecyloxyethyl benzyl benzyl octadecyloxyethyl 1-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]uracil 150 2,6- octadecyloxyethyl benzyl benzyl octadecyloxyethyl 9-(S)-[(3- diaminopurin- methoxy-2- 9-yl phosphonomethoxy)propyl]2,6- diaminopurine 151 guanin-9-yl hexadecyloxypropyl benzyl benzyl hexadecyloxypropyl 9-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]guanine 152 adenine-9-yl hexadecyloxypropyl benzyl benzyl hexadecyloxypropyl 9-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]adenine 153 cytosine-1-yl hexadecyloxypropyl benzyl benzyl hexadecyloxypropyl 1-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]cytosine 154 thymin-1-yl hexadecyloxypropyl benzyl benzyl hexadecyloxypropyl 1-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]thymine 155 uracil-1-yl hexadecyloxypropyl benzyl benzyl hexadecyloxypropyl 1-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]uracil 156 2,6- hexadecyloxypropyl benzyl benzyl hexadecyloxypropyl 9-(S)-[(3- diaminopurin- methoxy-2- 9-yl phosphonomethoxy)propyl]2,6- diaminopurine 157 guanin-9-yl 1-O-octadecyl-2-O- benzyl benzyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 9-(S)-[(3-methoxy-2- phosphonomethoxy)propyl]guanine 158 adenine-9-yl 1-O-octadecyl-2-O- benzyl benzyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 9-(S)-[(3-methoxy-2- phosphonomethoxy)propyl]adenine 159 cytosine-1-yl 1-O-octadecyl-2-O- benzyl benzyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(S)-[(3-methoxy-2- phosphonomethoxy)propyl]cytosine 160 thymin-1-yl 1-O-octadecyl-2-O- benzyl benzyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(S)-[(3-methoxy-2- phosphonomethoxy)propyl]thymine 161 uracil-1-yl 1-O-octadecyl-2-O- benzyl benzyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(S)-[(3-methoxy-2- phosphonomethoxy)propyl]uracil 162 2,6- 1-O-octadecyl-2-O- benzyl benzyl 1-O-octadecyl-2-O-benzyl-sn diaminopurin- benzyl-sn glyceryl glyceryl 9-(S)-[(3-methoxy-2- 9-yl phosphonomethoxy)propyl]2,6- diaminopurine 163 guanin-9-yl octadecyloxyethyl phenyl phenyl octadecyloxyethyl 9-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]guanine 164 adenine-9-yl octadecyloxyethyl phenyl phenyl octadecyloxyethyl 9-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]adenine 165 cytosine-1-yl octadecyloxyethyl phenyl phenyl octadecyloxyethyl 1-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]cytosine 166 thymin-1-yl octadecyloxyethyl phenyl phenyl octadecyloxyethyl 1-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]thymine 167 uracil-1-yl octadecyloxyethyl phenyl phenyl octadecyloxyethyl 1-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]uracil 168 2,6- octadecyloxyethyl phenyl phenyl octadecyloxyethyl 9-(S)-[(3- diaminopurin- methoxy-2- 9-yl phosphonomethoxy)propyl]2,6- diaminopurine 169 guanin-9-yl hexadecyloxypropyl phenyl phenyl hexadecyloxypropyl 9-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]guanine 170 adenine-9-yl hexadecyloxypropyl phenyl phenyl hexadecyloxypropyl 9-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]adenine 171 cytosine-1-yl hexadecyloxypropyl phenyl phenyl hexadecyloxypropyl 1-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]cytosine 172 thymin-1-yl hexadecyloxypropyl phenyl phenyl hexadecyloxypropyl 1-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]thymine 173 uracil-1-yl hexadecyloxypropyl phenyl phenyl hexadecyloxypropyl 1-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]uracil 174 2,6- hexadecyloxypropyl phenyl phenyl hexadecyloxypropyl 9-(S)-[(3- diaminopurin- methoxy-2- 9-yl phosphonomethoxy)propyl]2,6- diaminopurine 175 guanin-9-yl 1-O-octadecyl-2-O- phenyl phenyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 9-(S)-[(3-methoxy-2- phosphonomethoxy)propyl]guanine 176 adenine-9-yl 1-O-octadecyl-2-O- phenyl phenyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 9-(S)-[(3-methoxy-2- phosphonomethoxy)propyl]adenine 177 cytosine-1-yl 1-O-octadecyl-2-O- phenyl phenyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(S)-[(3-methoxy-2- phosphonomethoxy)propyl]cytosine 178 thymin-1-yl 1-O-octadecyl-2-O- phenyl phenyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(S)-[(3-methoxy-2- phosphonomethoxy)propyl]thymine 179 uracil-1-yl 1-O-octadecyl-2-O- phenyl phenyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(S)-[(3-methoxy-2- phosphonomethoxy)propyl]uracil 180 2,6- 1-O-octadecyl-2-O- phenyl phenyl 1-O-octadecyl-2-O-benzyl-sn diaminopurin- benzyl-sn glyceryl glyceryl 9-(S)-[(3-methoxy-2- 9-yl phosphonomethoxy)propyl]2,6- diaminopurine 181 guanin-9-yl octadecyloxyethyl ethyl ethyl octadecyloxyethyl 9-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]guanine 182 adenine-9-yl octadecyloxyethyl ethyl ethyl octadecyloxyethyl 9-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]adenine 183 cytosine-1-yl octadecyloxyethyl ethyl ethyl octadecyloxyethyl 1-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]cytosine 184 thymin-1-yl octadecyloxyethyl ethyl ethyl octadecyloxyethyl 1-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]thymine 185 uracil-1-yl octadecyloxyethyl ethyl ethyl octadecyloxyethyl 1-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]uracil 186 2,6- octadecyloxyethyl ethyl ethyl octadecyloxyethyl 9-(S)-[(3- diaminopurin- methoxy-2- 9-yl phosphonomethoxy)propyl]2,6- diaminopurine 187 guanin-9-yl hexadecyloxypropyl ethyl ethyl hexadecyloxypropyl 9-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]guanine 188 adenine-9-yl hexadecyloxypropyl ethyl ethyl hexadecyloxypropyl 9-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]adenine 189 cytosine-1-yl hexadecyloxypropyl ethyl ethyl hexadecyloxypropyl 1-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]cytosine 190 thymin-1-yl hexadecyloxypropyl ethyl ethyl hexadecyloxypropyl 1-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]thymine 191 uracil-1-yl hexadecyloxypropyl ethyl ethyl hexadecyloxypropyl 1-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]uracil 192 2,6- hexadecyloxypropyl ethyl ethyl hexadecyloxypropyl 9-(S)-[(3- diaminopurin- methoxy-2- 9-yl phosphonomethoxy)propyl]2,6- diaminopurine 193 guanin-9-yl 1-O-octadecyl-2-O- ethyl ethyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 9-(S)-[(3-methoxy-2- phosphonomethoxy)propyl]guanine 194 adenine-9-yl 1-O-octadecyl-2-O- ethyl ethyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 9-(S)-[(3-methoxy-2- phosphonomethoxy)propyl]adenine 195 cytosine-1-yl 1-O-octadecyl-2-O- ethyl ethyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(S)-[(3-methoxy-2- phosphonomethoxy)propyl]cytosine 196 thymin-1-yl 1-O-octadecyl-2-O- ethyl ethyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(S)-[(3-methoxy-2- phosphonomethoxy)propyl]thymine 197 uracil-1-yl 1-O-octadecyl-2-O- ethyl ethyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(S)-[(3-methoxy-2- phosphonomethoxy)propyl]uracil 198 2,6- 1-O-octadecyl-2-O- ethyl phenyl 1-O-octadecyl-2-O-benzyl-sn diaminopurin- benzyl-sn glyceryl glycerl 9-(S)-[(3-methoxy-2- 9-yl phosphonomethoxy)propyl]2,6- diaminopurine 199 guanin-9-yl octadecyloxyethyl galactosyl galactosyl octadecyloxyethyl 9-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]guanine 200 adenine-9-yl octadecyloxyethyl galactosyl galactosyl octadecyloxyethyl 9-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]adenine 201 cytosine-1- octadecyloxyethyl galactosyl galactosyl octadecyloxyethyl 1-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]cytosine 202 thymin-1-yl octadecyloxyethyl galactosyl galactosyl octadecyloxyethyl 1-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]thymine 203 uracil-1-yl octadecyloxyethyl galactosyl galactosyl octadecyloxyethyl 1-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]uracil 204 2,6- octadecyloxyethyl galactosyl galactosyl octadecyloxyethyl 9-(S)-[(3- diaminopurin- methoxy-2- 9-yl phosphonomethoxy)propyl]2,6- diaminopurine 205 guanin-9-yl hexadecyloxypropyl galactosyl galactosyl hexadecyloxypropyl 9-(S)- [(3-methoxy-2- phosphonomethoxy)propyl]guanine 206 adenine-9-yl hexadecyloxypropyl galactosyl galactosyl hexadecyloxypropyl 9-(S)- [(3-methoxy-2- phosphonomethoxy)propyl]adenine 207 cytosine-1-yl hexadecyloxypropyl galactosyl galactosyl hexadecyloxypropyl 1-(S)- [(3-methoxy-2- phosphonomethoxy)propyl]cytosine 208 thymin-1-yl hexadecyloxypropyl galactosyl galactosyl hexadecyloxypropyl 1-(S)- [(3-methoxy-2- phosphonomethoxy)propyl]thymine 209 uracil-1-yl hexadecyloxypropyl galactosyl galactosyl hexadecyloxypropyl 1-(S)- [(3-methoxy-2- phosphonomethoxy)propyl]uracil 210 2,6- hexadecyloxypropyl galactosyl galactosyl hexadecyloxypropyl 9-(S)- diaminopurin- [(3-methoxy-2- 9-yl phosphonomethoxy)propyl]2,6- diaminopurine 211 guanin-9-yl 1-O-octadecyl-2-O- galactosyl galactosyl 1-O-octadecyl-2-O-benzyl- benzyl-sn glyceryl sn glyceryl 9-(S)-[(3-methoxy-2- phosphonomethoxy)propyl]guanine 212 adenine-9-yl 1-O-octadecyl-2-O- galactosyl galactosyl 1-O-octadecyl-2-O-benzyl- benzyl-sn glyceryl sn glyceryl 9-(S)-[(3-methoxy-2- phosphonomethoxy)propyl]adenine 213 cytosine-1-yl 1-O-octadecyl-2-O- galactosyl galactosyl 1-O-octadecyl-2-O-benzyl- benzyl-sn glyceryl sn glyceryl 1-(S)-[(3-methoxy-2- phosphonomethoxy)propyl]cytosine 214 thymin-1-yl 1-O-octadecyl-2-O- galactosyl galactosyl 1-O-octadecyl-2-O-benzyl- benzyl-sn glyceryl sn glyceryl 1-(S)-[(3-methoxy-2- phosphonomethoxy)propyl]thymine 215 uracil-1-yl 1-O-octadecyl-2-O- galactosyl galactosyl 1-O-octadecyl-2-O-benzyl- benzyl-sn glyceryl sn glyceryl 1-(S)-[(3-methoxy-2- phosphonomethoxy)propyl]uracil 216 2,6- 1-O-octadecyl-2-O- galactosyl galactosyl 1-O-octadecyl-2-O-benzyl- diaminopurin- benzyl-sn glyceryl sn glyceryl 9-(S)-[(3-methoxy-2- 9-yl phosphonomethoxy)propyl]2,6- diaminopurine -
TABLE 4 (S)-3-hydroxy-2-phosphonomethoxypropyl [(S)-HPMP] diester compounds Cmpd No. BNuc/BNuc(a) L/La R/Ra Name 217 guanin-9-yl octadecyloxyethyl benzyl benzyl octadecyloxyethyl 9-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]guanine 218 adenine-9-yl octadecyloxyethyl benzyl benzyl octadecyloxyethyl 9-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]adenine 219 cytosine-1-yl octadecyloxyethyl benzyl benzyl octadecyloxyethyl 1-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]cytosine 220 thymin-1-yl octadecyloxyethyl benzyl benzyl octadecyloxyethyl 1-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]thymine 221 uracil-1-yl octadecyloxyethyl benzyl benzyl octadecyloxyethyl 1-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]uracil 222 2,6- octadecyloxyethyl benzyl benzyl octadecyloxyethyl 9-(S)-[(3- diaminopurin- hydroxy-2- 9-yl phosphonomethoxy)propyl]2,6- diaminopurine 223 guanin-9-yl hexadecyloxypropyl benzyl benzyl hexadecyloxypropyl 9-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]guanine 224 adenine-9-yl hexadecyloxypropyl benzyl benzyl hexadecyloxypropyl 9-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]adenine 225 cytosine-1-yl hexadecyloxypropyl benzyl benzyl hexadecyloxypropyl 1-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]cytosine 226 thymin-1-yl hexadecyloxypropyl benzyl benzyl hexadecyloxypropyl 1-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]thymine 227 uracil-1-yl hexadecyloxypropyl benzyl benzyl hexadecyloxypropyl 1-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]uracil 228 2,6- hexadecyloxypropyl benzyl benzyl hexadecyloxypropyl 9-(S)-[(3- diaminopurin- hydroxy-2- 9-yl phosphonomethoxy)propyl]2,6- diaminopurine 229 guanin-9-yl 1-O-octadecyl-2-O- benzyl benzyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 9-(S)-[(3-hydroxy-2- phosphonomethoxy)propyl]guanine 230 adenine-9-yl 1-O-octadecyl-2-O- benzyl benzyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 9-(S)-[(3-hydroxy-2- phosphonomethoxy)propyl]adenine 231 cytosine-1-yl 1-O-octadecyl-2-O- benzyl benzyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(S)-[(3-hydroxy-2- phosphonomethoxy)propyl]cytosine 232 thymin-1-yl 1-O-octadecyl-2-O- benzyl benzyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(S)-[(3-hydroxy-2- phosphonomethoxy)propyl]thymine 233 uracil-1-yl 1-O-octadecyl-2-O- benzyl benzyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(S)-[(3-hydroxy-2- phosphonomethoxy)propyl]uracil 234 2,6- 1-O-octadecyl-2-O- benzyl benzyl 1-O-octadecyl-2-O-benzyl-sn diaminopurin- benzyl-sn glyceryl glyceryl 9-(S)-[(3-hydroxy-2- 9-yl phosphonomethoxy)propyl]2,6- diaminopurine 235 guanin-9-yl octadecyloxyethyl phenyl phenyl octadecyloxyethyl 9-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]guanine 236 adenine-9-yl octadecyloxyethyl phenyl phenyl octadecyloxyethyl 9-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]adenine 237 cytosine-1-yl octadecyloxyethyl phenyl phenyl octadecyloxyethyl 1-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]cytosine 238 thymin-1-yl octadecyloxyethyl phenyl phenyl octadecyloxyethyl 1-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]thymine 239 uracil-1-yl octadecyloxyethyl phenyl phenyl octadecyloxyethyl 1-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]uracil 240 2,6- octadecyloxyethyl phenyl phenyl octadecyloxyethyl 9-(S)-[(3- diaminopurin- hydroxy-2- 9-yl phosphonomethoxy)propyl]2,6- diaminopurine 241 guanin-9-yl hexadecyloxypropyl phenyl phenyl hexadecyloxypropyl 9-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]guanine 242 adenine-9-yl hexadecyloxypropyl phenyl phenyl hexadecyloxypropyl 9-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]adenine 243 cytosine-1-yl hexadecyloxypropyl phenyl phenyl hexadecyloxypropyl 1-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]cytosine 244 thymin-1-yl hexadecyloxypropyl phenyl phenyl hexadecyloxypropyl 1-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]thymine 245 uracil-1-yl hexadecyloxypropyl phenyl phenyl hexadecyloxypropyl 1-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]uracil 246 2,6- hexadecyloxypropyl phenyl phenyl hexadecyloxypropyl 9-(S)-[(3- diaminopurin- hydroxy-2- 9-yl phosphonomethoxy)propyl]2,6- diaminopurine 247 guanin-9-yl 1-O-octadecyl-2-O- phenyl phenyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 9-(S)-[(3-hydroxy-2- phosphonomethoxy)propyl]guanine 248 adenine-9-yl 1-O-octadecyl-2-O- phenyl phenyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 9-(S)-[(3-hydroxy-2- phosphonomethoxy)propyl]adenine 249 cytosine-1-yl 1-O-octadecyl-2-O- phenyl phenyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(S)-[(3-hydroxy-2- phosphonomethoxy)propyl]cytosine 250 thymin-1-yl 1-O-octadecyl-2-O- phenyl phenyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(S)-[(3-hydroxy-2- phosphonomethoxy)propyl]thymine 251 uracil-1-yl 1-O-octadecyl-2-O- phenyl phenyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(S)-[(3-hydroxy-2- phosphonomethoxy)propyl]uracil 252 2,6- 1-O-octadecyl-2-O- phenyl phenyl 1-O-octadecyl-2-O-benzyl-sn diaminopurin- benzyl-sn glyceryl glyceryl 9-(S)-[(3-hydroxy-2- 9-yl phosphonomethoxy)propyl]2,6- diaminopurine 253 guanin-9-yl octadecyloxyethyl ethyl ethyl octadecyloxyethyl 9-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]guanine 254 adenine-9-yl octadecyloxyethyl ethyl ethyl octadecyloxyethyl 9-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]adenine 255 cytosine-1-yl octadecyloxyethyl ethyl ethyl octadecyloxyethyl 1-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]cytosine 256 thymin-1-yl octadecyloxyethyl ethyl ethyl octadecyloxyethyl 1-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]thymine 257 uracil-1-yl octadecyloxyethyl ethyl ethyl octadecyloxyethyl 1-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]uracil 258 2,6- octadecyloxyethyl ethyl ethyl octadecyloxyethyl 9-(S)-[(3- diaminopurin- hydroxy-2- 9-yl phosphonomethoxy)propyl]2,6- diaminopurine 259 guanin-9-yl hexadecyloxypropyl ethyl ethyl hexadecyloxypropyl 9-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]guanine 260 adenine-9-yl hexadecyloxypropyl ethyl ethyl hexadecyloxypropyl 9-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]adenine 261 cytosine-1-yl hexadecyloxypropyl ethyl ethyl hexadecyloxypropyl 1-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]cytosine 262 thymin-1-yl hexadecyloxypropyl ethyl ethyl hexadecyloxypropyl 1-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]thymine 263 uracil-1-yl hexadecyloxypropyl ethyl ethyl hexadecyloxypropyl 1-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]uracil 264 2,6- hexadecyloxypropyl ethyl ethyl hexadecyloxypropyl 9-(S)-[(3- diaminopurin- hydroxy-2- 9-yl phosphonomethoxy)propyl]2,6- diaminopurine 265 guanin-9-yl 1-O-octadecyl-2-O- ethyl ethyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 9-(S)-[(3-hydroxy-2- phosphonomethoxy)propyl]guanine 266 adenine-9-yl 1-O-octadecyl-2-O- ethyl ethyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 9-(S)-[(3-hydroxy-2- phosphonomethoxy)propyl]adenine 267 cytosine-1-yl 1-O-octadecyl-2-O- ethyl ethyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(S)-[(3-hydroxy-2- phosphonomethoxy)propyl]cytosine 268 thymin-1-yl 1-O-octadecyl-2-O- ethyl ethyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(S)-[(3-hydroxy-2- phosphonomethoxy)propyl]thymine 269 uracil-1-yl 1-O-octadecyl-2-O- ethyl ethyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(S)-[(3-hydroxy-2- phosphonomethoxy)propyl]uracil 270 2,6- 1-O-octadecyl-2-O- ethyl phenyl 1-O-octadecyl-2-O-benzyl-sn diaminopurin- benzyl-sn glyceryl glyceryl 9-(S)-[(3-hydroxy-2- 9-yl phosphonomethoxy)propyl]2,6- diaminopurine 271 guanin-9-yl octadecyloxyethyl galactosyl galactosyl octadecyloxyethyl 9-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]guanine 272 adenine-9-yl octadecyloxyethyl galactosyl galactosyl octadecyloxyethyl 9-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]adenine 273 cytosine-1-yl octadecyloxyethyl galactosyl galactosyl octadecyloxyethyl 1-(S)-[(3- hydrox-2- phosphonomethoxy)propyl]cytosine 274 thymin-1-yl octadecyloxyethyl galactosyl galactosyl octadecyloxyethyl 1-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]thymine 275 uracil-1-yl octadecyloxyethyl galactosyl galactosyl octadecyloxyethyl 1-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]uracil 276 2,6- octadecyloxyethyl galactosyl galactosyl octadecyloxyethyl 9-(S)-[(3- diaminopurin- hydroxy-2- 9-yl phosphonomethoxy)propyl]2,6- diaminopurine 277 guanin-9-yl hexadecyloxypropyl galactosyl galactosyl hexadecyloxypropyl 9-(S)- [(3-hydroxy-2- phosphonomethoxy)propyl]guanine 278 adenine-9-yl hexadecyloxypropyl galactosyl galactosyl hexadecyloxypropyl 9-(S)- [(3-hydroxy-2- phosphonomethoxy)propyl]adenine 279 cytosine-1-yl hexadecyloxypropyl galactosyl galactosyl hexadecyloxypropyl 1-(S)- [(3-hydroxy-2- phosphonomethoxy)propyl]cytosine 280 thymin-1-yl hexadecyloxypropyl galactosyl galactosyl hexadecyloxypropyl 1-(S)- [(3-hydroxy-2- phosphonomethoxy)propyl]thymine 281 uracil-1-yl hexadecyloxypropyl galactosyl galactosyl hexadecyloxypropyl 1-(S)- [(3-hydroxy-2- phosphonomethoxy)propyl]uracil 282 2,6- hexadecyloxypropyl galactosyl galactosyl hexadecyloxypropyl 9-(S)- diaminopurin- [(3-hydroxy-2- 9-yl phosphonomethoxy)propyl]2,6- diaminopurine 283 guanin-9-yl 1-O-octadecyl-2-O- galactosyl galactosyl 1-O-octadecyl-2-O-benzyl- benzyl-sn glyceryl sn glyceryl 9-(S)-[(3-hydroxy-2- phosphonomethoxy)propyl]guanine 284 adenine-9-yl 1-O-octadecyl-2-O- galactosyl galactosyl 1-O-octadecyl-2-O-benzyl- benzyl-sn glyceryl sn glyceryl 9-(S)-[(3-hydroxy-2- phosphonomethoxy)propyl]adenine 285 cytosine-1-yl 1-O-octadecyl-2-O- galactosyl galactosyl 1-O-octadecyl-2-O-benzyl- benzyl-sn glyceryl sn glyceryl 1-(S)-[(3-hydroxy-2- phosphonomethoxy)propyl]cytosine 286 thymin-1-yl 1-O-octadecyl-2-O- galactosyl galactosyl 1-O-octadecyl-2-O-benzyl- benzyl-sn glyceryl sn glyceryl 1-(S)-[(3-hydroxy-2- phosphonomethoxy)propyl]thymine 287 uracil-1-yl 1-O-octadecyl-2-O- galactosyl galactosyl 1-O-octadecyl-2-O-benzyl- benzyl-sn glyceryl sn glyceryl 1-(S)-[(3-hydroxy-2- phosphonomethoxy)propyl]uracil 288 2,6- 1-O-octadecyl-2-O- galactosyl galactosyl 1-O-octadecyl-2-O-benzyl- diaminopurin- benzyl-sn glyceryl sn glyceryl 9-(S)-[(3-hydroxy-2- 9-yl phosphonomethoxy)propyl]2,6- diaminopurine -
TABLE 5 (S)-3-fluoro-2-phosphonomethoxypropyl [(S)-FPMP] diester compounds Cmpd No. BNuc/BNuc(a) L/La R/Ra Name 289 guanin-9-yl octadecyloxyethyl benzyl benzyl octadecyloxyethyl 9-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]guanine 290 adenine-9-yl octadecyloxyethyl benzyl benzyl octadecyloxyethyl 9-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]adenine 291 cytosine-1-yl octadecyloxyethyl benzyl benzyl octadecyloxyethyl 1-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]cytosine 292 thymin-1-yl octadecyloxyethyl benzyl benzyl octadecyloxyethyl 1-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]thymine 293 uracil-1-yl octadecyloxyethyl benzyl benzyl octadecyloxyethyl 1-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]uracil 294 2,6- octadecyloxyethyl benzyl benzyl octadecyloxyethyl 9-(S)-[(3- diaminopurin- fluoro-2- 9-yl phosphonomethoxy)propyl]2,6- diaminopurine 295 guanin-9-yl hexadecyloxypropyl benzyl benzyl hexadecyloxypropyl 9-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]guanine 296 adenine-9-yl hexadecyloxypropyl benzyl benzyl hexadecyloxypropyl 9-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]adenine 297 cytosine-1-yl hexadecyloxypropyl benzyl benzyl hexadecyloxypropyl 1-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]cytosine 298 thymin-1-yl hexadecyloxypropyl benzyl benzyl hexadecyloxypropyl 1-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]thymine 299 uracil-1-yl hexadecyloxypropyl benzyl benzyl hexadecyloxypropyl 1-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]uracil 300 2,6- hexadecyloxypropyl benzyl benzyl hexadecyloxypropyl 9-(S)-[(3- diaminopurin- fluoro-2- 9-yl phosphonomethoxy)propyl]2,6- diaminopurine 301 guanin-9-yl 1-O-octadecyl-2-O- benzyl benzyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 9-(S)-[(3-fluoro-2- phosphonomethoxy)propyl]guanine 302 adenine-9-yl 1-O-octadecyl-2-O- benzyl benzyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 9-(S)-[(3-fluoro-2- phosphonomethoxy)propyl]adenine 303 cytosine-1-yl 1-O-octadecyl-2-O- benzyl benzyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(S)-[(3-fluoro-2- phosphonomethoxy)propyl]cytosine 304 thymin-1-yl 1-O-octadecyl-2-O- benzyl benzyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(S)-[(3-fluoro-2- phosphonomethoxy)propyl]thymine 305 uracil-1-yl 1-O-octadecyl-2-O- benzyl benzyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(S)-[(3-fluoro-2- phosphonomethoxy)propyl]uracil 306 2,6- 1-O-octadecyl-2-O- benzyl benzyl 1-O-octadecyl-2-O-benzyl-sn diaminopurin- benzyl-sn glyceryl glyceryl 9-(S)-[(3-fluoro-2- 9-yl phosphonomethoxy)propyl]2,6- diaminopurine 307 guanin-9-yl octadecyloxyethyl phenyl phenyl octadecyloxyethyl 9-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]guanine 308 adenine-9-yl octadecyloxyethyl phenyl phenyl octadecyloxyethyl 9-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]adenine 309 cytosine-1-yl octadecyloxyethyl phenyl phenyl octadecyloxyethyl 1-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]cytosine 310 thymin-1-yl octadecyloxyethyl phenyl phenyl octadecyloxyethyl 1-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]thymine 311 uracil-1-yl octadecyloxyethyl phenyl phenyl octadecyloxyethyl 1-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]uracil 312 2,6- octadecyloxyethyl phenyl phenyl octadecyloxyethyl 9-(S)-[(3- diaminopurin- fluoro-2- 9-yl phosphonomethoxy)propyl]2,6- diaminopurine 313 guanin-9-yl hexadecyloxypropyl phenyl phenyl hexadecyloxypropyl 9-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]guanine 314 adenine-9-yl hexadecyloxypropyl phenyl phenyl hexadecyloxypropyl 9-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]adenine 315 cytosine-1-yl hexadecyloxypropyl phenyl phenyl hexadecyloxypropyl 1-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]cytosine 316 thymin-1-yl hexadecyloxypropyl phenyl phenyl hexadecyloxypropyl 1-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]thymine 317 uracil-1-yl hexadecyloxypropyl phenyl phenyl hexadecyloxypropyl 1-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]uracil 318 2,6- hexadecyloxypropyl phenyl phenyl hexadecyloxypropyl 9-(S)-[(3- diaminopurin- fluoro-2- 9-yl phosphonomethoxy)propyl]2,6- diaminopurine 319 guanin-9-yl 1-O-octadecyl-2-O- phenyl phenyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 9-(S)-[(3-fluoro-2- phosphonomethoxy)propyl]guanine 320 adenine-9-yl 1-O-octadecyl-2-O- phenyl phenyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 9-(S)-[(3-fluoro-2- phosphonomethoxy)propyl]adenine 321 cytosine-1-yl 1-O-octadecyl-2-O- phenyl phenyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(S)-[(3-fluoro-2- phosphonomethoxy)propyl]cytosine 322 thymin-1-yl 1-O-octadecyl-2-O- phenyl phenyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(S)-[(3-fluoro-2- phosphonomethoxy)propyl]thymine 323 uracil-1-yl 1-O-octadecyl-2-O- phenyl phenyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(S)-[(3-fluoro-2- phosphonomethoxy)propyl]uracil 324 2,6- 1-O-octadecyl-2-O- phenyl phenyl 1-O-octadecyl-2-O-benzyl-sn diaminopurin- benzyl-sn glyceryl glyceryl 9-(S)-[(3-fluoro-2- 9-yl phosphonomethoxy)propyl]2,6- diaminopurine 325 guanin-9-yl octadecyloxyethyl ethyl ethyl octadecyloxyethyl 9-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]guanine 326 adenine-9-yl octadecyloxyethyl ethyl ethyl octadecyloxyethyl 9-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]adenine 327 cytosine-1-yl octadecyloxyethyl ethyl ethyl octadecyloxyethyl 1-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]cytosine 328 thymin-1-yl octadecyloxyethyl ethyl ethyl octadecyloxyethyl 1-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]thymine 329 uracil-1-yl octadecyloxyethyl ethyl ethyl octadecyloxyethyl 1-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]uracil 330 2,6- octadecyloxyethyl ethyl ethyl octadecyloxyethyl 9-(S)-[(3- diaminopurin- fluoro-2- 9-yl phosphonomethoxy)propyl]2,6- diaminopurine 331 guanin-9-yl hexadecyloxypropyl ethyl ethyl hexadecyloxypropyl 9-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]guanine 332 adenine-9-yl hexadecyloxypropyl ethyl ethyl hexadecyloxypropyl 9-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]adenine 333 cytosine-1-yl hexadecyloxypropyl ethyl ethyl hexadecyloxypropyl 1-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]cytosine 334 thymin-1-yl hexadecyloxypropyl ethyl ethyl hexadecyloxypropyl 1-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]thymine 335 uracil-1-yl hexadecyloxypropyl ethyl ethyl hexadecyloxypropyl 1-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]uracil 336 2,6- hexadecyloxypropyl ethyl ethyl hexadecyloxypropyl 9-(S)-[(3- diaminopurin- fluoro-2- 9-yl phosphonomethoxy)propyl]2,6- diaminopurine 337 guanin-9-yl 1-O-octadecyl-2-O- ethyl ethyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 9-(S)-[(3-fluoro-2- phosphonomethoxy)propyl]guanine 338 adenine-9-yl 1-O-octadecyl-2-O- ethyl ethyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 9-(S)-[(3-fluoro-2- phosphonomethoxy)propyl]adenine 339 cytosine-1-yl 1-O-octadecyl-2-O- ethyl ethyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(S)-[(3-fluoro-2- phosphonomethoxy)propyl]cytosine 340 thymin-1-yl 1-O-octadecyl-2-O- ethyl ethyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(S)-[(3-fluoro-2- phosphonomethoxy)propyl]thymine 341 uracil-1-yl 1-O-octadecyl-2-O- ethyl ethyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(S)-[(3-fluoro-2- phosphonomethoxy)propyl]uracil 342 2,6- 1-O-octadecyl-2-O- ethyl phenyl 1-O-octadecyl-2-O-benzyl-sn diaminopurin- benzyl-sn glyceryl glyceryl 9-(S)-[(3-fluoro-2- 9-yl phosphonomethoxy)propyl]2,6- diaminopurine 343 guanin-9-yl octadecyloxyethyl galactosyl galactosyl octadecyloxyethyl 9-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]guanine 344 adenine-9-yl octadecyloxyethyl galactosyl galactosyl octadecyloxyethyl 9-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]adenine 345 cytosine-1-yl octadecyloxyethyl galactosyl galactosyl octadecyloxyethyl 1-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]cytosine 346 thymin-1-yl octadecyloxyethyl galactosyl galactosyl octadecyloxyethyl 1-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]thymine 347 uracil-1-yl octadecyloxyethyl galactosyl galactosyl octadecyloxyethyl 1-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]uracil 348 2,6- octadecyloxyethyl galactosyl galactosyl octadecyloxyethyl 9-(S)-[(3- diaminopurin- fluoro-2- 9-yl phosphonomethoxy)propyl]2,6- diaminopurine 349 guanin-9-yl hexadecyloxypropyl galactosyl galactosyl hexadecyloxypropyl 9-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]guanine 350 adenine-9-yl hexadecyloxypropyl galactosyl galactosyl hexadecyloxypropyl 9-(S)- [(3-fluoro-2- phosphonomethoxy)propyl]adenine 351 cytosine-1-yl hexadecyloxypropyl galactosyl galactosyl hexadecyloxypropyl 1-(S)- [(3-fluoro-2- phosphonomethoxy)propyl]cytosine 352 thymin-1-yl hexadecyloxypropyl galactosyl galactosyl hexadecyloxypropyl 1-(S)- [(3-fluoro-2- phosphonomethoxy)propyl]thymine 353 uracil-1-yl hexadecyloxypropyl galactosyl galactosyl hexadecyloxypropyl 1-(S)- [(3-fluoro-2- phosphonomethoxy)propyl]uracil 354 2,6- hexadecyloxypropyl galactosyl galactosyl hexadecyloxypropyl 9-(S)- diaminopurin- [(3-fluoro-2- 9-yl phosphonomethoxy)propyl]2,6- diaminopurine 355 guanin-9-yl 1-O-octadecyl-2-O- galactosyl galactosyl 1-O-octadecyl-2-O-benzyl- benzyl-sn glyceryl sn glyceryl 9-(S)-[(3-fluoro-2- phosphonomethoxy)propyl]guanine 356 adenine-9-yl 1-O-octadecyl-2-O- galactosyl galactosyl 1-O-octadecyl-2-O-benzyl- benzyl-sn glyceryl sn glyceryl 9-(S)-[(3-fluoro-2- phosphonomethoxy)propyl]adenine 357 cytosine-1-yl 1-O-octadecyl-2-O- galactosyl galactosyl 1-O-octadecyl-2-O-benzyl- benzyl-sn glyceryl sn glyceryl 1-(S)-[(3-fluoro-2- phosphonomethoxy)propyl]cytosine 358 thymin-1-yl 1-O-octadecyl-2-O- galactosyl galactosyl 1-O-octadecyl-2-O-benzyl- benzyl-sn glyceryl sn glyceryl 1-(S)-[(3-fluoro-2- phosphonomethoxy)propyl]thymine 359 uracil-1-yl 1-O-octadecyl-2-O- galactosyl galactosyl 1-O-octadecyl-2-O-benzyl- benzyl-sn glyceryl sn glyceryl 1-(S)-[(3-fluoro-2- phosphonomethoxy)propyl]uracil 360 2,6- 1-O-octadecyl-2-O- galactosyl galactosyl 1-O-octadecyl-2-O-benzyl- diaminopurin- benzyl-sn glyceryl sn glyceryl 9-(S)-[(3-fluoro-2- 9-yl phosphonomethoxy)propyl]2,6- diaminopurine -
TABLE 6 Phosphonomethoxyethyl (PME) diester compounds Cmpd No. BNuc/BNuc(a) L/La R/Ra Name 361 guanin-9-yl octadecyloxyethyl naphthyl naphthyl octadecyloxyethyl 9-(2- phosphonomethoxyethyl)guanine 362 adenine-9-yl octadecyloxyethyl naphthyl naphthyl octadecyloxyethyl 9-(2- phosphonomethoxyethyl)adenine 363 cytosine-1-yl octadecyloxyethyl naphthyl naphthyl octadecyloxyethyl 1-(2- phosphonomethoxyethyl)cytosine 364 thymin-1-yl octadecyloxyethyl naphthyl naphthyl octadecyloxyethyl 1-(2- phosphonomethoxyethyl)thymine 365 uracil-1-yl octadecyloxyethyl naphthyl naphthyl octadecyloxyethyl 9-(2- phosphonomethoxyethyl)uracil 366 2,6- octadecyloxyethyl naphthyl naphthyl octadecyloxyethyl 9-(2- diaminopurin- phosphonomethoxyethyl)-2,6- 9-yl diaminopurine 367 guanin-9-yl hexadecyloxypropyl naphthyl naphthyl hexadecyloxypropyl 9-(2- phosphonomethoxyethyl)guanine 368 adenine-9-yl hexadecyloxypropyl naphthyl naphthyl hexadecyloxypropyl 9-(2- phosphonomethoxyethyl)adenine 369 cytosine-1-yl hexadecyloxypropyl naphthyl naphthyl hexadecyloxypropyl 1-(2- phosphonomethoxyethyl)cytosine 370 thymin-1-yl hexadecyloxypropyl naphthyl naphthyl hexadecyloxypropyl 1-(2- phosphonomethoxyethyl)thymine 371 uracil-1-yl hexadecyloxypropyl naphthyl naphthyl hexadecyloxypropyl 9-(2- phosphonomethoxyethyl)uracil 372 2,6- hexadecyloxypropyl naphthyl naphthyl hexadecyloxypropyl 9-(2- diaminopurin- phosphonomethoxyethyl)-2,6- 9-yl diaminopurine 373 guanin-9-yl 1-O-octadecyl-2-O- naphthyl naphthyl 1-O-octadecyl-2-O-benzyl- benzyl-sn glyceryl sn glyceryl 9-(2- phosphonomethoxyethyl)guanine 374 adenine-9-yl 1-O-octadecyl-2-O- naphthyl naphthyl 1-O-octadecyl-2-O-benzyl- benzyl-sn glyceryl sn glyceryl 9-(2- phosphonomethoxyethyl)adenine 375 cytosine-1-yl 1-O-octadecyl-2-O- naphthyl naphthyl 1-O-octadecyl-2-O-benzyl- benzyl-sn glyceryl sn glyceryl 1-(2- phosphonomethoxyethyl)cytosine 376 thymin-1-yl 1-O-octadecyl-2-O- naphthyl naphthyl 1-O-octadecyl-2-O-benzyl- benzyl-sn glyceryl sn glyceryl 1-(2-phosphonomethoxy- ethyl)thymine 377 uracil-1-yl 1-O-octadecyl-2-O- naphthyl naphthyl 1-O-octadecyl-2-O-benzyl- benzyl-sn glyceryl sn glyceryl 9-(2-phosphonomethoxy- ethyl)uracil 378 2,6- 1-O-octadecyl-2-O- naphthyl naphthyl 1-O-octadecyl-2-O-benzyl- diaminopurin- benzyl-sn glyceryl sn glyceryl 9-(2-phosphonomethoxy- 9-yl ethyl)-2,6-diaminopurine -
TABLE 7 (R)-phosphonomethoxypropyl [(R)-PMP] diester compounds Cmpd No. BNuc/BNuc(a) L/La R/Ra Name 379 guanin-9-yl octadecyloxyethyl naphthyl naphthyl octadecyloxyethyl 9-(R)-[(2- phosphonomethoxy)propyl]guanine 380 adenine-9-yl octadecyloxyethyl naphthyl naphthyl octadecyloxyethyl 9-(R)-[(2- phosphonomethoxy)propyl]adenine 381 cytosine-1-yl octadecyloxyethyl naphthyl naphthyl octadecyloxyethyl 1-(R)-[(2- phosphonomethoxy)propyl]cytosine 382 thymin-1-yl octadecyloxyethyl naphthyl naphthyl octadecyloxyethyl 1-(R)-[(2- phosphonomethoxy)propyl]thymine 383 uracil-1-yl octadecyloxyethyl naphthyl naphthyl octadecyloxyethyl 1-(R)-[(2- phosphonomethoxy)propyl]uracil 384 2,6- octadecyloxyethyl naphthyl naphthyl octadecyloxyethyl 9-(R)-[(2- diaminopurin- phosphonomethoxy)propyl]-2,6- 9-yl diaminopurine 385 guanin-9-yl hexadecyloxypropyl naphthyl naphthyl hexadecyloxypropyl 9-(R)- [(2-phosphonomethoxy)propyl]guanine 386 adenine-9-yl hexadecyloxypropyl naphthyl naphthyl hexadecyloxypropyl 9-(R)- [(2-phosphonomethoxy)propyl]adenine 387 cytosine-1-yl hexadecyloxypropyl naphthyl naphthyl hexadecyloxypropyl 1-(R)- [(2- phosphonomethoxy)propyl]cytosine 388 thymin-1-yl hexadecyloxypropyl naphthyl naphthyl hexadecyloxypropyl 1-(R)- [(2- phosphonomethoxy)propyl]thymine 389 uracil-1-yl hexadecyloxypropyl naphthyl naphthyl hexadecyloxypropyl 1-(R)- [(2phosphonomethoxy)propyl]uracil 390 2,6- hexadecyloxypropyl naphthyl naphthyl hexadecyloxypropyl 9-(R)- diaminopurin- [(2-phosphonomethoxy)propyl]-2,6- 9-yl diaminopurine 391 guanin-9-yl 1-O-octadecyl-2-O- naphthyl naphthyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 9-(R)-[(2- phosphonomethoxy)propyl]guanine 392 adenine-9-yl 1-O-octadecyl-2-O- naphthyl naphthyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 9-(R)-[(2- phosphonomethoxy)propyl]adenine 393 cytosine-1-yl 1-O-octadecyl-2-O- naphthyl naphthyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(R)-[(2- phosphonomethoxy)propyl]cytosine 394 thymin-1-yl 1-O-octadecyl-2-O- naphthyl naphthyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(R)-[(2- phosphonomethoxy)propyl]thymine 395 uracil-1-yl 1-O-octadecyl-2-O- naphthyl naphthyl 1-O-octatlecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 9-(R)-[(2- phosphonomethoxy)propyl]uracil 396 2,6- 1-O-octadecyl-2-O- naphthyl naphthyl 1-O-octadecyl-2-O-benzyl-sn diaminopurin- benzyl-sn glyceryl glyceryl 9-(R)-[(2- 9-yl phosphonomethoxy)propyl]-2,6- diaminopurine -
TABLE 8 (S)-3-methoxy-2-phosphonomethoxypropyl [(S)-MPMP] diester compounds Cmpd No. BNuc/BNuc(a) L/La R/Ra Name 397 guanin-9-yl octadecyloxyethyl naphthyl naphthyl octadecyloxyethyl 9-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]guanine 398 adenine-9-yl octadecyloxyethyl naphthyl naphthyl octadecyloxyethyl 9-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]adenine 399 cytosine-1-yl octadecyloxyethyl naphthyl naphthyl octadecyloxyethyl 1-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]cytosine 400 thymin-1-yl octadecyloxyethyl naphthyl naphthyl octadecyloxyethyl 1-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]thymine 401 uracil-1-yl octadecyloxyethyl naphthyl naphthyl octadecyloxyethyl 1-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]uracil 402 2,6- octadecyloxyethyl naphthyl naphthyl octadecyloxyethyl 9-(S)-[(3- diaminopurin- methoxy-2- 9-yl phosphonomethoxy)propyl]-2,6- diaminopurine 403 guanin-9-yl hexadecyloxypropyl naphthyl naphthyl hexadecyloxypropyl 9-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]guanine 404 adenine-9-yl hexadecyloxypropyl naphthyl naphthyl hexadecyloxypropyl 9-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]adenine 405 cytosine-1-yl hexadecyloxypropyl naphthyl naphthyl hexadecyloxypropyl 1-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]cytosine 406 thymin-1-yl hexadecyloxypropyl naphthyl naphthyl hexadecyloxypropyl 1-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]thymine 407 uracil-1-yl hexadecyloxypropyl naphthyl naphthyl hexadecyloxypropyl 1-(S)-[(3- methoxy-2- phosphonomethoxy)propyl]uracil 408 2,6- hexadecyloxypropyl naphthyl naphthyl hexadecyloxypropyl 9-(S)-[(3- diaminopurin- methoxy-2- 9-yl phosphonomethoxy)propyl]-2,6- diaminopurine 409 guanin-9-yl 1-O-octadecyl-2-O- naphthyl naphthyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 9-(S)-[(3-methoxy-2- phosphonomethoxy)propyl]guanine 410 adenine-9-yl 1-O-octadecyl-2-O- naphthyl naphthyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 9-(S)-[(3-methoxy-2- phosphonomethoxy)propyl]adenine 411 cytosine-1-yl 1-O-octadecyl-2-O- naphthyl naphthyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(S)-[(3-methoxy-2- phosphonomethoxy)propyl]cytosine 412 thymin-1-yl 1-O-octadecyl-2-O- naphthyl naphthyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(S)-[(3-methoxy-2- phosphonomethoxy)propyl]thymine 413 uracil-1-yl 1-O-octadecyl-2-O- naphthyl naphthyl 1-O-octatlecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(S)-[(3-methoxy-2- phosphonomethoxy)propyl]uracil 414 2,6- 1-O-octadecyl-2-O- naphthyl naphthyl 1-O-octadecyl-2-O-benzyl-sn diaminopurin- benzyl-sn glyceryl glyceryl 9-(S)-[(3-methoxy-2- 9-yl phosphonomethoxy)propyl]-2,6- diaminopurine -
TABLE 9 (S)-3-hydroxy-2-phosphonomethoxypropyl [(S)-HPMP] diester compounds Cmpd No. BNuc/BNuc(a) L/La R/Ra Name 415 guanin-9-yl octadecyloxyethyl naphthyl naphthyl octadecyloxyethyl 9-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]guanine 416 adenine-9-yl octadecyloxyethyl naphthyl naphthyl octadecyloxyethyl 9-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]adenine 417 cytosine-1-yl octadecyloxyethyl naphthyl naphthyl octadecyloxyethyl 1-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]cytosine 418 thymin-1-yl octadecyloxyethyl naphthyl naphthyl octadecyloxyethyl 1-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]thymine 419 uracil-1-yl octadecyloxyethyl naphthyl naphthyl octadecyloxyethyl 1-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]uracil 420 2,6- octadecyloxyethyl naphthyl naphthyl octadecyloxyethyl 9-(S)-[(3- diaminopurin- hydroxy-2- 9-yl phosphonomethoxy)propyl]-2,6- diaminopurine 421 guanin-9-yl hexadecyloxypropyl naphthyl naphthyl hexadecyloxypropyl 9-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]guanine 422 adenine-9-yl hexadecyloxypropyl naphthyl naphthyl hexadecyloxypropyl 9-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]adenine 423 cytosine-1-yl hexadecyloxypropyl naphthyl naphthyl hexadecyloxypropyl 1-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]cytosine 424 thymin-1-yl hexadecyloxypropyl naphthyl naphthyl hexadecyloxypropyl 1-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]thymine 425 uracil-1-yl hexadecyloxypropyl naphthyl naphthyl hexadecyloxypropyl 1-(S)-[(3- hydroxy-2- phosphonomethoxy)propyl]uracil 426 2,6- hexadecyloxypropyl naphthyl naphthyl hexadecyloxypropyl 9-(S)-[(3- diaminopurin- hydroxy-2- 9-yl phosphonomethoxy)propyl]-2,6- diaminopurine 427 guanin-9-yl 1-O-octadecyl-2-O- naphthyl naphthyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 9-(S)-[(3-hydroxy-2- phosphonomethoxy)propyl]guanine 428 adenine-9-yl 1-O-octadecyl-2-O- naphthyl naphthyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 9-(S)-[(3-hydroxy-2- phosphonomethoxy)propyl]adenine 429 cytosine-1-yl 1-O-octadecyl-2-O- naphthyl naphthyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(S)-[(3-hydroxy-2- phosphonomethoxy)propyl]cytosine 430 thymin-1-yl 1-O-octadecyl-2-O- naphthyl naphthyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(S)-[(3-hydroxy-2- phosphonomethoxy)propyl]thymine 431 uracil-1-yl 1-O-octadecyl-2-O- naphthyl naphthyl 1-O-octatlecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(S)-[(3-hydroxy-2- phosphonomethoxy)propyl]uracil 432 2,6- 1-O-octadecyl-2-O- naphthyl naphthyl 1-O-octadecyl-2-O-benzyl-sn diaminopurin- benzyl-sn glyceryl glyceryl 9-(S)-[(3-hydroxy-2- 9-yl phosphonomethoxy)propyl]-2,6- diaminopurine -
TABLE 10 (S)-3-fluoro-2-phosphonomethoxypropyl [(S)-FPMP] diester compounds Cmpd No. BNuc/BNuc(a) L/La R/Ra Name 433 guanin-9-yl octadecyloxyethyl naphthyl naphthyl octadecyloxyethyl 9-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]guanine 434 adenine-9-yl octadecyloxyethyl naphthyl naphthyl octadecyloxyethyl 9-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]adenine 435 cytosine-1-yl octadecyloxyethyl naphthyl naphthyl octadecyloxyethyl 1-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]cytosine 436 thymin-1-yl octadecyloxyethyl naphthyl naphthyl octadecyloxyethyl 1-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]thymine 437 uracil-1-yl octadecyloxyethyl naphthyl naphthyl octadecyloxyethyl 1-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]uracil 438 2,6- octadecyloxyethyl naphthyl naphthyl octadecyloxyethyl 9-(S)-[(3- diaminopurin- fluoro-2- 9-yl phosphonomethoxy)propyl]-2,6- diaminopurine 439 guanin-9-yl hexadecyloxypropyl naphthyl naphthyl hexadecyloxypropyl 9-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]guanine 440 adenine-9-yl hexadecyloxypropyl naphthyl naphthyl hexadecyloxypropyl 9-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]adenine 441 cytosine-1-yl hexadecyloxypropyl naphthyl naphthyl hexadecyloxypropyl 1-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]cytosine 442 thymin-1-yl hexadecyloxypropyl naphthyl naphthyl hexadecyloxypropyl 1-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]thymine 443 uracil-1-yl hexadecyloxypropyl naphthyl naphthyl hexadecyloxypropyl 1-(S)-[(3- fluoro-2- phosphonomethoxy)propyl]uracil 444 2,6- hexadecyloxypropyl naphthyl naphthyl hexadecyloxypropyl 9-(S)-[(3- diaminopurin- fluoro-2- 9-yl phosphonomethoxy)propyl]-2,6- diaminopurine 445 guanin-9-yl 1-O-octadecyl-2-O- naphthyl naphthyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 9-(S)-[(3-fluoro-2- phosphonomethoxy)propyl]guanine 446 adenine-9-yl 1-O-octadecyl-2-O- naphthyl naphthyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 9-(S)-[(3-fluoro-2- phosphonomethoxy)propyl]adenine 447 cytosine-1-yl 1-O-octadecyl-2-O- naphthyl naphthyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(S)-[(3-fluoro-2- phosphonomethoxy)propyl]cytosine 448 thymin-1-yl 1-O-octadecyl-2-O- naphthyl naphthyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(S)-[(3-fluoro-2- phosphonomethoxy)propyl]thymine 449 uracil-1-yl 1-O-octadecyl-2-O- naphthyl naphthyl 1-O-octadecyl-2-O-benzyl-sn benzyl-sn glyceryl glyceryl 1-(S)-[(3-fluoro-2- phosphonomethoxy)propyl]uracil 450 2,6- 1-O-octadecyl-2-O- naphthyl naphthyl 1-O-octadecyl-2-O-benzyl-sn diaminopurin- benzyl-sn glyceryl glyceryl 9-(S)-[(3-fluoro-2- 9-yl phosphonomethoxy)propyl]-2,6- diaminopurine - Specific compounds contemplated herein include:
- Methods of Use
- In another aspect, there is provided a method for treating a viral disease in a subject. The method includes administering to a subject in need thereof a therapeutically effective amount of a compound with structure of any of Formulae (I), (I-1), (I-2), (I-3), (I-4), (I-5) and/or (Ia). In embodiments, L/La of any of Formulae (I), (I-1), (I-2), (I-3), (I-4), (I-5) and/or (Ia) is a lipophilic promoiety.
- Exemplary viral diseases include human papilloma virus, HIV, hepatitis B virus, hepatitis C virus, variola virus (smallpox), vaccinia virus, adenovirus, cytomegalovirus (CMV), herpes simplex viruses, Epstein Barr virus, BK virus, JC virus, any double stranded DNA virus, feline leukemia virus, feline immunodeficiency virus, and the like. A therapeutically effective amount of a compound of Formula (I) can be administered to a human or mammal in need of treatment of a viral disease.
- In embodiments, the compound is administered by a route (topical, intravitreal, oral, intravenous etc.) which results in delivery of an amount sufficient to inhibit replication of the virus. In embodiments, the compound can be administered topically. For example, the compound can be administered topically in the form of a cream, a gel or an ointment
- In another aspect, there is provided a method for treating a disease or disorder in a subject in need thereof, the method including administering to a subject in need thereof a therapeutically effective amount of a compound with structure of any of Formulae (I), (I-1), (I-2), (I-3), (I-4), (I-5) and/or (Ia). Aspects for the treatment of cancer and other neoplastic disorders contemplated herein are based on the surprising discovery that compounds of Formulae (I) and/or (Ia) are effective in killing or inhibiting growth of cells that are transformed by human papillomavirus (HPV), for example cervical cancer cells and cervical intraepithelial neoplasia (CIN) lesions. Accordingly, a therapeutically effective amount of a compound of Formula (I), (I-1), (I-2), (I-3), (I-4), (I-5) and/or (Ia) can be administered by an appropriate route (topical, orally, intravenous etc.) to kill or inhibit growth of infected/transformed cells. Cells that are transformed by other types of viruses, such as herpes simplex virus-2 (HSV-2), also may be treated with a compound of Formula (I), (I-1), (I-2), (I-3), (I-4), (I-5) and/or (Ia).
- In another aspect, there is provided a method for treating cancer in a subject. The method includes administering to a subject in need thereof a therapeutically effective amount of a compound with the structure of any of Formulae (I), (I-1), (I-2), (I-3), (I-4), (I-5) and/or (Ia). In embodiments, L/La of any of Formulae (I), (I-1), (I-2), (I-3), (I-4), (I-5) and/or (Ia) is a lipophilic promoiety.
- In embodiments, the cancer is leukemia, carcinoma and/or sarcoma, such as cancer of the brain, breast, cervix, colon, pancreas, head and neck, liver, kidney, lung, non-small cell lung, prostate, melanoma, mesothelioma, ovary, sarcoma, stomach, uterus and/or medulloblastoma. Additional examples include, Hodgkin's Disease, Non-Hodgkin's Lymphoma, multiple myeloma, neuroblastoma, ovarian cancer, rhabdomyosarcoma, primary thrombocytosis, primary macroglobulinemia, primary brain tumors, malignant pancreatic insulanoma, malignant carcinoid, urinary bladder cancer, premalignant skin lesions, testicular cancer, lymphomas, thyroid cancer, neuroblastoma, esophageal cancer, genitourinary tract cancer, malignant hypercalcemia, endometrial cancer, adrenal cortical cancer, and neoplasms of the endocrine and exocrine pancreas. In embodiments, the cancer is liver cancer, colon cancer, breast cancer, melanoma, acute myelogenous leukemia, chronic myelogenous leukemia, and/or non-small-cell lung cancer.
- In another aspect, there is provided a method for treating a proliferative disorder in a subject. The method includes administering to a subject in need thereof a therapeutically effective amount of a compound with the structure of any of Formulae (I), (I-1), (I-2), (I-3), (I-4), (I-5) and/or (Ia). The proliferative disorder may be caused by the human papilloma virus. Exemplary proliferative disorders include, e.g., cervical intraepithelial neoplasia (CIN), vulvar intraepithelial neoplasia (VIN), anal intraepithelial neoplasia (AIN), or penile and venereal warts. In embodiments, L/La of any of Formulae (I), (I-1), (I-2), (I-3), (I-4), (I-5) and/or (Ia) is a lipophilic promoiety.
- In another aspect, there is provided a method for killing or inhibiting the growth of a transformed cell. The method includes contacting a transformed cell with a therapeutically effective amount of a compound of any one of Formulae (I), (I-1), (I-2), (I-3), (I-4), (I-5) and/or (Ia).
- In another aspect, there is provided a compound of Formula (Ia) or embodiment thereof, or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof, for use in treating a viral disease in a subject, wherein the viral disease can be selected from human papilloma virus (HPV), HIV, hepatitis B virus, hepatitis C virus, variola virus, vaccinia virus, an adenovirus, a cytomegalovirus, herpes simplex virus 1, herpes simplex virus 2, Epstein Barr virus, BK virus, JC virus, feline leukemia virus and feline immunodeficiency virus.
- In embodiments, the virus can be human papilloma virus. According to the CDC, HPV is the most common sexually transmitted infection (STI). HPV viruses can be classified into mucosal and cutaneous HPVs. Within each of these groups, the individual viruses are designated high risk or low risk. More than 40 types of HPV's can infect the genital areas of women and men, and several HPV types can infect the mouth and throat. Additionally, HPV is the most common cause of cervical cancer. Type 16 is one of the most prominent strains of HPV and can cause cervical cancer. Other types of HPVs include, but are not limited to, 2, 3, 4, 5, 6, 8, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 63, 66, 68, 69 and 82. In embodiments, the use is for treating a plurality of types of human papilloma virus, for example, types described herein. In embodiments, the use is for more than 2 types of HPV, more than 5 types of HPV or more than 10 types of HPV. In embodiments, the human papilloma virus can be selected from human papilloma virus type 11, type 16 and type 18.
- In another aspect, there is provided use of a compound of Formula (Ia) or embodiment thereof, or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof, in the preparation of a medicament for treating a viral disease in a subject, wherein the viral disease can be selected from human papilloma virus, HIV, hepatitis B virus, hepatitis C virus, variola virus, vaccinia virus, an adenovirus, a cytomegalovirus, herpes simplex virus 1, herpes simplex virus 2, Epstein Barr virus, BK virus, JC virus, feline leukemia virus and feline immunodeficiency virus.
- In embodiments, the virus can be human papilloma virus. In embodiments, the use is for treating a plurality of types of human papilloma virus, for example, types described herein. In embodiments, the use is for more than 2 types of HPV, more than 5 types of HPV or more than 10 types of HPV. In embodiments, the human papilloma virus can be selected from human papilloma virus type 11, type 16 and type 18.
- In another aspect, there is provided a method of treating a subject having a viral disease. The method include administering to the subject having a viral disease in need thereof an effective amount of a compound of Formula (Ia) or embodiment thereof, or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof, wherein the viral disease can be selected from human papilloma virus, HIV, hepatitis B virus, hepatitis C virus, variola virus, vaccinia virus, an adenovirus, a cytomegalovirus, herpes simplex virus 1, herpes simplex virus 2, Epstein Barr virus, BK virus, JC virus, feline leukemia virus and feline immunodeficiency virus, thereby treating the viral disease.
- In another aspect, there is provided a compound of Formula (Ia) or embodiment thereof, or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof, for use in treating cancer of the cervix in a subject. In some embodiments, the cancer of the cervix can be caused by a HPV infection, for example, a HPV infection of type 16.
- In another aspect, there is provided use of a compound of Formula (Ia) or embodiment thereof, or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof, in the preparation of a medicament for treating cancer of the cervix in a subject. In some embodiments, the cancer of the cervix can be caused by a HPV infection, for example, a HPV infection of type 16.
- In another aspect, there is provided a method of treating a subject having cancer of the cervix. The method includes administering an effective amount of a compound of Formula (Ia) or embodiment thereof, or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof, to a subject having cancer of the cervix in need thereof, thereby treating the subject having cancer of the cervix. In some embodiments, the cancer of the cervix can be caused by a HPV infection, for example, a HPV infection of type 16.
- In another aspect, there is provided a compound of Formula (Ia) or embodiment thereof, or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof, for use in inhibiting growth of a cell transformed by a virus, wherein the virus can be selected from human papilloma virus, HIV, hepatitis B virus, hepatitis C virus, variola virus, vaccinia virus, an adenovirus, a cytomegalovirus, herpes simplex virus 1, herpes simplex virus 2, Epstein Barr virus, BK virus, JC virus, feline leukemia virus and feline immunodeficiency virus.
- In another aspect, there is provided use of a compound of Formula (Ia) or embodiment thereof, or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof, in the preparation of a medicament for inhibiting growth of a cell transformed by a virus, wherein the virus can be selected from human papilloma virus, HIV, hepatitis B virus, hepatitis C virus, variola virus, vaccinia virus, an adenovirus, a cytomegalovirus, herpes simplex virus 1, herpes simplex virus 2, Epstein Barr virus, BK virus, JC virus, feline leukemia virus and feline immunodeficiency virus.
- In another aspect, there is provided a method of inhibiting growth of a cell transformed by a virus. The method includes contacting a compound of Formula (Ia) or embodiment thereof, or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof, with a cell transformed by a virus, wherein the virus can be selected from human papilloma virus, HIV, hepatitis B virus, hepatitis C virus, variola virus, vaccinia virus, an adenovirus, a cytomegalovirus, herpes simplex virus 1, herpes simplex virus 2, Epstein Barr virus, BK virus, JC virus, feline leukemia virus and feline immunodeficiency virus, thereby inhibiting growth of the cell transformed by a virus.
- Methods of Synthesis
- In another aspect, there is provided a method for synthesis of compounds of Formula (I), as depicted in Scheme 1 following. For Scheme 1, substituents BNuc, X, R and L are as described for Formula (I) herein.
- In another aspect, there is provided a method for synthesis of compounds of Formula (Ia), as depicted in Scheme 1a following. For Scheme 1a, substituents BNuc(a), Xa, Ra and La are as described for Formula (Ia) herein.
- The method includes reacting a suitably substituted ANP monoester with R—OH or Ra—OH in the presence of a coupling agent such as (benzotriazol-1-yloxy)-tripyrrolidinophosphonium hexafluorophosphate (PYBOP®) to give a diester. Methods for preparing the ANP monoesters are well known. For examples, see Beadle, J. R et al. Journal of Medicinal Chemistry, 2006, 49:2010-2015, and Valiaeva, N. et al. Antiviral Research, 2006, 72:10-19. The use of PYBOP® for synthesis of phosphonate diesters was first described in Campagne, J-M. et al. Tetrahedron Letters, 1993, 34:6743-6744. Other coupling/condensation reagents, for example uronium, carbodiimide, imidazolium and acid chloride reagents, may also be used (for a review of coupling agents see, e.g., El-Faham, A. & Albericio, F. Chemical Reviews, 2011, 111:6557-6602).
- In another aspect, there is provided a method for synthesis of compounds of Formula (I). The method includes the steps provided in Scheme 2 following:
- In the method of Scheme 2, BNuc is a naturally occurring purine or pyrimidine base, or analog thereof; L is a lipophilic promoiety, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, or O-substituted glyceryl having the formula —CH2CH(OR1)—CH2(OR2) (II), wherein R1 and R2 are independently substituted or unsubstituted alkyl or substituted or unsubstituted aryl; R is substituted or unsubstituted lower alkyl, substituted or unsubstituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, substituted or unsubstituted lower heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted lower heteroaryl; X is hydrogen, substituted or unsubstituted lower alkyl, or substituted or unsubstituted lower heteroalkyl; and Y is a leaving group.
- The method includes: 1) contacting a protected nucleoside BNuc with structure of Formula (2-1) with an ester with structure of Formula (2-2) in the presence of a strong base under conditions suitable to afford a monoester with structure of Formula (2-3); and 2) reacting the monoester so formed with structure of Formula (2-3) with L-OH in the presence of a coupling agent as known in the art, thereby synthesizing a compound with structure of Formula (I).
- In another aspect, there is provided a method for synthesis of compounds of Formula (Ia). The method includes the following as provided in Scheme 2a. For Scheme 2a, substituents BNuc(a), Xa, Ra and La are as described for Formula (Ia) herein, and Ya can be a leaving group.
- The method includes: 1) contacting a protected nucleoside BNuc(a) with structure of Formula (2-1a) with an ester with structure of Formula (2-2a) in the presence of a strong base under conditions suitable to afford a monoester with structure of Formula (2-3a); and 2) reacting the monoester so formed with structure of Formula (2-3a) with La-OH in the presence of a coupling agent as known in the art, thereby synthesizing a compound with structure of Formula (Ia).
- In embodiments, the method includes the steps provided in Scheme 2-1 following, specifically, contacting a suitably protected nucleoside (general structure 2-1 where BNuc is a naturally occurring or modified purine or pyrimidine base, with an ester of general structure 2-2 (where Y is a leaving group such as p-toluenesulfonyl, methanesulfonyl, trifluoromethanesulfonyl, bromo, iodo, or the like) in the presence of a strong base and suitable solvent to yield ANP monoesters of Formula 2-3, and secondly, reacting ANP monoester 2-3 with L-OH (i.e., hydroxy form of L) in the presence of a coupling agent such as PYBOP® to give a diester of Formula (I).
- In another aspect, there is provided method for synthesis of a compound with structure of Formula (I) according to Scheme 2-1. BNuc, X, R and L are as described for Formula (I) herein, and Y can be a leaving group; said method comprising: contacting a compound of Formula (2-1) that has a protected BNuc with a compound of Formula (2-2) in the presence of a strong base to form a compound of Formula (2-3); and reacting the compound of Formula (2-3) with L-OH in the presence of a coupling agent to form the compound of Formula (I).
- In another aspect, there is provided method for synthesis of a compound with structure of Formula (Ia) according to Scheme 2-1a. For this method, BNuc(a) can be a naturally occurring purine, a naturally occurring pyrimidine, a non-naturally occurring purine or a non-naturally occurring pyrimidine; La can be an unsubstituted C12-24 alkyl, an unsubstituted C13-29 heteroalkyl or a substituted glyceryl moiety, wherein the glyceryl moiety can be substituted with one or more groups selected from an unsubstituted C13-29 alkyl, an unsubstituted C13-29 heteroalkyl, a substituted or unsubstituted aryl(C1-6 alkyl), a substituted or unsubstituted heteroaryl(C1-6 alkyl) and a substituted or unsubstituted heterocycloalkyl(C1-6 alkyl); Ra can be selected from an unsubstituted C1-6 alkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aryl(C1-6 alkyl), a substituted or unsubstituted heteroaryl(C1-6 alkyl) and a substituted or unsubstituted heterocycloalkyl(C1-6 alkyl); Xa can be hydrogen, an unsubstituted C1-6 alkyl, a halogen substituted C1-6 alkyl, a hydroxy substituted C1-6 alkyl or an unsubstituted C1-6 alkoxy; and Ya can be a leaving group; said method comprising: contacting a compound of Formula (2-1a) that has a protected BNuc(a) with a compound of Formula (2-2a) in the presence of a strong base to form a compound of Formula (2-3a); and reacting the compound of Formula (2-3a) with La-OH in the presence of a coupling agent to form the compound of Formula (Ia).
- In another aspect, there is provided a method for synthesizing a compound of Formula (I) as described in Scheme 3 following. For Scheme 3, substituents BNuc, X, R and L are as described for Formula (I) herein.
- The method includes contacting a suitably protected nucleoside (general structure 3-1 where BNuc is a naturally occurring or modified purine or pyrimidine base), with a diester of general structure 3-2 (where Y is a leaving group such as p-toluenesulfonyl, methanesulfonyl, trifluoromethanesulfonyl, bromo, iodo, or the like) in the presence of a strong base and suitable solvent to yield a compound of Formula (I).
- In another aspect, there is provided a method for synthesizing a compound of Formula (Ia) as described in Scheme 3a. For Scheme 3a, substituents BNuc(a), Xa, Ra and La are as described for Formula (Ia) herein, and Ya is a leaving group.
- The method includes contacting a suitably protected nucleoside (3-1a), with a diester 3-2 (where Ya is a leaving group such as p-toluenesulfonyl, methanesulfonyl, trifluoromethanesulfonyl, bromo, iodo, or the like) in the presence of a strong base and suitable solvent to yield a compound of Formula (Ia).
- Pharmaceutical Compositions
- In another aspect, there is provided a pharmaceutical compositions including a compound of Formula (I) and/or a compound of Formula (Ia) in combination with a pharmaceutically acceptable excipient (e.g., carrier).
- The terms “pharmaceutically acceptable carrier,” “pharmaceutically acceptable excipient” and the like as used herein refer to pharmaceutical excipients, for example, pharmaceutically, physiologically, acceptable organic or inorganic carrier substances suitable for enteral or parenteral application that do not deleteriously react with the active agent. Suitable pharmaceutically acceptable carriers include water, salt solutions (such as Ringer's solution), alcohols, oils, gelatins, and carbohydrates such as lactose, amylose or starch, fatty acid esters, hydroxymethycellulose, and polyvinyl pyrrolidine. Such preparations can be sterilized and, if desired, mixed with auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like that do not deleteriously react with the compounds described herein.
- The compounds described herein can be administered alone or can be coadministered to the subject. Coadministration is meant to include simultaneous or sequential administration of the compounds individually or in combination (more than one compound). The preparations can also be combined, when desired, with other active substances (e.g., to reduce metabolic degradation).
- Formulations
- The compounds described herein can be prepared and administered in a wide variety of oral, parenteral, and topical dosage forms. Thus, the compounds described herein can be administered by injection (e.g. intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally). Also, the compounds described herein can be administered by inhalation, for example, intranasally. Additionally, the compounds described herein can be administered transdermally. It is also envisioned that multiple routes of administration (e.g., intramuscular, oral, transdermal) can be used to administer the compounds described herein. Accordingly, pharmaceutical compositions comprising a pharmaceutically acceptable carrier or excipient and one or more compounds are contemplated.
- For preparing pharmaceutical compositions, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances that may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
- In powders, the carrier is a finely divided solid in a mixture with the finely divided active component. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
- The powders and tablets preferably contain from 5% to 70% of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term “preparation” is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.
- For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.
- Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water/propylene glycol solutions. For parenteral injection, liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.
- When parenteral application is needed or desired, particularly suitable admixtures are injectable, sterile solutions, preferably oily or aqueous solutions, as well as suspensions, emulsions, or implants, including suppositories. In particular, carriers for parenteral administration include aqueous solutions of dextrose, cyclodextrins, saline, pure water, ethanol, glycerol, propylene glycol, peanut oil, sesame oil, polyoxyethylene-block polymers, and the like. Ampoules are convenient unit dosages. The compounds described herein can also be incorporated into liposomes or administered via transdermal pumps or patches. Pharmaceutical admixtures suitable for use include those described, for example, in PHARMACEUTICAL SCIENCES (17th Ed., Mack Pub. Co., Easton, Pa.) and WO 96/05309, the teachings of both of which are hereby incorporated by reference.
- Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizers, and/or thickening agents as desired. Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.
- Also included are solid form preparations that are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
- The pharmaceutical preparation is preferably in unit dosage form. In such form the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form. In embodiments, the unit dosage form can be in the form of an applicator pre-filled with a pharmaceutical composition described herein (for example, a pharmaceutical composition that contains an effective amount of a compound of Formula (I) and/or a compound of Formula (Ia)). In embodiments, the pre-filled applicator can be filled with a pharmaceutical composition in the form of a cream, a gel or an ointment that contains a compound described herein (for example, a compound of Formula (I) and/or a compound of Formula (Ia)).
- The quantity of active component in a unit dose preparation may be varied or adjusted from 0.1 mg to 10000 mg, more typically 1.0 mg to 1000 mg, most typically 10 mg to 500 mg, according to the particular application and the potency of the active component. The composition can, if desired, also contain other compatible therapeutic agents.
- Some compounds may have limited solubility in water and therefore may require a surfactant or other appropriate co-solvent in the composition. Such co-solvents include:
Polysorbate polyoxyl 35 castor oil. Such co-solvents are typically employed at a level between about 0.01% and about 2% by weight. - Viscosity greater than that of simple aqueous solutions may be desirable to decrease variability in dispensing the formulations, to decrease physical separation of components of a suspension or emulsion of formulation, and/or otherwise to improve the formulation. Such viscosity building agents include, for example, polyvinyl alcohol, polyvinyl pyrrolidone, methyl cellulose, hydroxy propyl methylcellulose, hydroxyethyl cellulose, carboxymethyl cellulose, hydroxy propyl cellulose, chondroitin sulfate and salts thereof, hyaluronic acid and salts thereof, and combinations of the foregoing. Such agents are typically employed at a level between about 0.01% and about 2% by weight.
- The compositions may additionally include components to provide sustained release and/or comfort. Such components include high molecular weight, anionic mucomimetic polymers, gelling polysaccharides, and finely-divided drug carrier substrates. These components are discussed in greater detail in U.S. Pat. Nos. 4,911,920; 5,403,841; 5,212,162; and 4,861,760. The entire contents of these patents are incorporated herein by reference in their entirety for all purposes.
- Effective Dosages
- Pharmaceutical compositions include compositions wherein the active ingredient is contained in a therapeutically effective amount, i.e., in an amount effective to achieve its intended purpose. The actual amount effective for a particular application will depend, inter alia, on the condition being treated. For example, when administered in methods to treat cancer, such compositions will contain an amount of active ingredient effective to achieve the desired result (e.g., decreasing the number of cancer cells in a subject).
- The dosage and frequency (single or multiple doses) of compound administered can vary depending upon a variety of factors, including route of administration; size, age, sex, health, body weight, body mass index, and diet of the recipient; nature and extent of symptoms of the disease being treated; presence of other diseases or other health-related problems; kind of concurrent treatment; and complications from any disease or treatment regimen. Other therapeutic regimens or agents can be used in conjunction with the methods and compounds described herein.
- For any compound described herein, the therapeutically effective amount can be initially determined from cell culture assays. Therapeutically effective amounts for use in humans may subsequently be estimated from animal models using conventional techniques that are confirmed or refined in actual clinical trials.
- Dosages may be varied depending upon the requirements of the patient and the compound being employed. The dose administered to a patient should be sufficient to effect a beneficial therapeutic response in the patient over time. The size of the dose also will be determined by the existence, nature, and extent of any adverse side effects. Generally, treatment is initiated with smaller dosages, which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under circumstances is reached. In one embodiment, the dosage range is 0.001% to 10% w/v. In another embodiment, the dosage range is 0.1% to 5% w/v.
- Dosage amounts and intervals can be adjusted individually to provide levels of the administered compound effective for the particular clinical indication being treated. This will provide a therapeutic regimen that is commensurate with the severity of the individual's disease state.
- Utilizing the teachings provided herein, an effective prophylactic or therapeutic treatment regimen can be planned that does not cause substantial toxicity and yet is entirely effective to treat the clinical symptoms demonstrated by the particular patient. This planning should involve the careful choice of active compound by considering factors such as compound potency, relative bioavailability, patient body weight, presence and severity of adverse side effects, preferred mode of administration, and the toxicity profile of the selected agent.
- Toxicity
- The ratio between toxicity and therapeutic effect for a particular compound is its therapeutic index and can be expressed as the ratio between LD50 (the amount of compound lethal in 50% of the population) and ED50 (the amount of compound effective in 50% of the population). Compounds that exhibit high therapeutic indices are preferred. Therapeutic index data obtained from cell culture assays and/or animal studies can be used in formulating a range of dosages for use in humans. The dosage of such compounds preferably lies within a range of plasma concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. See, e.g. Fingl et al., In: T
HE PHARMACOLOGICAL BASIS OF THERAPEUTICS , Ch. 1, p. 1, 1975. The exact formulation, route of administration, and dosage can be chosen by the individual physician in view of the patient's condition and the particular method in which the compound is used. - General Chemistry Methods:
- All reagents were of commercial quality and used without further purification unless indicated otherwise. Chromatographic purification was done using the flash method with silica gel 60 (EMD Chemicals, Inc., 230-400 mesh). 1H NMR spectra were recorded on a Varian HG spectrophotometer operating at 400 MHz and are reported in units of parts per million (ppm) relative to internal tetramethylsilane at 0.00 ppm. Routine electrospray ionization mass spectra (ESI-MS) were recorded on a Finnigan LCQ DECA spectrometer, and high resolution mass spectra (HRMS) were recorded on an Agilent 6230 Accurate-Mass TOFMS mass spectrometer in ESI negative mode. Purity of the target compounds was characterized by high performance liquid chromatography (HPLC) using a Beckman Coulter SYSTEM GOLD® chromatography system. The analytical column was PHENOMENEX® SYNERGI™ Polar-RP (4.6×150 mm) equipped with a SECURITYGUARD™ protection column. Mobile phase A was 95% water/5% methanol and mobile phase B was 95% methanol/5% water. At a flow rate of 0.8 mL/min, isocratic elution was used. Compounds were detected by ultraviolet light (UV) absorption at 274 nm. Homogeneity of the target compounds was also confirmed by thin layer chromatography (TLC) using Analtech silica gel-GF (250 μm) plates and the solvent system: CHCl3/MeOH/con NH4OH/H2O (70:30:3:3 v/v). TLC results were visualized with UV light, phospray (SUPELCO®, Bellefonte, Pa., USA) and charring at 400° C.
-
- To a solution of octadecyloxyethyl 9-[2-(phosphonomethoxy)ethyl]guanine (ODE-PMEG) [prepared according to: Valiaeva, N. et al.; Antiviral Research, 2006, 72:10-19] (0.21 g, 0.35 mmol), (benzotriazol-1-yloxy)-tripyrrolidinophosphonium hexafluorophosphate (PYBOP®, 0.27 g, 0.525 mmol) and anhydrous benzyl alcohol (0.05 ml, 0.525 mmol) in dry N,N-DMF, diisopropylethylamine (DIEA, 0.24 ml, 1.4 mmol) was added. The mixture was stirred at room temperature for 30 min. The solvents were evaporated in vacuo. The residue was dissolved in ethyl acetate (50 ml) and extracted with saturated sodium bicarbonate (2×10 ml). The ethyl acetate layer was evaporated, and then the residue was adsorbed on silica gel and purified by flash column chromatography. Elution with CH2Cl2/MeOH (0-5%) gave 0.15 g (62%) of Cmpd 1 as a white powder. 1H NMR (CDCl3/methanol-d4) δ 7.56 (s, 1H); 7.35-7.40 (m, 5H); 5.08 (dd, J=9 Hz, J1=2 Hz, 2H); 4.19 (t, J=7 Hz, 2H); 4.09-4.17 (m, 2H); 3.87 (t, J=5 Hz, 2H), 3.85 (dd, J=8 Hz, J1=2 Hz, 2H); 3.57 (t, J=5 Hz, 2H); 3.44 (t, J=7 Hz, 2H); 1.50-1.60 (m, 2H); 1.20-1.38 (m, 30H); 0.89 (t, J=7 Hz, 3H). MS (EI): 676.34 (M+H)+, 698.41 (M+Na)+.
-
- Bn-ODE-PMEG of Example 1 was obtained as a mixture of enantiomers because of the chirality at phosphorus. The enantiomers were separated on a Lux™ Cellulose-1 column (Phenomenex®, Torrance, Calif. USA) using reverse phase conditions (mobile phase of 50:50:0.1 20 mM AmmAc:AcN:TFA). The absolute stereochemistry of the P-chiral enantiomers was not determined. The preparative chromatographic resolution of the material obtained in Example 1 provided two enantiomers that are characterized as 1a (fast eluting enantiomer) and 1b (slow eluting enantiomer). An example chromatogram is provided in the FIGURE.
- In the following examples, preparation of the racemic mixture is described, however, the method of Example 2, or modifications thereof known in the art, can be used to resolve each into optically active enantiomers or diastereomers as needed.
-
- To a solution of octadecyloxyethyl 9-[2-(phosphonomethoxy)ethyl]adenine (ODE PMEA) [prepared according to: Valiaeva, N. et al. Antiviral Research 2006, 72:10-19] (0.2 g, 0.35 mmol), (benzotriazol-1-yloxy)-tripyrrolidinophosphonium hexafluorophosphate (PYBOP®, 0.27 g, 0.525 mmol), anhydrous benzyl alcohol (0.05 ml, 0.525 mmol) in dry N,N-DMF, diisopropylethylamine (DIEA, 0.24 ml, 1.4 mmol) was added. The mixture was stirred at room temperature for 30 min. The solvents were evaporated. The residue was dissolved in ethyl acetate (50 ml) and washed with a saturated solution of sodium bicarbonate (2×10 ml). The ethyl acetate layer was evaporated, and then the residue was purified by column chromatography on silica gel using CH2Cl2/MeOH (0-5%) to give 0.12 g (50%) of compound 2. 1H NMR (CDCl3/methanol-d4) δ 8.25 (s, 1H); 7.99 (s, 1H); 7.30-7.40 (m, 5H); 5.07 (dd, J=9 Hz, J1=2 Hz, 2H); 4.38 (t, J=7 Hz, 2H); 4.08-4.18 (m, 2H); 3.88 (t, J=5 Hz, 2H), 3.83 (dd, J=8 Hz, J1=2 Hz, 2H); 3.56 (t, J=5 Hz, 2H); 3.42 (t, J=7 Hz, 2H); 1.50-1.60 (m, 2H); 1.20-1.38 (m, 30H); 0.88 (t, J=7 Hz, 3H). MS (EI): 660.55 (M+H)+.
- Method 1:
- To a solution of octadecyloxyethyl 9-(S)-[3-trityloxy-2-(phosphonomethoxy) propyl]-N6-trityladenine (prepared as described in: Beadle, J. R. et al. Journal of Medicinal Chemistry 2006, 49:2010-2015) (0.42 g, 0.38 mmol), (benzotriazol-1-yloxy)-tripyrrolidinophosphonium hexafluorophosphate (PYBOP®, 0.30 g, 0.58 mmol), benzyl alcohol (0.06 ml, 0.58 mmol) in dry N,N-DMF (2 ml), diisopropylethylamine (DIEA, 0.4 ml, 1.52 mmol) was added. The mixture was stirred at room temperature for 30 min. The solvents were evaporated. The residue was dissolved in ethyl acetate (50 ml), and then washed with saturated solution of sodium bicarbonate (2×10 ml). Ethyl acetate was evaporated, and the residue was purified by column chromatography on silica gel using CH2Cl2/MeOH (0-5%) to give 0.23 g (51%) of the product. 1H NMR (CDCl3/methanol-d4) δ 7.89 (s, 1H); 7.16-7.40 (m, 36H); 5.03 (dd, J=9 Hz, J1=2 Hz, 2H); 4.27-4.44 (m, 2H); 4.06-4.14 (m, 1H); 3.91-4.04 (m, 2H), 3.83 (dd, J=8 Hz, J1=2 Hz, 2H); 3.40-3.50 (m, 2H); 3.27-3.40 (m, 4H); 1.42-1.58 (m, 2H); 1.18-1.38 (m, 30H); 0.88 (t, J=7 Hz, 3H). MS (EI): 1174.27 (M+H)+.
- The protected intermediate (0.13 g, 0.11 mmol) was added to 80% aq acetic acid (10 ml) and stirred at 30° C. for 3 h. After cooling, the solvent was evaporated and the residue was purified by column chromatography on silica gel to give compound 218 (0.04 g, 52% yield). 1H NMR (CDCl3/methanol-d4) δ 8.25 (s, 1H); 7.89 (s, 1H); 7.26-7.38 (m, 5H); 5.09 (dd, J=9 Hz, J1=2 Hz, 2H); 4.28-4.43 (m, 2H); 4.06-4.18 (m, 1H); 3.95-4.05 (m, 2H), 3.80 (dd, J=8 Hz, J1=2 Hz, 2H); 3.50-3.60 (m, 2H); 3.25-3.38 (m, 4H); 1.49-1.60 (m, 2H); 1.10-1.40 (m, 30H); 0.88 (t, J=7 Hz, 3H). MS (EI): 690.49 (M+H)+, 712.47 (M+H)+.
- Method 2:
- A mixture of 9-(S)-[3-trityloxy-2-hydroxypropyl]-N6-trityladenine [prepared as in: Webb, R. R., Nucleosides & Nucleotides, 1989, 8:619-24] (1.4 g, 2.0 mmol) and sodium tert-butoxide (0.39 g, 4 mmol) in dry N,N-DMF (10 ml) were stirred at room temperature for 30 min, then benzyl p-toluenesulfonyloxymethylphosphonate (0.94 g, 2.5 mmol, see Example 6) was added. The mixture was stirred at 80° C. overnight. The solvent was evaporated, and then the residue was purified by column chromatography on silica gel to give benzyl 9-(S)-[3-trityloxy-2-(phosphonomethoxy)propyl]-N6-trityladenine 0.75 g (42%). 1H NMR (CDCl3/methanol-d4) δ 8.09 (s, 1H); 7.88 (s, 1H); 7.08-7.60 (m, 30H); 4.84-4.88 (m, 2H); 4.20-4.30 (m, 2H); 3.78-4.90 (m, 1H); 3.50-3.72 (m, 2H), 2.99-3.18 (m, 2H).
- To a solution of this intermediate (0.2 g, 0.22 mmol), (benzotriazol-1-yloxy)-tripyrrolidinophosphonium hexafluorophosphate (PYBOP®, 0.17 g, 0.33 mmol) and octadecyloxyethanol (0.10 g, 0.33 mmol) in dry N,N-DMF (2 ml), diisopropylethylamine (DIEA, 0.15 ml, 0.88 mmol) was added. The mixture was stirred at room temperature for 30 min and the solvent was evaporated. The residue was dissolved in ethyl acetate (50 ml) and washed with saturated solution of sodium bicarbonate (2×10 ml). The ethyl acetate layer was evaporated, and then the residue was purified by column chromatography on silica gel using CH2Cl2/MeOH (0-5%) to give 0.15 g (58%) of the product. 1H NMR (CDCl3/methanol-d4) δ: 7.93 (s, 1H); 7.87 (s, 1H); 7.16-7.42 (m, 35H); 5.00 (dd, J=9 Hz, J1=2 Hz, 2H); 4.27-4.44 (m, 2H); 4.06-4.14 (m, 1H); 3.91-4.04 (m, 2H), 3.83 (dd, J=8 Hz, J1=2 Hz, 2H); 3.40-3.50 (m, 2H); 3.27-3.40 (m, 4H); 1.42-1.58 (m, 2H); 1.18-1.38 (m, 30H); 0.88 (t, J=7 Hz, 3H). MS (EI): 1174.29 (M+H)+; 1196.52 (M+Na)+.
- The protected compound (0.15 g, 0.13 mmol) was treated with 80% aq acetic acid (10 ml) at 30° C. for 3 h. The solvents were evaporated, and then the residue was purified by column chromatography on silica gel to give compound 218 (0.06 g, 68%). 1H NMR (CDCl3/methanol-d4) δ: 8.24 (s, 1H); 7.52 (s, 1H); 7.34-7.38 (m, 5H); 5.06 (dd, J=9 Hz, J1=2 Hz, 2H); 4.28-4.46 (m, 2H); 4.06-4.16 (m, 2H); 3.95-4.16 (m, 1H), 3.76-3.87 (m, 2H); 3.52-3.66 (m, 4H); 3.39-3.48 (m, 2H); 1.49-1.60 (m, 2H); 1.20-1.40 (m, 30H); 0.89 (t, J=7 Hz, 3H). MS (EI): 690.47 (M+H)+, 712.45 (M+Na)+.
-
- To a suspension of octadecyloxyethyl 9-[2-(phosphonomethoxy)ethyl]guanine (ODE PMEG)) [prepared according to: Valiaeva, N. et al.; Antiviral Research, 2006, 72:10-19] (0.18 g, 0.30 mmol), oxalyl chloride (0.56 ml, 0.48 mmol) in dry toluene (5 ml), DMF (0.06 ml) was added. The mixture was stirred at room temperature for 1 h. The solvent was evaporated in vacuum and co-evaporated with toluene (2×10 ml). The residue was dissolved in toluene (5 ml) and isopropylidene glycerol (0.09 g, 0.6 mmol) was added. The mixture was stirred at room temperature overnight. A solution of saturated sodium bicarbonate (5 ml) was added, and the mixture was stirred for 30 min. The toluene fraction was evaporated and purified by column chromatography on silica gel to give 0.05 g of IPG-ODE-PMEG (23%). 1H NMR (CDCl3/methanol-d4) δ: 8.91 (s, 1H); 8.15 (s, 1H); 4.44-4.52 (m, 2H); 4.18-4.34 (m, 2H); 4.13-4.18 (m, 1H); 4.02-4.13 (m, 2H); 3.95-4.18 (m, 2H); 3.68-3.84 (m, 2H); 3.60-3.67 (m, 2H); 3.44-3.52 (m, 2H); 1.42 (t, J=7 Hz, 3H); 1.36 (t, J=7 Hz, 3H); 1.22-1.34 (m, 30H), 0.89 (t, J=7 Hz, 3H). MS (EI): 700.37 (M+H)+, 722.43 (M+Na)+.
- Diethyl p-toluenesulfonyloxymethyl phosphonate (3.2 g, 9.9 mmol) was dissolved in N,N-DMF (10 ml) and then bromotrimethylsilane (10 ml) was added. The mixture was stirred at room temperature overnight. The solvent was evaporated, and co-evaporated with toluene (2×10 ml). An ethanol/water mixture (10 ml) was added, and then mixture was stirred for 30 min at room temperature. The solvents were evaporated and co-evaporated with toluene (2×10 ml). The residue was suspended in toluene (50 ml), and then oxalyl chloride (1.3 ml, 15.0 mmol) was added followed by N,N-DMF (0.01 ml). The mixture was stirred at room temperature for 1 h. The solvents were evaporated and co-evaporated with toluene (2×10 ml). The residue was suspended in toluene (25 ml), and then anhydrous benzyl alcohol (1.5 ml, 15.0 mmol) was added. The mixture was stirred at room temperature overnight. A solution of saturated sodium bicarbonate (15 ml) was added, and then the mixture was stirred for 30 min. The toluene fraction was evaporated, and the residue was purified by column chromatography on silica gel to give 2.94 g of benzyl p-toluenesulfonyloxymethyl phosphonate, sodium salt (81%). 1H NMR (CDCl3/methanol-d4) δ: 7.72 (d, J=8 Hz, 2H); 7.30-7.33 (m, 7H); 4.88 (d, J=7 Hz, 2H); 4.02 (d, J=9 Hz, 2H); 2.44 (s, 3H).
-
- To a solution of benzyl 9-(S)-[3-trityloxy-2-(phosphonomethoxy)propyl]-N6-trityladenine (prepared as in Example 4, method 2) (0.4 g, 0.44 mmol), (benzotriazol-1-yloxy)-tripyrrolidinophosphonium hexafluorophosphate (PYBOP®, 0.27 g, 0.51 mmol), 1-O-octadecyl-2-O-benzyl-sn-glycerol (0.22 g, 0.51 mmol) in dry N,N-DMF (1 ml), diisopropylethylamine (DIEA, 0.30 ml, 1.7 mmol) was added. The mixture was stirred at room temperature for 30 min. The solvents were evaporated. The residue was dissolved in ethyl acetate (50 ml), and then washed with a solution of saturated sodium bicarbonate (2×10 ml). The ethyl acetate layer was evaporated and then the residue was purified by column chromatography on silica gel using CH2Cl2/MeOH (0-5%) to give 0.15 g (58%) of the product. 1H NMR (CDCl3/methanol-d4) δ: 7.88 (s, 1H); 7.87 (s, 1H); 7.19-7.42 (m, 40H); 4.95-5.03 (m, 2H); 4.57-4.60 (m, 2H); 4.29-4.39 (m, 2H); 4.16-4.28 (m, 2H), 4.00-4.12 (m, 1H); 3.90-3.98 (m, 1H); 3.65-3.81 (m, 4H); 3.45-3.49 (m, 2H); 1.46-1.53 (m, 2H); 1.22-1.32 (m, 30H); 0.88 (t, J=7 Hz, 3H). MS (EI): 1294.27 (M+H)+; 1316.57 (M+Na)+.
- The protected compound (0.33 g, 0.13 mmol) was treated with 80% aq acetic acid (20 ml) at 30° C. for 3 h. The solvents were then evaporated and the residue was purified by column chromatography on silica gel to give compound 230 (0.13 g, 65%). 1H NMR (CDCl3/methanol-d4) δ: 8.22 (s, 1H); 7.65 (s, 1H); 7.27-7.35 (m, 10H); 4.99-5.04 (m, 2H); 4.58-4.66 (m, 2H); 4.33-4.43 (m, 1H); 4.16-4.33 (m, 2H), 3.94-4.12 (m, 2H); 3.80-3.88 (m, 1H); 3.68-3.78 (m, 2H); 3.38-3.62 (m, 4H); 1.50-1.58 (m, 2H); 1.22-1.38 (m, 30H); 0.89 (t, J=7 Hz, 3H). MS (EI): 810.47 (M+H)+, 832.44 (M+Na)+.
-
- A mixture of 1-(S)-[3-trityloxy-2-hydroxypropyl]-N4-monomethoxytritylcytosine [prepared as described in: Beadle, J. R., et al., PCT Int. Appl. WO 2005/087788 A2, published Sep. 22, 2005] (1.84 g, 2.63 mmol) and sodium tert-butoxide (1.24 g, 3.29 mmol) in dry DMF (20 ml) were stirred at room temperature for 30 min. Benzyl p-toluenesulfonyloxymethylphosphonate (0.94 g, 2.5 mmol, see Example 6) were added and the mixture was stirred at 80° C. overnight. The solvent was evaporated, and the residue was purified by column chromatography on silica gel to give benzyl 1-(S)-[3-trityloxy-2-(phosphonomethoxy)propyl]-N4-monomethoxytritylcytosine 1.25 g (52%). 1H NMR (CDCl3/methanol-d4) δ: 7.12-7.48 (m, 24H); 7.05 (d, J=9 Hz, 1H); 6.79 (d, J=9 Hz, 1H); 4.70 (dd, J1=30 Hz, J2=6 Hz, 2H); 4.20-4.30 (m, 2H); 3.78-4.90 (m, 1H); 3.77 (s, 3H); 3.50-3.72 (m, 2H), 2.99-3.18 (m, 2H). (EI): 883.99 (M+H)+, 906.22 (M+Na)+.
- To a solution of this intermediate (0.6 g, 0.66 mmol), (benzotriazol-1-yloxy)-tripyrrolidinophosphonium hexafluorophosphate (PYBOP®, 0.52 g, 0.99 mmol), octadecyloxyethanol (0.31 g, 0.52 mmol) in dry DMF (5 ml), diisopropylethylamine (DIEA, 0.46 ml, 2.65 mmol) was added. The mixture was stirred at room temperature for 30 min and then the solvents were evaporated. The residue was dissolved in ethyl acetate (50 ml), and washed with saturated solution of sodium bicarbonate (2×10 ml). Ethyl acetate was evaporated, and the residue was purified by column chromatography on silica gel using CH2Cl2/MeOH (0-5%) to give the product. 1H NMR (CDCl3/methanol-d4) δ: 7.18-7.44 (m, 34H); 7.13 (dd, J=14 Hz, J2=7 Hz, 1H); 6.85 (dd, J1=14 Hz, J2=7 Hz, 1H); 5.00 (dd, J1=8 Hz, J2=3 Hz, 2H); 4.04-4.12 (m, 2H); 3.88-3.95 (m, 1H); 3.80 (s, 3H); 3.58-3.79 (m, 4H); 3.45-3.57 (m, 2H); 3.16-3.22 (m, 1H); 3.02-3.08 (m, 1H); 1.43-1.52 (m, 2H); 1.08-1.38 (m, 30H); 0.88 (t, J=7 Hz, 3H). (EI): 1180.10 (M+H)+, 1202.57 (M+Na)+.
- The protected compound (0.44 g, 0.37 mmol) was treated with 80% acetic acid (20 ml) at 30° C. for 3 h. The solvents were evaporated, and the residue was purified by column chromatography to give compound 219 (0.16 g, 64%). 1H NMR (CDCl3/methanol-d4) δ: 7.40-7.42 (m, 5H); 7.38 (dd, J1=14 Hz, J2=7 Hz, 1H); 5.73 (dd, J1=14 Hz, J2=7 Hz, 1H); 5.12 (dd, J1=8 Hz, J2=3 Hz, 2H); 4.10-4.20 (m, 2H), 3.99-4.10 (m, 2H), 3.50-3.80 (m, 7H), 3.40-3.50 (m, 2H); 1.50-1.62 (m, 2H), 1.20-1.40 (m, 30H), 0.89 (t, J=7 Hz, 3H). Mass spec (ESI): 666.54 (M+H)+, 688.52 (M+Na)+.
- To a solution of the intermediate from Example 8, benzyl 1-(S)-[3-trityloxy-2-(phosphonomethoxy)propyl] N4-monomethoxytrityl cytosine (0.57 g, 0.63 mmol), (benzotriazol-1-yloxy)-tripyrrolidinophosphonium hexafluorophosphate (PYBOP®, 0.49 g, 0.95 mmol) and 1-O-octadecyl-2-O-benzyl-sn-glycerol (0.41 g, 0.95 mmol) in dry DMF (5 ml), diisopropylethylamine (DIEA, 0.44 ml, 2.52 mmol) was added. The mixture was stirred at room temperature for 30 min. The solvents were evaporated. The residue was dissolved in ethyl acetate (50 ml) and washed with saturated solution of sodium bicarbonate (2×10 ml). Ethyl acetate was evaporated, and the residue was purified by column chromatography on silica gel using CH2Cl2/MeOH (0-5%) to give 0.30 g (36%) of the product. 1H NMR (CDCl3/methanol-d4) δ: 7.19-7.45 (m, 39H); 7.15 (dd, J1=14 Hz, J2=7 Hz, 1H); 6.82 (dd, J1=14 Hz, J2=7 Hz, 1H); 5.00 (dd, J1=8 Hz, J2=3 Hz, 2H); 4.69-4.71 (m, 2H); 4.05 (s, 3H), 3.96-4.05 (m, 2H); 3.82-3.90 (m, 1H); 3.50-3.80 (m, 4H); 3.40-3.53 (m, 2H); 3.24-3.40 (m, 4H); 3.02-3.08 (m, 1H); 1.43-1.50 (m, 2H); 1.20-1.40 (m, 30H); 0.88 (t, J=7 Hz, 3H). (EI): 1301.06 (M+H)+, 1322.58 (M+Na)+.
- The protected compound (0.30 g, 0.23 mmol) was then treated with 80% acetic acid (20 ml) at 30° C. for 3 h. The solvents were evaporated, and the residue was purified by column chromatography to give compound 231 (0.10 g, 55%). 1H NMR (CDCl3/methanol-d4) δ: 7.31-7.40 (m, 10H); 7.28 (dd, J1=14 Hz, J2=7 Hz, 1H); 5.66 (dd, J1=14 Hz, J2=7 Hz, 1H); 5.07 (dd, J1=8 Hz, J2=3 Hz, 2H); 4.63-4.66 (m, 2H), 4.18-4.27 (m, 2H), 4.02-4.14 (m, 2H), 3.90-3.98 (m, 2H), 3.40-3.84 (m, 8H); 1.50-1.62 (m, 2H), 1.20-1.40 (m, 30H), 0.89 (t, J=7 Hz, 3H). Mass spec (ESI): 786.43 (M+H)+, 808.41 (M+Na)+.
-
- To a solution of octadecyloxyethyl 9-[2-(phosphonomethoxy)ethyl]guanine (ODE-PMEG, 0.26 g, 0.44 mmol) [prepared according to: Valiaeva, N. et al. Antiviral Research 2006, 72:10-19], (benzotriazol-1-yloxy)-tripyrrolidinophosphonium hexafluorophosphate (PYBOP®, 0.34 g, 0.66 mmol), and phenol (0.06 g, 0.66 mmol) in anhydrous N,N-DMF, was added diisopropylethylamine (DIEA, 0.30 ml, 1.8 mmol). The mixture was stirred at room temperature for 30 min, and then the solvent was evaporated in vacuo. The residue was dissolved in ethyl acetate (50 ml) and washed with saturated sodium bicarbonate (2×10 ml) solution. The ethyl acetate layer was evaporated, and the crude residue was purified by flash column chromatography on silica gel using CH2Cl2/MeOH (0-5%) to afford 0.09 g (31%) of compound 19 as a white powder. 1H NMR (CDCl3/methanol-d4) δ: 7.66 (s, 1H); 7.36 (t, J=8 Hz, 2H); 7.20 (t, J=7 Hz, 1H); 7.13 (d, J=8 Hz, 2H); 4.23-4.30 (m, 4H); 4.03 (dd, J=8 Hz, J1=2 Hz, 2H); 3.93 (t, J=5 Hz, 2H); 3.61 (t, J=5 Hz, 2H), 3.41-3.45 (m, 2H); 1.50-1.60 (m, 2H); 1.20-1.38 (m, 30H); 0.89 (t, J=7 Hz, 3H). MS (EI): 662.43 (M+H)+, 684.39 (M+Na)+.
-
- To a solution of octadecyloxyethyl 9-[3-methoxy-2-(phosphonomethoxy)propyl]adenine (ODE-S)-MPMPA, 0.62 g, 1.00 mmol) [prepared as described in: Valiaeva, N. et al. Bioorganic & Medicinal Chemistry, 2011, 19:4616-4625]), (benzotriazol-1-yloxy)-tripyrrolidinophosphonium hexafluorophosphate (PYBOP®, 0.78 g, 0.66 mmol), and benzyl alcohol (0.16 ml, 1.50 mmol) in anhydrous N,N-DMF, was added diisopropylethylamine (DIEA, 0.70 ml, 4.0 mmol). The mixture was stirred at room temperature for 30 min, and then solvents was evaporated in vacuo. The residue was dissolved in ethyl acetate (50 ml) and then washed with saturated NaHCO3 (2×10 ml). The ethyl acetate layer was evaporated, and the residue was purified by flash column chromatography on silica gel using CH2Cl2/MeOH (0-5%) to give 0.29 g (41%) of compound 146. 1H NMR (CDCl3/methanol-d4) δ 8.24 (d, J=5.50 Hz, 1H), 8.05 (d, J=7.33 Hz, 1H), 7.30-7.39 (m, 5H), 5.00-5.15 (m, 2H); 4.40-4.45 (m, 1H); 4.28-4.36 (m, 1H); 4.00-4.18 (m, 3H); 3.80-3.98 (m, 2H); 3.40-3.60 (m, 6H); 3.35 (s, 3H); 1.45-1.60 (m, 2H), 1.22-1.36 (m, 30H), 0.89 (t, J=7 Hz, 3H). MS (EI): 704.52 (M+H)+, 726.45 (M+Na)+.
-
- To a solution of octadecyloxyethyl 9-[3-methoxy-2-(phosphonomethoxy)propyl]adenine (ODE (S)-MPMPA, 0.62 g, 1.00 mmol) [prepared as described in: Valiaeva, N. et al. Bioorganic & Medicinal Chemistry, 2011, 19:4616-4625], (benzotriazol-1-yloxy)-tripyrrolidinophosphonium hexafluorophosphate (PYBOP®, 0.78 g, 0.66 mmol), and phenol (0.14 g, 1.50 mmol) in dry N,N-DMF, was added diisopropylethylamine (DIEA, 0.70 ml, 4.0 mmol). The mixture was stirred at room temperature for 30 min, and then the solvent was evaporated in vacuo. The residue was dissolved in ethyl acetate (50 ml), and then washed with saturated sodium bicarbonate (2×10 ml). The ethyl acetate layer was evaporated. The crude residue was purified by flash column chromatography on silica gel using CH2Cl2/MeOH (0-5%) to give 0.29 g (41%) of compound 164 as an off white solid. 1H NMR (CDCl3/methanol-d4) δ 8.23 (d, J=5.50 Hz, 1H), 8.05 (d, J=7.33 Hz, 1H), 7.29-7.37 (m, 2H), 7.20 (d, J=6.60 Hz, 1H), 7.12-7.16 (m, 1H), 7.08 (dt, J=8.71, 1.15 Hz, 1H), 4.30-4.45 (m, 2H), 4.11-4.28 (m, 3H), 3.98-4.07 (m, 2H), 3.42-3.63 (m, 6H), 3.34 (s, 3H), 1.48-1.59 (m, 2H), 1.22-1.36 (m, 30H), 0.89 (t, J=7 Hz, 3H). MS (EI): 704.52 (M+H)+, 726.45 (M+Na)+.
-
- To a solution of hexadecyloxypropyl 9-[2-(phosphonomethoxy)propyl]guanine (HDP PMEG, 0.28 g, 0.49 mmol) [prepared according to: Valiaeva, N. et al., Antiviral Research, 2006, 72:10-19], (benzotriazol-1-yloxy)-tripyrrolidinophosphonium hexafluorophosphate (PYBOP®, 0.39 g, 0.74 mmol), and benzyl alcohol (0.10 ml, 0.74 mmol) in dry N,N-DMF, was added diisopropylethylamine (DIEA, 0.35 ml, 2.0 mmol). The mixture was stirred at room temperature for 30 min. The mixture was concentrated under vacuum. The resulting residue was dissolved in ethyl acetate (50 ml) and then washed with saturated sodium bicarbonate (2×10 ml). The ethyl acetate layer was evaporated, and the crude product was purified by flash column chromatography on silica gel using CH2Cl2/MeOH (0-5%) to give 0.03 g (10%) of
compound 25 as a powdery white solid. 1H NMR (CDCl3/methanol-d4) δ: 7.62 (s, 1H), 7.30-7.44 (m, 5H), 5.07 (dd, J=8.98, 2.02 Hz, 2H), 4.05-4.24 (m, 4H), 3.83 (m, 4H), 3.31-3.42 (m, 4H), 1.87 (m, 2H), 1.54 (m, 2H), 1.17-1.38 (m, 26H), 0.86-0.91 (m, 3H). MS (EI): 662.46 (M+H)+, 684.46 (M+Na)+. -
- To a solution of octadecyloxyethyl 9-[2-(phosphonomethoxy)propyl]adenine (ODE-(R)-PMPA, 0.30 g, 0.51 mmol) [prepared as described in: Painter, G et al. Antimicrobial Agents and Chemotherapy, 2007, 51:3505-3509], (benzotriazol-1-yloxy)-tripyrrolidinophosphonium hexafluorophosphate (PYBOP®, 0.40 g, 0.77 mmol), and benzyl alcohol (0.08 ml, 0.77 mmol) in dry N,N-DMF, was added diisopropylethylamine (DIEA, 0.35 ml, 2.0 mmol). The mixture was stirred at room temperature for 30 min, and then the solvent was evaporated under vacuum. The resulting residue was dissolved in ethyl acetate (50 ml) and washed with saturated NaHCO3 (2×10 ml). The ethyl acetate layer was evaporated, and the crude product was purified by flash column chromatography on silica gel using CH2Cl2/MeOH (0-5%) to give 0.24 g (70%) of compound 74. 1H NMR (400 MHz, CDCl3+methanol-d4) δ ppm 8.24 (s, 1H), 8.03 (d, J=4.40 Hz, 1H), 7.30-7.42 (m, 5H), 4.99-5.14 (m, 2H), 4.35 (d, J=14.66 Hz, 1H), 4.07-4.20 (m, 3H), 3.92 (ddd, J=13.75, 8.98, 4.77 Hz, 2H), 3.65-3.73 (m, 1H), 3.50-3.61 (m, 2H), 3.38-3.47 (m, 2H), 1.49-1.61 (m, 2H), 1.27 (m, 30H), 1.21 (d, J=6.23 Hz, 3H), 0.09 (t, J=8.00 Hz, 3H). MS (EI): 674.48 (M+H)+, 693.46 (M+Na)+.
-
- To a solution of octadecyloxyethyl 9-[2-(phosphonomethoxy)propyl]adenine (ODE PMPA, 0.30 g, 0.51 mmol) [prepared as described in: Painter, G et al. Antimicrobial Agents and Chemotherapy, 2007, 51:3505-3509], (benzotriazol-1-yloxy)-tripyrrolidinophosphonium hexafluorophosphate (PYBOP®, 0.40 g, 0.77 mmol), and phenol (0.072 g, 0.77 mmol) in dry N,N-DMF, was added diisopropylethylamine (DIEA, 0.35 ml, 2.0 mmol). The mixture was stirred at room temperature for 30 min, and then the solvent was evaporated under vacuum. The residue was dissolved in ethyl acetate (50 ml), and washed with saturated sodium bicarbonate solution (2×10 ml). The ethyl acetate layer was evaporated, and then the crude product was purified by column chromatography on silica gel using CH2Cl2/MeOH (0-5%) to afford 0.25 g (75%) of compound 94. 1H NMR (400 MHz, CDCl3+methanol-d4) δ ppm 8.24 (d, J=3.30 Hz, 1H), 8.05 (d, J=6.23 Hz, 1H), 7.29-7.37 (m, 2H), 7.17-7.24 (m, 1H), 7.05-7.15 (m, 2H), 4.37 (d, J=1.47 Hz, 1H), 4.04-4.31 (m, 4H), 3.94-4.03 (m, 1H), 3.86 (dd, J=9.53, 1.10 Hz, 1H), 3.60 (d, J=4.03 Hz, 2H), 3.38-3.47 (m, 2H), 1.48-1.60 (m, 2H), 1.21-1.35 (m, 33H), 0.89 (t, J=8.00 Hz, 3H). MS (EI): 660.47 (M+H)+, 682.41 (M+Na)+.
-
- To a solution of octadecyloxyethyl 9-(R)-[2-(phosphonomethoxy)propyl]guanine (Bn-ODE-(R)-PMPG, 180 mg, 0.3 mmol) [prepared as described in: Painter, G et al. Antimicrobial Agents and Chemotherapy, 2007, 51:3505-3509], (benzotriazol-1-yloxy)-tripyrrolidinophosphonium hexafluorophosphate (PYBOP®, 312 mg, 0.6 mmol), and benzyl alcohol (97 mg, 0.9 mmol) in dry N,N-DMF (30 ml), was added diisopropylethylamine (DIEA, 77 mg, 0.6 mmol). The mixture was stirred at room temperature for 30 min, and then the solvent was evaporated under vacuum. The residue was dissolved in ethyl acetate (50 ml), and washed with saturated sodium bicarbonate solution (2×10 ml). The ethyl acetate layer was evaporated, and then the crude product was purified by column chromatography on silica gel using CH2Cl2/MeOH (0-5%) to afford 60 mg (29%) of compound 73. 1H NMR (400 MHz, CDCl3+methanol-d4) δ ppm 7.82 (d, J=5.50 Hz, 1H), 7.75 (d, J=7.33 Hz, 1H), 7.43-7.53 (m, 2H), 7.33-7.43 (m, 3H), 5.01-5.17 (m, 1H), 4.07-4.18 (m, 2H), 3.82-4.03 (m, 2H), 3.69-3.81 (m, 1H), 3.51-3.64 (m, 1H), 3.44 (d, J=7.70 Hz, 1H), 3.36 (dt, J=3.30, 1.65 Hz, 3H), 1.54 (m, 2H), 1.21-1.35 (m, 30H), 1.18 (dd, J=6.23, 2.57 Hz, 3H), 0.88 (t, J=8.00 Hz, 3H). MS (EI): 690.49 (M+H)+, 712.48 (M+Na)+.
-
- 9-(S)-[3-Fluoro-2-(phosphonomethoxy)propyl] guanine [(S)-FPMPG, 0.32 g, 1.05 mmol) [prepared as described in: Jindiich, J. et al., Collect. Czech. Chem. Commun., 1993, 58:1645-1667], was esterified with octadecyloxyethanol (0.33 g, 1.05 mmol) using N,N-dicyclohexylcarbodiimide (DCC, 0.43 g, 2.1 mmol) in dry N,N-DMF (25 ml) at 50° C. overnight. Octadecyloxyethyl (S)-9-[3-fluoro-2-(phosphonomethoxy)propyl] guanine (ODE(S)-FPMPG) was isolated by column chromatography to give 0.11 g (17%) of the product. 1H NMR (CDCl3/methanol-d4), δ 8.18 (s, 1H); 4.50-4.75 (m, 2H); 4.43-4.49 (m, 1H); 4.07-4.16 (m, 1H); 3.98-4.17 (m, 2H); 3.84-3.72 (m, 1H); 3.56-3.60 (m, 2H); 3.42-3.48 (m, 2H); 3.35-3.37 (m, 1H); 1.52-1.60 (m, 2H); 1.20-1.34 (m, 30H); 0.88 (t, J=7 Hz, 3H). MS (EI): 600.30 (M−H)−.
- A stirred mixture of ODE-(S)-FPMPG (0.11 g, 0.18 mmol), benzyl alcohol (0.06 ml, 0.54 mmol) and (benzotriazol-1-yloxy)-tripyrrolidinophosphonium hexafluorophosphate (PYBOP®, 0.28 g, 0.54 mmol) in dry DMF was treated with diisopropylethylamine (DIEA, 0.25 ml, 1.44 mmol) for 4 hours at room temperature. The solvent was evaporated under vacuum. The residue was dissolved in ethyl acetate (50 ml), and washed with saturated sodium bicarbonate solution (2×10 ml). The ethyl acetate layer was evaporated, and then the crude product was purified by column chromatography on silica gel using CH2Cl2/MeOH (0-5%) to afford 90 mg (71%) of compound 289. 1H NMR (400 MHz, CDCl3+methanol-d4) δ ppm 7.77 (s, 1H), 7.46-7.54 (m, 2H), 7.34-7.42 (m, 3H), 5.04-5.17 (m, 1H), 4.42-4.52 (m, 2H), 4.19-4.38 (m, 2H), 4.09-4.19 (m, 2H), 3.88-4.06 (m, 2H), 3.64-3.73 (m, 1H), 3.55-3.64 (m, 1H), 3.41-3.50 (m, 1H), 3.18 (d, J=7.33 Hz, 1H), 1.49-1.60 (m, 2H), 1.21-1.35 (m, 30H), 0.88 (t, J=7 Hz, 3H). MS (EI): 708.50 (M−H)−, 730.52 (M+Na)+.
-
- To a solution of octadecyloxyethyl 9-[3-methoxy-2-(phosphonomethoxy) propyl]adenine (ODE MPMPA, 0.30 g, 0.49 mmol) [prepared as described in: Valiaeva, N. et al. Bioorganic & Medicinal Chemistry, 2011, 19: 4616-4625], (benzotriazol-1-yloxy)-tripyrrolidinophosphonium hexafluorophosphate (PYBOP®, 0.38 g, 0.73 mmol), and 1-naphthol (0.11 g, 0.73 mmol) in dry N,N-DMF, was added diisopropylethylamine (DIEA, 0.35 ml, 2.0 mmol). The mixture was stirred at room temperature overnight, and then the solvent was evaporated under vacuum. The residue was dissolved in ethyl acetate (50 ml) and washed with saturated sodium bicarbonate (2×10 ml). The ethyl acetate layer was evaporated, and then the crude product was purified by column chromatography on silica gel using CH2Cl2/MeOH (0-5%) to yield 0.20 g (56%) of compound 398 as an off white solid. 1H NMR (400 MHz, CDCl3+methanol-d4) δ ppm 8.18 (d, J=8.07 Hz, 1H), 8.02-8.11 (m, 1H), 7.94 (s, 1H), 7.86-7.90 (m, 1H), 7.69-7.74 (m, 1H), 7.48-7.57 (m, 2H), 7.34-7.43 (m, 2H), 4.38-4.46 (m, 1H), 4.26-4.37 (m, 3H), 4.09-4.24 (m, 2H), 3.99-4.09 (m, 1H), 3.59 (t, J=4.58 Hz, 1H), 3.47-3.56 (m, 2H), 3.30-3.45 (m, 5H), 1.49 (d, J=6.60 Hz, 2H), 1.19-1.34 (m, 30H), 0.85-0.93 (t, J=7 Hz, 3H). MS (EI): 740.54 (M+H)+, 762.52 (M+Na)+.
-
- To a solution of octadecyloxyethyl 9-[2-(phosphonomethoxy)ethyl]guanine (ODE PMEG, 0.29 g, 0.50 mmol) [prepared according to: Valiaeva, N. et al. Antiviral Research 2006, 72: 10-19], (benzotriazol-1-yloxy)-tripyrrolidinophosphonium hexafluorophosphate (PYBOP®, 0.39 g, 0.75 mmol), and 1-naphthol (0.11 g, 0.75 mmol) in dry N,N-DMF, was added diisopropylethylamine (DIEA, 0.35 ml, 2.0 mmol). The mixture was stirred at room temperature overnight and then the solvent was evaporated under vacuum. The residue was dissolved in ethyl acetate (50 ml) and then washed with saturated sodium bicarbonate (2×10 ml). The ethyl acetate layer was evaporated. The crude product was purified by flash column chromatography on silica gel using CH2Cl2/MeOH (0-5%) to give 0.23 g (65%) of compound 361. 1H NMR (CDCl3/methanol-d4) δ: 1H NMR (400 MHz, CDCl3+methanol-d4) δ ppm 8.07-8.12 (m, 1H), 7.87 (dd, J=5.87, 3.30 Hz, 1H), 7.71 (d, J=5.87 Hz, 1H), 7.59 (d, J=4.40 Hz, 1H), 7.52-7.56 (m, 1H), 7.39-7.43 (m, 1H), 4.30 (ddd, J=8.62, 5.68, 3.30 Hz, 2H), 4.16-4.21 (m, 2H), 4.14 (d, J=8.07 Hz, 2H), 3.64-3.72 (m, 2H), 3.56-3.61 (m, 1H), 3.38 (d, J=4.77 Hz, 1H), 3.19 (q, J=7.45 Hz, 2H), 1.45-1.54 (m, 2H), 1.15-1.35 (m, 30H), 0.88 (t, J=7 Hz, 3H). MS (EI): 712.49 (M+H)+, 734.41 (M+Na)+.
-
- To a solution of benzyl 9-[3-trityloxy-2-(phosphonomethoxy)propyl]-4-methoxy-uracil (0.1 g, 0.15 mmol), (benzotriazol-1-yloxy)-tripyrrolidinophosphonium hexafluorophosphate (PYBOP®, 0.11 g, 0.20 mmol), and octadecyloxyethanol (0.06 g, 0.20 mmol) in dry N,N-DMF was added diisopropylethylamine (DIEA, 0.03 ml, 0.20 mmol). The mixture was stirred at room temperature overnight. The solvent was evaporated under vacuum. The residue was dissolved in ethyl acetate (50 ml), washed with saturated sodium bicarbonate (2×10 ml), and then the ethyl acetate layer was concentrated under vacuum. The resulting crude product was purified by flash column chromatography on silica gel using CH2Cl2/MeOH (0-5%) to give 0.024 g (17%) of benzyl octadecyloxyethyl 9-[3-trityloxy-2-(phosphonomethoxy)propyl]-4-methoxyuracil 1H NMR (400 MHz, CDCl3+methanol) δ ppm 7.56 (d, J=5.50 Hz, 1H), 7.16-7.51 (m, 15H), 5.46 (d, J=5.50 Hz, 1H), 5.10 (d, J=8.80 Hz, 2H), 4.03-4.21 (m, 2H), 3.86-3.99 (m, 1H), 3.65-3.85 (m, 2H), 3.37-3.60 (m, 4H), 3.25 (s, 3H), 3.12 (m, 1H), 1.42-1.62 (m, 2H), 1.-5-1.38 (m, 30H), 0.88 (t, J=6.97 Hz, 3H). MS (EI): 945.66 (M+Na)+
- The protected intermediate was then stirred in 80% aq acetic acid overnight at 50° C. The solvent was then evaporated under vacuum, and the residue was purified by flash column chromatography to give 0.01 g (59%) of compound 221. MS (EI): 667.54 (M+H)+, 689.56 (M+Na)+.
-
- To a solution of octadecyloxyethyl 9-(S)-[3-methoxy-2-(phosphonomethoxy) propyl]-adenine (ODE-(S)-MPMPA, 0.30 g, 0.49 mmol) [prepared as described in: Valiaeva, N. et al. Bioorganic & Medicinal Chemistry, 2011, 19:4616-4625], (benzotriazol-1-yloxy)-tripyrrolidinophosphonium hexafluorophosphate, (PYBOP®, 0.38 g, 0.73 mmol), in ethanol (25 ml), was added diisopropylethylamine (DIEA, 0.35 ml, 2.0 mmol). The mixture was stirred at room temperature overnight. The solvent was then evaporated under vacuum. The residue was dissolved in ethyl acetate (50 ml), and then washed with saturated sodium bicarbonate (2×10 ml). Ethyl acetate was evaporated, and the residue was purified by flash column chromatography on silica gel using CH2Cl2/MeOH (0-5%) to give 0.26 g (84%) of compound 182 as a white solid. 1H NMR (400 MHz, CDCl3+methanol-d4) δ ppm 8.26 (s, 1H), 8.08 (d, J=2.20 Hz, 1H), 4.72-4.74 (m, 1H), 4.62-64 (m, 1H), 4.44-4.50 (m, 1H), 4.28-4.35 (m, 1H), 4.10-4.18 (m, 2H), 4.03-4.10 (m, 2H), 3.81-3.89 (m, 1H), 3.53-3.64 (m, 3H), 3.42-3.52 (m, 3H), 3.40 (s, 3H), 1.56 (m, 2H), 1.19-1.37 (m, 33H), 0.89 (t, J=7.20 Hz, 3H). MS (EI): 642.69 (M+H)+, 664.61 (M+Na)+.
-
- To a solution of octadecyloxyethyl 9-(S)-[3-methoxy-2-(phosphonomethoxy) propyl]-2,6-diaminopurine (ODE-(S)-MPMP DAP, 0.20 g, 0.32 mmol) [prepared as described in: Valiaeva, N. et al. Bioorganic & Medicinal Chemistry, 2011, 19:4616-4625], ((benzotriazol-1-yloxy)-tripyrrolidinophosphonium hexafluorophosphate (PYBOP®) (0.21 g, 0.40 mmol), and benzyl alcohol (0.04 ml, 0.40 mmol) in dry N,N-DMF, was added diisopropylethylamine (DIEA, 0.07 ml, 0.40 mmol). The mixture was stirred at room temperature overnight, and then the solvent was evaporated under vacuum. The residue was dissolved in ethyl acetate (50 ml), and then washed with saturated sodium bicarbonate (2×10 ml). The ethyl acetate layer was evaporated, and then the residue was purified by flash column chromatography on silica gel using CH2Cl2/MeOH (0-5%) to give 0.12 g (54%) of compound 150. 1H NMR (400 MHz, CDCl3+methanol-d4) δ ppm 7.63-7.68 (m, 1H), 7.31-7.43 (m, 5H), 5.02-5.13 (m, 2H), 4.59 (s, 1H), 4.50 (s, 1H), 4.23 (d, J=3.67 Hz, 1H), 3.99-4.15 (m, 3H), 3.84-3.92 (m, 2H), 3.39-3.56 (m, 5H), 3.36 (s, 3H), 1.49-1.58 (m, 2H), 1.17-1.35 (m, 30H), 0.89 (t, J=6.6 Hz, 3H). MS (EI): 719.62 (M+H)+, 741.56 (M+Na)+.
- Method. Compounds at a range of concentrations were incubated with normal fibroblasts or human cervical cancer cell lines in monolayer culture and after 4 days, viable cell number was determined by neutral red reduction as previously described (Valiaeva N, et al., Chemotherapy, 2010, 56(1):54-9). Cell lines were obtained from American Type Culture Collection. The results were plotted and the concentration which reduced neutral red levels by 50% (CC50) was determined in triplicate. Although viral replication is no longer occurring in the human cervical cancer cell lines, Caski cells were transformed by HPV-16 and Hela cells were transformed by HPV-18.
- Results.
- As tabulated in Table 11 following, these results demonstrate that compounds described herein were 23.6 fold (e.g., Cmpd 219) to 3,750 fold (e.g., Cmpd 1) more effective in reducing viable cell number in the cervical cancer lines than in normal, non-transformed human fibroblasts.
-
TABLE 11 Antiproliferative activity of nucleoside phosphonate diesters in normal human fibroblasts and in human cervical cancer lines in vitro Cytotoxic concentration 50% (CC50) μMNormal human fibroblasts Caski Hela Compound # (HFF) (HPV-16) (HPV-18) 219 52 2.0 2.2 218 5.2 0.055 0.029 1 15 0.004 0.009 - Method of cytotoxicity determination. MT-2 cells were incubated with drug for 72 hrs and harvested. Flow count beads (Beckman Coulter, Miami, Fla.) were added to the cell suspension followed by propidium iodide staining and analysis using flow cytometer and the 50% cytotoxic concentration (CC50) was calculated from the cell counts and viability.
- Results.
- Compounds disclosed herein are effective antiproliferative agents in human T cell leukemia (MT-2) cells (Table 12).
-
TABLE 12 Antiproliferative activity in human MT-2 leukemic cells in vitro CC50, 50% Cytotoxic concentration μMMT2 Compound # cells T cell leukemia 1 0.036 ± 0.04 1a <0.01 1b <0.01 2 <0.010 - Method HIV Antiviral Assays.
- MT-2 cells were maintained in RPMI 1640 supplemented with 10% FBS, 10 mM HEPES buffer, 50 IU of penicillin/ml, and 50 μg of streptomycin/ml. The antiviral activity of each compound was determined by inoculating MT-2 cells with HIV-1LAI at a multiplicity of infection (MOI) of 0.001 TCID50/cell, followed by incubation in the presence of threefold serial drug dilutions (three wells per dilution). Four days after infection, culture supernatants were harvested, lysed with 0.5% Triton X-100, and assayed for p24 antigen concentration using a commercial ELISA assay (Perkin Elmer Life Sciences, Boston, Mass.). The antiviral activity of each compound is expressed as the EC50, which is the concentration required to inhibit p24 antigen production by 50%.
- Method Cytotoxicity Determination.
- MT-2 cells were incubated with drug for 72 hrs and harvested. Flow count beads (Beckman Coulter, Miami, Fla.) were added to the cell suspension followed by propidium iodide staining and analysis using flow cytometer and the 50% cytotoxic concentration (CC50) was calculated from the cell counts and viability.
- Results.
- Table 13 shows that compounds disclosed herein have considerable antiviral activity against HIV-1 and exhibit selectivity.
-
TABLE 13 Antiviral activity in HIV-1 infected human lymphoblastic leukemia cells HIV ANTIVIRAL ACTIVITY IN MT-2 CELLS EC50, CC50, Selectivity Compound # μM μM Index 1 <1 × 10−5 0.036 ± 0.04 >3600 2 <1 × 10−5 <1 × 10−2 — 218 0.13 ± 0.14 (3) 2.3 ± 1.6 (3) 17.7 219 2.7 ± 2.1 (3) 18 ± 3.6 (3) 6.7 230 0.05 ± 0.03 (3) 19 ± 2.6 (3) 380 231 2.2 ± 2.1 (3) 22 ± 3.0 (3) 10 EC50, effective dose 50%; CC50,cytotoxic dose 50%, selectivity index CC50/EC50.Assay: p24 reduction. - Method.
- Primary low passage human foreskin fibroblast (HFF) cells in 96-well plates were infected at an MOI of 0.01 PFU/cell with the G strain of herpes simplex virus type 2 and incubated for 3 days. Media was then aspirated and cell monolayers were stained with crystal violet and rinsed with distilled water. Crystal violet associated with the cells was then quantified in a spectrophotometer and the concentration of the compound that was sufficient to reduce virus replication by 50% (EC50) was calculated. Cytotoxicity was measured in parallel by similar methods to yield the concentration that reduced cell number by 50% (CC50).
- Results.
- Results are tabulated in Table 14 following.
-
TABLE 14 Antiviral Effect of ANP diesters in HFF cells infected with HSV-2 EC50, CC50, Selectivity Compound # μM μM Index 219 0.10 13.1 131 218 0.04 6.91 173 231 0.80 34.8 43.5 230 0.71 37.1 52.2 221 3.8 10 2.6 - Method.
- Compounds were administered at the indicated doses by oral gavage daily for 5 days. Weights measured before and on day 6 after 5 doses.
- Results.
- As tabulated in Table 15 following, these results demonstrate that ODE-monoesters of Cidofovir (CDV) and PMEG lost 14.7% and 19.1% of body weight, respectively, which was highly statistically significant versus day zero (p=0.0007 and p<0.001). However, oral ODE-benzyl diesters of the CDV and PMEG nucleoside phosphonates exhibited no statistically significant effects (“ns”) on body weight compared with the unmodified compounds.
-
TABLE 15 Effect of oral Octadecyloxyethyl-benzyl-(ODE-bn-) acyclic phosphonate diesters and Octadecyloxyethyl-monoesters of acyclic nucleoside phosphonates on body weight in Balb-c Mice p value, Compound Dose Day 0 Day 6 0 vs 6 ODE- CDV 20 mg/kg/day 19.88 ± 0.55 (6) 16.96 ± 01.38 (6) 0.0007 ODE-bn- CDV 20 mg/kg/day 19.03 ± 1.16 (6) 19.27 ± 1.32 (6) ns (Cmpd 219) ODE-PMEG 4 mg/kg/day 19.17 ± 0.581 (3) 15.5 ± 0.514 (3) <0.001 ODE-bn-PMEG 4 mg/kg/day 18.63 ± 0.728 (3) 18.42 ± 1.00 (3) ns (Cmpd 1) - Method. Primary low passage human foreskin fibroblast (HFF) cells in 96-well plates were infected at an MOI of 0.01 PFU/cell with the AD169 strain of human cytomegalovirus and incubated for 14 days. Media was then aspirated and cell monolayers were stained with crystal violet and rinsed with distilled water. Crystal violet associated with the cells was then quantified in a spectrophotometer and the concentration of the compound that was sufficient to reduce virus replication by 50% (EC50) was calculated. Cytotoxicity was measured in parallel by similar methods to yield the concentration that reduced cell number by 50% (CC50).
- Results.
- Results are tabulated in Table 16 following.
-
TABLE 16 Antiviral Effect of ANP diesters in cells infected with human cytomegalovirus (AD169) EC50, CC50, Selectivity Compound # μM μM Index 219 <0.03 84.2 >2807 218 <0.03 7.49 >250 231 <0.03 19.0 >633 230 <0.03 3.72 >124 1 <0.03 51.5 >1717 2 0.11 18.3 166 - Method: Primary low passage human foreskin fibroblast (HFF) cells in 96-well plates were infected at an MOI of 0.01 PFU/cell with the Copenhagen strain of vaccinia virus and incubated for 7 days. Media was then aspirated and cell monolayers were stained with crystal violet and rinsed with distilled water. Crystal violet associated with the cells was then quantified in a spectrophotometer and the concentration of the compound that was sufficient to reduce virus replication by 50% (EC50) was calculated. Cytotoxicity was measured in parallel by similar methods to yield the concentration that reduced cell number by 50% (CC50).
- Results.
- Results are tabulated in Table 17 following.
-
TABLE 17 Antiviral Effect of ANP diesters in cells infected with vaccinia virus (Copenhagen) EC50, CC50, Selectivity Compound # μM μM Index 219 0.09 >100 >1110 218 <0.03 >100 >3330 231 0.23 >100 >435 230 0.06 97.5 1625 - Method:
- Primary low passage human foreskin fibroblast (HFF) cells in 96-well plates were infected at an MOI of 0.01 PFU/cell and incubated for 14 days. Media was then aspirated and total DNA was isolated and genome copy number was quantified by qPCR using the
primers 5′-AGT GGA TGG GCA GCC TAT GTA-3′ (SEQ ID NO:1), 5′-TCA TAT CTG GGT CCC CTG GA-3′ (SEQ ID NO:2) andprobe 5′-6-FAM AGG TAG AAG AGG TTA GGG TGT TTG ATG GCA CAG TAMRA-3′(SEQ ID NO:3). In a parallel experiment in uninfected cells cytotoxicity was determined by CELLTITER-GLO® find the concentration that reduced cell number by 50% (CC50). - Results.
- Results are tabulated in Table 18 following.
-
TABLE 18 Antiviral Effect of ANP diesters in cells infected BK virus (Gardner strain) EC50, CC50, Selectivity Compound # μM μM Index 219 <0.03 6.54 >218 218 <0.03 2.80 >93 231 <0.03 13.29 >443 230 0.06 19.61 327 1 <0.03 3.06 >102 2 <0.03 7.14 >238 - Method.
- Primary low passage human foreskin fibroblast (HFF) cells in 96-well plates were infected at an MOI of 0.01 PFU/cell with the E377 strain of herpes simplex virus type 1 and incubated for 3 days. Media was then aspirated and cell monolayers were stained with crystal violet and rinsed with distilled water. Crystal violet associated with the cells was then quantified in a spectrophotometer and the concentration of the compound that was sufficient to reduce virus replication by 50% (EC50) was calculated. Cytotoxicity was measured in parallel by similar methods to yield the concentration that reduced cell number by 50% (CC50).
- Results.
- Results are tabulated in Table 19 following.
-
TABLE 19 Antiviral Effect of ANP diesters in HFF cells infected with HSV-1 (E-377) EC50, CC50, Selectivity Compound # μM μM Index 219 1.25 19.3 15.4 218 0.92 14.5 15.8 231 1.40 88.3 63 230 2.77 82.2 30 1 1.08 >100 >93 2 >4.0 16.6 <4.2 - Method.
- An origin-containing plasmid was co-transfected with HPV-11 E1 and E2 protein expression vectors into HEK 293 cells. At 4 hr post-transfection, cells were treated with compound dilutions and the cells were incubated for 48 hr. Replication of the virus origin was detected with DpnI and exonuclease III to remove unreplicated input bacterial plasmid DNA. Remaining replicated DNA was quantified by qPCR. Toxicity was determined by trypan blue exclusion.
- Results.
- Results are tabulated in Table 20 following.
-
TABLE 20 Antiviral effect of ANP diesters in HPV-11 infected HEK 293 cells EC50, CC50, Selectivity Compound # μM μM Index 1 0.49 >100 >204 1a [1.06, EC90] — — 1b [1.16, EC90] — — 218 0.77 >100 >370 2 0.27 >100 >130 219 2.04 >10 >4.9 230 0.56 >10 >17.9 231 1.56 >10 >6.41 ** EC90 is the concentration required to reduce viral replication by 90%. - Method. An origin-containing plasmid was co-transfected with HPV-16 E1 and E2 protein expression vectors into HEK 293 cells. At 4 hr post-transfection, cells were treated with compound dilutions and the cells were incubated for 48 hr. Replication of the virus origin was detected with DpnI and exonuclease III to remove unreplicated input bacterial plasmid DNA. Remaining replicated DNA was quantified by qPCR. Toxicity was determined by trypan blue exclusion.
- Results.
- Results are tabulated in Table 21 following.
-
TABLE 21 Antiviral effect of ANP diesters in HPV-16 infected HEK 293 cells. EC50, CC50, Selectivity Compound # μM μM Index 218 0.24 >10 >41.7 219 2.23 >10 >4.48 1 0.20 >10 >50 19 5.27 >10 >1.9 2 0.99 >10 >10.1 - Method.
- Primary human keratinocytes (PHKs) were transfected with an HPV-18 genomic plasmid containing G418 resistance gene which was generated by Cre-loxP-mediated excision recombination. After a 4 day selection with G418, the surviving cells were cultured for 2-3 day and used to develop into raft cultures where the PHK cells stratify and differentiate into a squamous epithelium in 10 or more days. HPV-18 viral DNA usually amplifies between 10-14 days after the raft cultures are lifted to the air-medium interface. Efficacy and toxicity of the test compounds were determined at three concentrations added to the media from day 6 or 8 until day 14. Medium is changed every other day. Prior to harvest, BrdU is added to the medium at 100 μg/ml to document host cell DNA replication. One set of raft cultures (with or without test compounds) is harvested for quantitative real time PCR (qPCR) to determine the copy number of HPV-18 DNA/cell. Another set of the raft cultures are fixed in formalin, embedded in paraffin and toxicity is determined by histology. Additional sections are subjected to in situ hybridization to localize viral DNA amplification and BrdU incorporation which denotes host DNA replication in basal and suprabasal strata.
- Results.
- Results are tabulated in Table 22 following.
-
TABLE 22 Antiviral effect of ANP diesters in HPV-18 infected primary human keratinocyte rafts EC50, CC50, Selectivity Compound # μM μM Index 218 0.25 >10 >39 219 1.06 >10 >9.4 1 0.21 10 48 - Method.
- COS7 cells in 96-well plates were infected at an MOI of 0.01 PFU/cell with the MAD-1 strain of JC virus and incubated for 7 days. Media was then aspirated and total DNA was isolated and genome copy number was quantified by
qPCR using primers 5′-CTG GTC ATG TGG ATG CTG TCA-3′ (SEQ ID NO:4) and 5′-GCC AGC AGG CTG TTG ATA CTG-3′ (SEQ ID NO:5) andprobe 5′-6-FAM-CCC TTT GTT TGG CTG CT-TAMRA-3 (SEQ ID NO:6) together with the plasmid pMP508 to provide a standard curve for quantitation. In a parallel experiment in uninfected cells, cytotoxicity was determined by CELLTITER-GLO® to find the concentration that reduced cell number by 50% (CC50). - Results.
- Results are tabulated in Table 23 following.
-
TABLE 23 Antiviral effect of ANP diesters in JC virus (MAD-1) infected COS7 cells EC50, CC50, Selectivity Compound # μM μM Index 1 0.07 63.8 911 2 >4 10.6 <2.7 218 >4 10.2 <2.6 219 >4 12.8 <3.2 230 >4 18.4 <4.6 231 >20 62.6 <3 - Method.
- Human peripheral blood monocyte (PBMC) based anti-HIV assays were performed as previously described (K. M. Watson, et al., 2008, Antimicrob Agents Chemother. 52:2787). Briefly, PHA-stimulated PBMCs cultured in the presence of IL-2 were suspended at 1×106 cells/mL and were added to a 96-well round-bottom plate. Serially diluted test materials were added to the plate in triplicate followed by the appropriate pre-titered strain of HIV. The culture was incubated for 7 days at 37° C./5% CO2. Following the incubation, supernatants were collected for analysis of virus replication by supernatant reverse transcriptase activity and cells analyzed for viability by tetrazolium dye XTT reduction (2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide). All the assays were carried out in triplicate. Microsoft Excel 2007 was used to analyze and graph data. The percent reduction in virus replication compared to the untreated virus controls was calculated for each compound. The percent cell control value was calculated for each compound comparing the drug treated uninfected cells to the uninfected cells in medium alone.
- Results.
- Results are tabulated in Table 24 following.
-
TABLE 24 Antiviral effect of ANP diesters in HIV-192US727 infected human peripheral blood monocytes EC50, CC50, Selectivity Compound # μM μM Index 218 <0.010 0.23 >23.0 230 <0.10 0.55 >25.5 219 <0.10 2.87 >28.7 231 <0.30 19.0 >63.3 2 <0.010 11.0 >1100 1 <0.010 0.04 >4.0 19 <0.003 0.018 >9.0 25 <0.002 0.25 >125 164 <0.40 15.0 >37.5 146 <0.04 12.5 >312 74 <0.005 24.6 >4920 92 <0.005 24.1 >4820 73 <0.005 11.3 >2260 - Method. HBV antiviral assays (Korba & Gerin, Antivir. Res., 1992, 19:55 and Iyer, et al., Antivir Agents Chem Chemother., 2004, 48:2199) are conducted using confluent cultures of 2.2.15 cells (genotype ayw; parental cell HepG2) maintained on 96-well flat-bottomed tissue culture plates. Confluence in this culture system is required for active, high levels of HBV replication equivalent to that observed in chronically-infected individuals (Sells, et al., J. Virol., 1988, 62:2836; Korba & Gerin, Antivir. Res., 1992, 19:55). Cultures are treated for 7 days. HBV DNA levels in the culture medium (representing HBV virion production) are assessed by quantitative blot hybridization 24 hrs. after the last treatment. Cytotoxicity is assessed (A510) by uptake of neutral red dye 24 hr. following the last treatment. Lamivudine (LMV) is used as the standard assay control. EC50, EC90 and CC50 values are calculated by linear regression analysis (MS EXCEL®, QUATTROPRO®) using data combined from all treated cultures (Korba & Gerin, 1992, Id.; Okuse, et al., Antivir. Res., 2005, 65:23). Standard deviations for EC50 and EC90 values are calculated from the standard errors generated by the regression analyses. EC50 and EC90 are drug concentrations at which a 2-fold, or a 10-fold depression of HBV DNA (relative to the average levels in untreated cultures), respectively, is observed. CC50 is the drug concentration at which a 2-fold lower level of neutral red dye uptake (relative to the average levels in untreated cultures) is observed.
- Results.
- Results are tabulated in Table 25 following.
-
TABLE 25 Antiviral effect of ANP diesters on hepatitis B virus replication in 2.2.15 cells in vitro. EC50, EC50, Selectivity Compound # μM μM Index 2 0.88 >100 >113 218 0.76 >100 >132 219 0.45 >100 >223 19 43.0 >100 >2.33 1 0.44 >100 >226 146 33.0 >100 >3.03 164 0.46 >100 >216 74 6.5 64 10 92 7.3 68 9.3 73 34 63 1.9 - A first set of embodiments P1-P7 follows.
- A compound with structure of Formula (I):
- or stereoisomer, salt, hydrate, solvate, or crystalline form thereof, wherein BNuc is a naturally occurring purine or pyrimidine base, or analog thereof; L is a lipophilic promoiety, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, or O-substituted glyceryl having the formula —CH2CH(OR1)—CH2(OR2) (II), wherein R1 and R2 are independently substituted or unsubstituted alkyl, or substituted or unsubstituted aryl; R is substituted or unsubstituted lower alkyl, substituted or unsubstituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, substituted or unsubstituted lower heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted lower heteroaryl; and X is hydrogen, substituted or unsubstituted lower alkyl, or substituted or unsubstituted lower heteroalkyl.
- A method of treating a viral disease in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of embodiment P1.
- A method for treating cancer in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of embodiment P1.
- A method of killing or inhibiting the growth of a transformed cell, comprising contacting a transformed cell with a therapeutically effective amount of a compound of embodiment P1.
- A method for treating a proliferative disorder in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of embodiment P1.
- A pharmaceutical composition comprising a compound according to embodiment P1, and pharmaceutically acceptable excipient.
- A method for synthesis of a compound with structure of Formula (I) according to Scheme 2:
- wherein BNuc is a naturally occurring purine or pyrimidine base, or analog thereof; L is a lipophilic promoiety, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, or O-substituted glyceryl having the formula —CH2CH(OR1)—CH2(OR2) (II), wherein R1 and R2 are independently substituted or unsubstituted alkyl, or substituted or unsubstituted aryl; R is substituted or unsubstituted lower alkyl, substituted or unsubstituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, substituted or unsubstituted lower heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted lower heteroaryl; and X is hydrogen, substituted or unsubstituted lower alkyl, or substituted or unsubstituted lower heteroalkyl; and Y is a leaving group; the method including: 1) contacting a protected nucleoside BNuc with structure of Formula (2-1) with an ester with structure of Formula (2-2) in the presence of a strong base under conditions suitable to afford a monoester with structure of Formula (2-3); and 2) reacting said monoester with structure of Formula (2-3) with L-OH in the presence of a coupling agent, thereby synthesizing a compound with structure of Formula (I).
- Further embodiments include the following.
- A compound of Formula (Ia), or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof:
- wherein: BNuc(a) is a naturally occurring purine, a naturally occurring pyrimidine, a non-naturally occurring purine or a non-naturally occurring pyrimidine; La is an unsubstituted C12-24 alkyl, an unsubstituted C13-29 heteroalkyl or a substituted glyceryl moiety, wherein the glyceryl moiety is substituted with one or more groups selected from an unsubstituted C13-29 alkyl, an unsubstituted C13-29 heteroalkyl, a substituted or unsubstituted aryl(C1-6 alkyl), a substituted or unsubstituted heteroaryl(C1-6 alkyl) and a substituted or unsubstituted heterocycloalkyl(C1-6 alkyl); Ra is selected from the group consisting of an unsubstituted C1-6 alkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aryl(C1-6 alkyl), a substituted or unsubstituted heteroaryl(C1-6 alkyl) and a substituted or unsubstituted heterocycloalkyl(C1-6 alkyl); and Xa is hydrogen, an unsubstituted C1-6 alkyl, a halogen substituted C1-6 alkyl, a hydroxy substituted C1-6 alkyl or an unsubstituted C1-6 alkoxy.
- The compound of embodiment 1 wherein Xa is hydrogen.
- The compound of embodiment 1 wherein Xa is methyl.
- The compound of embodiment 1, wherein Xa is methoxy.
- The compound of embodiment 1, wherein Xa is a fluoro substituted C1-6 alkyl.
- The compound of
embodiment 5, wherein Xa is a CH2F. - The compound of embodiment 1, wherein Xa is a CH2OH.
- The compound of any one of embodiments 1-7, wherein La is an unsubstituted C13-29 heteroalkyl.
- The compound of embodiment 8, wherein La has the structure —(CH2)1-6—O—(CH2)11-21—CH3.
- The compound of embodiment 9, wherein La has the structure —(CH2)2—O—(CH2)17—CH3.
- The compound of embodiment 9, wherein La has the structure —(CH2)3—O—(CH2)15-CH3.
- The compound of embodiment 8, wherein La has the structure —(CH2)1-6—O—(CH2)10-20—(CHCH3)—CH3.
- The compound of any one of embodiments 1-7, wherein La is a substituted glyceryl moiety.
- The compound of embodiment 13, wherein La has the structure —(CH2)—CH(ORa1)—(CH2)—O(CH2)11-21—CH3, wherein Ra1 is a substituted or unsubstituted aryl(C1-6 alkyl), a substituted or unsubstituted heteroaryl(C1-6 alkyl) and a substituted or unsubstituted heterocycloalkyl(C1-6 alkyl).
- The compound of embodiment 14, wherein La has the structure
- The compound of embodiment 1, wherein Ra is a substituted or unsubstituted aryl.
- The compound of embodiment 16, wherein the substituted or unsubstituted aryl is a substituted or unsubstituted phenyl.
- The compound of embodiment 16, wherein the substituted or unsubstituted aryl is a substituted or unsubstituted naphthyl.
- The compound of embodiment 1, wherein Ra is a substituted or unsubstituted aryl(C1-6 alkyl).
- The compound of embodiment 19, wherein the substituted or unsubstituted aryl(C1-6 alkyl) is a substituted or unsubstituted benzyl.
- The compound of embodiment 1, wherein Ra is a substituted or unsubstituted heterocycloalkyl(C1-6 alkyl).
- The compound of embodiment 21, wherein the substituted or unsubstituted heterocycloalkyl(C1-6 alkyl) is a substituted or unsubstituted galactosyl.
- The compound of embodiment 1, wherein BNuc(a) is a naturally occurring purine.
- The compound of embodiment 1, wherein BNuc(a) is a naturally occurring pyrimidine.
- The compound of embodiment 1, wherein BNuc(a) is a non-naturally occurring purine.
- The compound of embodiment 1, wherein BNuc(a) is a non-naturally occurring pyrimidine.
- The compound of embodiment 1, wherein BNuc(a) is selected from the group consisting of:
- The compound of embodiment 1, wherein the compound has the structure:
- The compound of embodiment 1, wherein the compound has the structure:
- The compound of embodiment 1, wherein the compound has the
- The compound of embodiment 1, wherein the compound is selected from any one of the compounds in Tables 1-10, or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof.
- The compound of embodiment 1, wherein the compound is selected from the group consisting of:
- or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form of any of the foregoing.
- A pharmaceutical composition including an effective amount of a compound of any one of embodiments 1-32, or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof, and a pharmaceutically acceptable excipient.
- The pharmaceutical composition of embodiment 33, wherein the pharmaceutical composition is in the form of a cream, a gel or an ointment.
- The pharmaceutical composition of embodiment 33 or 34, wherein the pharmaceutical composition is a topical formulation.
- Use of a compound of any one of embodiments 1-32, or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof, in the preparation of a medicament for treating a viral disease in a subject, wherein the viral disease is selected from the group consisting of human papilloma virus, HIV, hepatitis B virus, hepatitis C virus, variola virus, vaccinia virus, an adenovirus, a cytomegalovirus, herpes simplex virus 1, herpes simplex virus 2, Epstein Barr virus, BK virus, JC virus, feline leukemia virus and feline immunodeficiency virus.
- The use of embodiment 36, wherein said virus is human papilloma virus.
- The use of embodiment 37, said compound, or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof, for use in treating a plurality of types of human papilloma virus.
- The use of embodiment 37, wherein the human papilloma virus is selected from the group consisting human papilloma virus type 11, type 16 and type 18.
- Use of a compound of any one of embodiments 1-32, or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof, in the preparation of a medicament for treating cancer of the cervix in a subject.
- Use of a compound of any one of embodiments 1-32, or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof, in the preparation of a medicament for inhibiting growth of a cell transformed by a virus, wherein the virus is selected from the group consisting of human papilloma virus, HIV, hepatitis B virus, hepatitis C virus, variola virus, vaccinia virus, an adenovirus, a cytomegalovirus, herpes simplex virus 1, herpes simplex virus 2, Epstein Barr virus, BK virus, JC virus, feline leukemia virus and feline immunodeficiency virus.
- A compound of any one of embodiments 1-32, or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof, for use in treating a viral disease in a subject, wherein the viral disease is selected from the group consisting of human papilloma virus, HIV, hepatitis B virus, hepatitis C virus, variola virus, vaccinia virus, an adenovirus, a cytomegalovirus, herpes simplex virus 1, herpes simplex virus 2, Epstein Barr virus, BK virus, JC virus, feline leukemia virus and feline immunodeficiency virus.
- The compound of embodiment 42, wherein said virus is human papilloma virus.
- The compound of embodiment 43, or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof, for use in treating a plurality of types of human papilloma virus.
- The compound of embodiment 43, wherein the human papilloma virus is selected from the group consisting human papilloma virus type 11, type 16 and type 18.
- A compound of any one of embodiments 1-32, or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof, for use in treating cancer of the cervix in a subject.
- A compound of any one of embodiments 1-32, or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof, for use in inhibiting growth of a cell transformed by a virus, wherein the virus is selected from the group consisting of human papilloma virus, HIV, hepatitis B virus, hepatitis C virus, variola virus, vaccinia virus, an adenovirus, a cytomegalovirus, herpes simplex virus 1, herpes simplex virus 2, Epstein Barr virus, BK virus, JC virus, feline leukemia virus and feline immunodeficiency virus.
- A method for synthesis of the compound of Formula (Ia) according to Embodiment 1:
- wherein: BNuc(a) is a naturally occurring purine, a naturally occurring pyrimidine, a non-naturally occurring purine or a non-naturally occurring pyrimidine; La is an unsubstituted C12-24 alkyl, an unsubstituted C13-29 heteroalkyl or a substituted glyceryl moiety, wherein the glyceryl moiety is substituted with one or more groups selected from an unsubstituted C13-29 alkyl, an unsubstituted C13-29 heteroalkyl, a substituted or unsubstituted aryl(C1-6 alkyl), a substituted or unsubstituted heteroaryl(C1-6 alkyl) and a substituted or unsubstituted heterocycloalkyl(C1-6 alkyl); Ra is selected from the group consisting of an unsubstituted C1-6 alkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aryl(C1-6 alkyl), a substituted or unsubstituted heteroaryl(C1-6 alkyl) and a substituted or unsubstituted heterocycloalkyl(C1-6 alkyl); Xa is hydrogen, an unsubstituted C1-6 alkyl, a halogen substituted C1-6 alkyl, a hydroxy substituted C1-6 alkyl or an unsubstituted C1-6 alkoxy; and Ya is a leaving group; the method including: contacting a compound of Formula (2-1a) that has a protected BNuc(a) with a compound of Formula (2-2a) in the presence of a strong base to form a compound of Formula (2-3a); and reacting the compound of Formula (2-3a) with La-OH in the presence of a coupling agent to form the compound of Formula (Ia).
Claims (36)
1. A compound of Formula (Ia), or a pharmaceutically acceptable salt thereof:
wherein:
BNuc(a) is a naturally occurring purine, a naturally occurring pyrimidine, or 2,6-diaminopurine;
La is a substituted glyceryl moiety having the formula —CH2CH(OR1)—CH2(OR2), wherein R1 and R2 are independently selected from an unsubstituted C13-29 alkyl, an unsubstituted C13-29 heteroalkyl, a substituted or unsubstituted aryl-C1-6 alkyl, a substituted or unsubstituted heteroaryl-C1-6 alky and a substituted or unsubstituted heterocycloalkyl-C1-6 alkyl;
Ra is selected from the group consisting of a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aryl-C1-6 alkyl, a substituted or unsubstituted heteroaryl-C1-6 alkyl and a substituted or unsubstituted heterocycloalkyl-C1-6 alkyl;
Xa is hydrogen, an unsubstituted C1-6 alkyl, a halogen substituted C1-6 alkyl, a hydroxy substituted C1-6 alkyl or an unsubstituted C1-6 alkoxy; and
wherein the substituent is selected from —OH, —NH2, —SH, —CN, —CF3, —NO2, oxo, halogen, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, and unsubstituted heteroaryl.
2. The compound of claim 1 , wherein Xa is hydrogen.
3. The compound of claim 1 , wherein Xa is methyl.
4. The compound of claim 1 , wherein Xa is methoxy.
5. The compound of claim 1 , wherein Xa is a fluoro substituted C1-6 alkyl.
6. The compound of claim 5 , wherein Xa is a CH2F.
7. The compound of claim 1 , wherein Xa is a CH2OH.
8. The compound of claim 1 , wherein La is a substituted glyceryl moiety, wherein the glyceryl moiety is substituted with an unsubstituted C13-29 alkyl.
9. The compound of claim 8 , wherein La has the structure —(CH2)—CH(ORa1)—(CH2)—O(CH2)11-21—CH3, wherein Ra1 is a substituted or unsubstituted aryl-C1-6 alkyl, a substituted or unsubstituted heteroaryl-C1-6 alkyl or a substituted or unsubstituted heterocycloalkyl-C1-6 alkyl.
11. The compound of claim 1 , wherein Ra is a substituted or unsubstituted aryl.
12. The compound of claim 11 , wherein the substituted or unsubstituted aryl is a substituted or unsubstituted phenyl.
13. The compound of claim 11 wherein the substituted or unsubstituted aryl is a substituted or unsubstituted naphthyl.
14. The compound of claim 1 , wherein Ra is a substituted or unsubstituted aryl-C1-6 alkyl.
15. The compound of claim 14 , wherein the substituted or unsubstituted aryl-C1-6 alkyl is a substituted or unsubstituted benzyl.
16. The compound of claim 1 , wherein Ra is a substituted or unsubstituted heterocycloalkyl-C1-6 alkyl.
17. The compound of claim 16 , wherein the substituted or unsubstituted heterocycloalkyl-C1-6 alkyl is a substituted or unsubstituted galactosyl.
18. The compound of claim 1 , wherein BNuc(a) is a naturally occurring purine.
19. The compound of claim 1 , wherein BNuc(a) is a naturally occurring pyrimidine.
20. The compound of claim 1 , wherein BNuc(a) is 2,6-diaminopurine.
21. The compound of claim 1 , wherein BNuc(a) is guanine, adenine, cytosine, thymine, or uracil.
29. A pharmaceutical composition comprising an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
30. The pharmaceutical composition of claim 29 , wherein the pharmaceutical composition is a topical formulation.
31. The pharmaceutical composition of claim 30 , wherein the pharmaceutical composition is in the form of a cream, a gel or an ointment.
32. A method for treating human papilloma virus in a subject in need thereof, comprising administering a compound of claim 1 , optionally in a pharmaceutically acceptable carrier.
33. The method of claim 32 , wherein the human papilloma virus is type 52 or 58.
34. The method of claim 32 , wherein the human papilloma virus is type 11, type 16 or type 18.
35. A method for treating cancer of the cervix in a subject in need thereof, comprising administering a compound of claim 1 , optionally in a pharmaceutically acceptable carrier.
36. A method for treating cervical intraepithelial neoplasia (CIN), anal intraepithelial neoplasia (AIN), and vulvar intraepithelial neoplasia (VIN) in a subject in need thereof, comprising administering a compound of claim 1 , optionally in a pharmaceutically acceptable carrier.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/567,092 US20190388442A1 (en) | 2013-03-15 | 2019-09-11 | Acyclic Nucleoside Phosphonate Diesters |
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361793993P | 2013-03-15 | 2013-03-15 | |
US14/211,235 US8835630B1 (en) | 2013-03-15 | 2014-03-14 | Acyclic nucleoside phosphonate diesters |
US14/463,908 US9156867B2 (en) | 2013-03-15 | 2014-08-20 | Acyclic nucleoside phosphonate diesters |
US14/874,027 US9387217B2 (en) | 2013-03-15 | 2015-10-02 | Acyclic nucleoside phosphonate diesters |
US15/179,209 US9775852B2 (en) | 2013-03-15 | 2016-06-10 | Acyclic nucleoside phosphonate diesters |
US15/617,841 US10076532B2 (en) | 2013-03-15 | 2017-06-08 | Acyclic nucleoside phosphonate diesters |
US15/809,400 US10076533B2 (en) | 2013-03-15 | 2017-11-10 | Acyclic nucleoside phosphonate diesters |
US16/111,378 US10449207B2 (en) | 2013-03-15 | 2018-08-24 | Acyclic nucleoside phosphonate diesters |
US16/567,092 US20190388442A1 (en) | 2013-03-15 | 2019-09-11 | Acyclic Nucleoside Phosphonate Diesters |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/111,378 Continuation US10449207B2 (en) | 2013-03-15 | 2018-08-24 | Acyclic nucleoside phosphonate diesters |
Publications (1)
Publication Number | Publication Date |
---|---|
US20190388442A1 true US20190388442A1 (en) | 2019-12-26 |
Family
ID=51493342
Family Applications (11)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/211,235 Active US8835630B1 (en) | 2013-03-15 | 2014-03-14 | Acyclic nucleoside phosphonate diesters |
US14/211,002 Active US9629860B2 (en) | 2013-03-15 | 2014-03-14 | Acyclic nucleoside phosphonate diesters |
US14/463,908 Active US9156867B2 (en) | 2013-03-15 | 2014-08-20 | Acyclic nucleoside phosphonate diesters |
US14/874,027 Active US9387217B2 (en) | 2013-03-15 | 2015-10-02 | Acyclic nucleoside phosphonate diesters |
US15/179,209 Active US9775852B2 (en) | 2013-03-15 | 2016-06-10 | Acyclic nucleoside phosphonate diesters |
US15/463,962 Abandoned US20170189430A1 (en) | 2013-03-15 | 2017-03-20 | Acyclic nucleoside phosphonate diesters |
US15/617,841 Active US10076532B2 (en) | 2013-03-15 | 2017-06-08 | Acyclic nucleoside phosphonate diesters |
US15/809,400 Active US10076533B2 (en) | 2013-03-15 | 2017-11-10 | Acyclic nucleoside phosphonate diesters |
US15/812,814 Active US10195222B2 (en) | 2013-03-15 | 2017-11-14 | Acyclic nucleoside phosphonate diesters |
US16/111,378 Active US10449207B2 (en) | 2013-03-15 | 2018-08-24 | Acyclic nucleoside phosphonate diesters |
US16/567,092 Abandoned US20190388442A1 (en) | 2013-03-15 | 2019-09-11 | Acyclic Nucleoside Phosphonate Diesters |
Family Applications Before (10)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/211,235 Active US8835630B1 (en) | 2013-03-15 | 2014-03-14 | Acyclic nucleoside phosphonate diesters |
US14/211,002 Active US9629860B2 (en) | 2013-03-15 | 2014-03-14 | Acyclic nucleoside phosphonate diesters |
US14/463,908 Active US9156867B2 (en) | 2013-03-15 | 2014-08-20 | Acyclic nucleoside phosphonate diesters |
US14/874,027 Active US9387217B2 (en) | 2013-03-15 | 2015-10-02 | Acyclic nucleoside phosphonate diesters |
US15/179,209 Active US9775852B2 (en) | 2013-03-15 | 2016-06-10 | Acyclic nucleoside phosphonate diesters |
US15/463,962 Abandoned US20170189430A1 (en) | 2013-03-15 | 2017-03-20 | Acyclic nucleoside phosphonate diesters |
US15/617,841 Active US10076532B2 (en) | 2013-03-15 | 2017-06-08 | Acyclic nucleoside phosphonate diesters |
US15/809,400 Active US10076533B2 (en) | 2013-03-15 | 2017-11-10 | Acyclic nucleoside phosphonate diesters |
US15/812,814 Active US10195222B2 (en) | 2013-03-15 | 2017-11-14 | Acyclic nucleoside phosphonate diesters |
US16/111,378 Active US10449207B2 (en) | 2013-03-15 | 2018-08-24 | Acyclic nucleoside phosphonate diesters |
Country Status (25)
Country | Link |
---|---|
US (11) | US8835630B1 (en) |
EP (2) | EP2970346B1 (en) |
JP (2) | JP6462659B2 (en) |
KR (1) | KR20150130355A (en) |
CN (3) | CN108619161A (en) |
AU (2) | AU2014228321C1 (en) |
BR (1) | BR112015023705A8 (en) |
CA (1) | CA2906680A1 (en) |
CY (1) | CY1120839T1 (en) |
DK (1) | DK2970346T3 (en) |
EA (2) | EA201892769A3 (en) |
ES (1) | ES2687958T3 (en) |
HK (1) | HK1219279A1 (en) |
HR (1) | HRP20181871T1 (en) |
HU (1) | HUE041346T2 (en) |
IL (1) | IL241554B (en) |
LT (1) | LT2970346T (en) |
MX (1) | MX367403B (en) |
PL (1) | PL2970346T3 (en) |
PT (1) | PT2970346T (en) |
RS (1) | RS57796B1 (en) |
SG (2) | SG10201800188SA (en) |
SI (1) | SI2970346T1 (en) |
TW (1) | TWI642677B (en) |
WO (1) | WO2014143643A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11344555B2 (en) | 2014-09-15 | 2022-05-31 | The Regents Of The University Of California | Nucleotide analogs |
US11572377B2 (en) | 2015-09-15 | 2023-02-07 | The Regents Of The University Of California | Nucleotide analogs |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103665043B (en) | 2012-08-30 | 2017-11-10 | 江苏豪森药业集团有限公司 | A kind of tenofovir prodrug and its application in medicine |
ES2687958T3 (en) | 2013-03-15 | 2018-10-30 | The Regents Of The University Of California | Acyclic nucleoside diester phosphonate |
WO2018055071A1 (en) * | 2016-09-23 | 2018-03-29 | Katholieke Universiteit Leuven | Prodrugs of fluorinated acyclic nucleoside phosphonates |
WO2018113652A1 (en) * | 2016-12-23 | 2018-06-28 | 四川科伦博泰生物医药股份有限公司 | Nucleoside phosphate compound and preparation method and use thereof |
CN108276444A (en) * | 2017-01-06 | 2018-07-13 | 米文君 | A new class of compound and application thereof |
CN107011383A (en) * | 2017-04-28 | 2017-08-04 | 朱孝云 | Deuterated acyclic nucleoside phosphonate diester |
WO2019080724A1 (en) * | 2017-10-23 | 2019-05-02 | 四川科伦博泰生物医药股份有限公司 | Nucleoside phosphate compound and preparation method therefor and use thereof |
WO2019237957A1 (en) | 2018-06-12 | 2019-12-19 | 四川科伦博泰生物医药股份有限公司 | Phosphonamide ester compound, salt thereof, related crystal form thereof, preparation method therefor and use thereof |
EP4017499A4 (en) * | 2019-08-22 | 2024-01-10 | Emory University | Nucleoside prodrugs and uses related thereto |
EP4185300A1 (en) * | 2020-07-24 | 2023-05-31 | The Regents of the University of California | Antiviral prodrugs, pharmaceutical formulations, and methods |
MX2023002233A (en) | 2020-08-24 | 2023-03-15 | Gilead Sciences Inc | Phospholipid compounds and uses thereof. |
TWI811812B (en) | 2020-10-16 | 2023-08-11 | 美商基利科學股份有限公司 | Phospholipid compounds and uses thereof |
WO2022271880A1 (en) * | 2021-06-22 | 2022-12-29 | Rome Therapeutics, Inc. | Methods of treating medical conditions and inhibiting line1 reverse transcriptase using a substituted adeninyl-propyloxy phosphonic acid or related compound |
WO2023183852A1 (en) * | 2022-03-23 | 2023-09-28 | Board Of Regents Of The University Of Nebraska | Phosphonate prodrugs and use thereof |
EP4337667A1 (en) | 2022-07-21 | 2024-03-20 | Antiva Biosciences, Inc. | Compositions and dosage forms for treatment of hpv infection and hpv-induced neoplasia |
Family Cites Families (122)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
CS233665B1 (en) | 1983-01-06 | 1985-03-14 | Antonin Holy | Processing of isomere o-phosphonylmethylderivative of anantiomere racemic vicinal diene |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
US6448392B1 (en) | 1985-03-06 | 2002-09-10 | Chimerix, Inc. | Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use |
CS263951B1 (en) | 1985-04-25 | 1989-05-12 | Antonin Holy | 9-(phosponylmethoxyalkyl)adenines and method of their preparation |
CS263952B1 (en) | 1985-04-25 | 1989-05-12 | Holy Antonin | Remedy with antiviral effect |
FR2588189B1 (en) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | LIQUID-GEL PHASE TRANSITION PHARMACEUTICAL COMPOSITION |
CS263956B1 (en) | 1986-07-18 | 1989-05-12 | Holy Antonin | Method of 9-(s)-(3-hydroxy-2-phosphonylmethoxypropyl)adenine production |
CS263953B1 (en) | 1986-07-18 | 1989-05-12 | Holy Antonin | Method of 9-(s) or 9-(rs)-(3-hydroxy-2-phosponylmethoxypropyl)adenine production |
CS264222B1 (en) | 1986-07-18 | 1989-06-13 | Holy Antonin | N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them |
CS263955B1 (en) | 1986-07-18 | 1989-05-12 | Holy Antonin | Method of heterocyclic bases' n-(3-hydroxy-2-phosphonylmethoxypropyl)derivatives production |
EP0262876B1 (en) | 1986-09-27 | 1992-04-29 | Toyo Jozo Kabushiki Kaisha | Nucleoside-phospholipid conjugate |
US5650510A (en) | 1986-11-18 | 1997-07-22 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives |
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
US6599887B2 (en) | 1988-07-07 | 2003-07-29 | Chimerix, Inc. | Methods of treating viral infections using antiviral liponucleotides |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
US5033352A (en) | 1989-01-19 | 1991-07-23 | Yamaha Corporation | Electronic musical instrument with frequency modulation |
IT1229203B (en) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS. |
US5688778A (en) | 1989-05-15 | 1997-11-18 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Nucleoside analogs |
US5411947A (en) | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
CZ285420B6 (en) | 1990-04-24 | 1999-08-11 | Ústav Organické Chemie A Biochemie Avčr | N-(3-fluoro-2-phosphonylmethoxypropyl) derivatives of purine and pyrimidine heterocyclic bases, processes of their preparation and use |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
CA2085354C (en) | 1990-06-15 | 2002-08-27 | Claude Piantadosi | Ether lipid-nucleoside covalent conjugates |
DE4026265A1 (en) | 1990-08-20 | 1992-02-27 | Boehringer Mannheim Gmbh | NEW PHOSPHOLIPID DERIVATIVES OF NUCLEOSIDES, THEIR PRODUCTION AND THEIR USE AS ANTIVIRAL MEDICINAL PRODUCTS |
DK0481214T3 (en) * | 1990-09-14 | 1999-02-22 | Acad Of Science Czech Republic | Prophylactic drugs of phosphonates |
DE552178T1 (en) | 1990-10-12 | 1994-02-03 | Max Planck Gesellschaft | MODIFIED RIBOZYMS. |
DE69212850T2 (en) | 1991-01-15 | 1997-03-06 | Alcon Lab Inc | Use of carrageenan in topical ophthalmic compositions |
US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
GB9126209D0 (en) | 1991-12-10 | 1992-02-12 | Orion Yhtymae Oy | Drug formulations for parenteral use |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5652094A (en) | 1992-01-31 | 1997-07-29 | University Of Montreal | Nucleozymes |
GB9205917D0 (en) | 1992-03-18 | 1992-04-29 | Smithkline Beecham Plc | Pharmaceuticals |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
US5532225A (en) | 1992-07-31 | 1996-07-02 | Sri International | Acyclic purine phosphonate nucleotide analogs as antiviral agents, and related synthetic methods |
US6057305A (en) | 1992-08-05 | 2000-05-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Antiretroviral enantiomeric nucleotide analogs |
US6005107A (en) | 1992-12-23 | 1999-12-21 | Biochem Pharma, Inc. | Antiviral compounds |
US6444656B1 (en) | 1992-12-23 | 2002-09-03 | Biochem Pharma, Inc. | Antiviral phosphonate nucleotides |
GB9226879D0 (en) | 1992-12-23 | 1993-02-17 | Iaf Biochem Int | Anti-viral compounds |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
US5817647A (en) | 1993-04-01 | 1998-10-06 | Merrell Pharmaceuticals Inc. | Unsaturated acetylene phosphonate derivatives of purines |
EP0632048B1 (en) | 1993-06-29 | 2001-03-21 | Mitsubishi Chemical Corporation | Phosphonate-nucleotide ester derivatives |
US5656745A (en) | 1993-09-17 | 1997-08-12 | Gilead Sciences, Inc. | Nucleotide analogs |
AU690587B2 (en) | 1993-09-17 | 1998-04-30 | Gilead Sciences, Inc. | Method for dosing therapeutic compounds |
US5798340A (en) | 1993-09-17 | 1998-08-25 | Gilead Sciences, Inc. | Nucleotide analogs |
DE4418690A1 (en) | 1994-05-28 | 1996-01-11 | Boehringer Mannheim Gmbh | Nucleoside 5'-mono-phosphate ester(s) of glyceryl di:ether derivs. |
EP0690058B1 (en) | 1994-06-29 | 1999-09-08 | Ciba SC Holding AG | Crystal modification of a diketopyrrolopyrrole pigment |
IT1270594B (en) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
US5696277A (en) | 1994-11-15 | 1997-12-09 | Karl Y. Hostetler | Antiviral prodrugs |
US5977061A (en) | 1995-04-21 | 1999-11-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | N6 - substituted nucleotide analagues and their use |
US7517858B1 (en) | 1995-06-07 | 2009-04-14 | The Regents Of The University Of California | Prodrugs of pharmaceuticals with improved bioavailability |
CN1078593C (en) | 1995-06-15 | 2002-01-30 | 三菱化学株式会社 | Phosphonate nucleotide derivatives |
US5717095A (en) | 1995-12-29 | 1998-02-10 | Gilead Sciences, Inc. | Nucleotide analogs |
TW369536B (en) | 1996-01-18 | 1999-09-11 | Mitsubishi Chem Corp | Phosphonate nucleotide compounds |
US5877166A (en) | 1996-04-29 | 1999-03-02 | Sri International | Enantiomerically pure 2-aminopurine phosphonate nucleotide analogs as antiviral agents |
US6686462B2 (en) | 1997-02-28 | 2004-02-03 | The Regents Of The University Of California | Antiviral compounds and methods of administration |
AU6473098A (en) | 1997-03-24 | 1998-10-20 | Eli Lilly And Company | Difluoronucleoside phosphonic acids and derivatives thereof |
ATE425955T1 (en) | 1997-12-17 | 2009-04-15 | Biocryst Pharm Inc | SUBSTITUTED CYCLOPENTAN AND CYCLOPENTEN COMPOUNDS AS NEURAMINIDASE BLOCKERS |
US6350458B1 (en) | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
US6455571B1 (en) | 1998-04-23 | 2002-09-24 | Abbott Laboratories | Inhibitors of neuraminidases |
AU4125099A (en) | 1998-06-01 | 1999-12-20 | S & T Science And Technology Inc. | Antiviral phosphorus derivatives of 4'-thio-5-ethyl-2'-deoxyuridine |
WO2000029414A1 (en) | 1998-11-18 | 2000-05-25 | Viktor Veniaminovich Tets | Dialkyl-1-aryl-1-(2,4-dioxo-5-amino-1,3-pyrimidin-5-yl)methylphosphonates |
US7026469B2 (en) | 2000-10-19 | 2006-04-11 | Wake Forest University School Of Medicine | Compositions and methods of double-targeting virus infections and cancer cells |
CA2747954C (en) | 1999-12-03 | 2014-02-25 | The Regents Of The University Of California | Phosphonate compounds |
KR20020093824A (en) | 2000-02-29 | 2002-12-16 | 미쯔비시 웰 파마 가부시키가이샤 | Phosphonate nucleotide compound |
MY141789A (en) | 2001-01-19 | 2010-06-30 | Lg Chem Investment Ltd | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same. |
CZ292199B6 (en) | 2001-03-08 | 2003-08-13 | Ústav organické chemie a biochemie AV ČR | O-phosphonomethyl choline and alkyl esters thereof, process of their preparation and use |
RU2187509C1 (en) | 2001-03-26 | 2002-08-20 | Закрытое акционерное общество "Производственно-коммерческая Ассоциация АЗТ" | Derivatives of 3'-azido-3'-deoxythymidine 5'-h-phosphonate and pharmaceutical compositions based on thereof |
KR20020097384A (en) | 2001-06-20 | 2002-12-31 | 미쯔비시 도꾜 세이야꾸 가부시끼가이샤 | A Medicament which is Effective for a Virus Having a Resistance Mutation against a Known Medicament |
KR100891366B1 (en) | 2001-06-29 | 2009-04-02 | 인스티튜트 오브 오르가닉 케미스트리 앤드 바이오케미스트리, 어케더미 오브 사이언시스 오브 더 체크 리퍼블릭 | 6-?2-phosphonomethoxyalkoxy pyrimidine derivatives having antiviral activity |
US20040023928A1 (en) | 2001-10-31 | 2004-02-05 | Colacino Joseph Matthew | Phosphonate nucleotide and thiadiazole compounds for the treatment of smallpox |
US7388002B2 (en) * | 2001-11-14 | 2008-06-17 | Biocryst Pharmaceuticals, Inc. | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
JP2005511749A (en) | 2001-12-07 | 2005-04-28 | 三菱ウェルファーマ株式会社 | Use of phosphonate nucleotide analogues to treat hepatitis B virus infection |
CN1313472C (en) | 2002-04-26 | 2007-05-02 | 吉里德科学公司 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds and the compounds as such |
US7247621B2 (en) | 2002-04-30 | 2007-07-24 | Valeant Research & Development | Antiviral phosphonate compounds and methods therefor |
AU2003242428A1 (en) | 2002-05-24 | 2003-12-12 | Mitsubishi Pharma Corporation | Drugs improved in tissue selectivity |
US7452901B2 (en) | 2003-04-25 | 2008-11-18 | Gilead Sciences, Inc. | Anti-cancer phosphonate analogs |
EA014685B1 (en) | 2003-04-25 | 2010-12-30 | Джилид Сайэнс, Инк. | Phosphonate-containing antiviral compounds (variants) and pharmaceutical composition based thereon |
KR20060061930A (en) | 2003-04-25 | 2006-06-08 | 길리애드 사이언시즈, 인코포레이티드 | Anti-cancer phosphonate analogues |
KR101102815B1 (en) | 2003-06-16 | 2012-01-05 | 케이.유.루벤 리서치 앤드 디벨럽먼트 | Pyrimidine compounds having phosphonate groups as antiviral nucleotide analogs |
RS52433B (en) | 2003-12-30 | 2013-02-28 | Gilead Sciences Inc. | Nucleoside phosphonates and analogs thereof for the treatment of hpv-infections |
WO2005090370A1 (en) | 2004-02-05 | 2005-09-29 | The Regents Of The University Of California | Pharmacologically active agents containing esterified phosphonates and methods for use thereof |
WO2005087788A2 (en) | 2004-03-04 | 2005-09-22 | The Regents Of The University Of California | Methods for preparation of nucleoside phosphonate esters |
WO2006076015A2 (en) * | 2004-04-30 | 2006-07-20 | The Regents Of The University Of California | 1-[2-(phosphonomethoxy)ethyl]-cytosine and analogs thereof |
ES2401285T3 (en) | 2004-12-16 | 2013-04-18 | The Regents Of The University Of California | Drugs with lung as target |
CN1827627B (en) * | 2005-03-04 | 2011-05-11 | 北京美倍他药物研究有限公司 | Novel acyclic nucleoside phosphonic acid and its ester derivatives and pharmaceutical use thereof |
EP2842559A3 (en) * | 2005-04-08 | 2015-03-18 | Chimerix, Inc. | Compounds, compositions and methods for the treatment of viral infections and other medical disorders |
CA2606399A1 (en) | 2005-04-25 | 2006-11-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Scienc Es Of The Czech Republic | Use of compounds to enhance processivity of telomerase |
WO2007002808A1 (en) | 2005-06-29 | 2007-01-04 | Gilead Sciences, Inc. | Anti-nonmelanoma carcinoma compounds, compositions, and methods of use thereof |
EP2012799B1 (en) * | 2006-05-03 | 2016-08-24 | Chimerix, Inc. | Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates |
CN101089004A (en) * | 2006-06-13 | 2007-12-19 | 上海舒盟化学科技有限公司 | New type of phosphonate-nucleotide compound |
EP2117555B1 (en) * | 2006-12-20 | 2012-10-17 | Universitätsklinikum Hamburg-Eppendorf | Use of tri-substituted glycerol compounds for the treatment of hematological malignancies |
EP2144921A2 (en) | 2007-02-27 | 2010-01-20 | K.U. Leuven Research and Development | Phosphate modified nucleosides useful as substrates for polymerases and as antiviral agents |
JP2010525063A (en) | 2007-04-27 | 2010-07-22 | キメリクス,インコーポレイテッド | Methods for reducing nephrotoxicity in subjects administered nucleoside phosphonates |
CN105055432A (en) | 2008-01-25 | 2015-11-18 | 奇默里克斯公司 | Methods of treating viral infections |
TWI444384B (en) | 2008-02-20 | 2014-07-11 | Gilead Sciences Inc | Nucleotide analogues and their use in the treatment of malignancies |
CN101307076A (en) * | 2008-05-30 | 2008-11-19 | 秦引林 | Prodrug with liver-targeted anti-HBV effect |
KR101774429B1 (en) | 2009-02-06 | 2017-09-04 | 코크리스탈 파마, 아이엔씨. | Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections |
DE102009020261A1 (en) | 2009-05-07 | 2010-11-11 | Universität Hamburg | Process for the solid-phase preparation of phosphate-bridged nucleoside conjugates |
TW201107342A (en) | 2009-05-20 | 2011-03-01 | Chimerix Inc | Compounds, compositions and methods for treating viral infection |
WO2011011519A1 (en) | 2009-07-21 | 2011-01-27 | Chimerix, Inc. | Compounds, compositions and methods for treating ocular conditions |
WO2011011710A1 (en) | 2009-07-24 | 2011-01-27 | Chimerix, Inc. | Methods of treating viral infections |
WO2011017253A1 (en) | 2009-08-03 | 2011-02-10 | Chimerix, Inc. | Composition and methods of treating viral infections and viral induced tumors |
EP2493479A4 (en) | 2009-10-30 | 2013-04-17 | Chimerix Inc | Methods of treating viral associated diseases |
EP3216789A1 (en) | 2010-02-12 | 2017-09-13 | Chimerix, Inc. | Methods of treating viral infection |
US20110218241A1 (en) | 2010-03-06 | 2011-09-08 | Cacao Bio-Technologies, Llc | Antiviral epicatechins, epicatechin oligomers, or thiolated epicatechins from theobroma cacao for treatment of genital warts |
EP2558466A4 (en) | 2010-04-14 | 2013-11-13 | Univ California | Phosphonates with reduced toxicity for treatment of viral infections |
AU2011295937B2 (en) | 2010-08-31 | 2015-04-16 | Emergent Biodefence Operations Lansing Llc | Phosphonate ester derivatives and methods of synthesis thereof |
ES2687958T3 (en) | 2013-03-15 | 2018-10-30 | The Regents Of The University Of California | Acyclic nucleoside diester phosphonate |
MX362752B (en) | 2013-11-15 | 2019-02-07 | Chimerix Inc | Morphic forms of hexadecyloxypropyl-phosphonate esters. |
SG11201701957XA (en) | 2014-09-15 | 2017-04-27 | Univ California | Nucleotide analogs |
EP3350191B9 (en) | 2015-09-15 | 2021-12-22 | The Regents of the University of California | Nucleotide analogs |
-
2014
- 2014-03-14 ES ES14764430.6T patent/ES2687958T3/en active Active
- 2014-03-14 BR BR112015023705A patent/BR112015023705A8/en not_active Application Discontinuation
- 2014-03-14 EA EA201892769A patent/EA201892769A3/en unknown
- 2014-03-14 EP EP14764430.6A patent/EP2970346B1/en active Active
- 2014-03-14 HU HUE14764430A patent/HUE041346T2/en unknown
- 2014-03-14 SG SG10201800188SA patent/SG10201800188SA/en unknown
- 2014-03-14 SG SG11201507101XA patent/SG11201507101XA/en unknown
- 2014-03-14 PT PT14764430T patent/PT2970346T/en unknown
- 2014-03-14 SI SI201430875T patent/SI2970346T1/en unknown
- 2014-03-14 LT LTEP14764430.6T patent/LT2970346T/en unknown
- 2014-03-14 AU AU2014228321A patent/AU2014228321C1/en not_active Ceased
- 2014-03-14 KR KR1020157027425A patent/KR20150130355A/en not_active Application Discontinuation
- 2014-03-14 CN CN201810387212.8A patent/CN108619161A/en active Pending
- 2014-03-14 PL PL14764430T patent/PL2970346T3/en unknown
- 2014-03-14 MX MX2015012633A patent/MX367403B/en active IP Right Grant
- 2014-03-14 TW TW103109799A patent/TWI642677B/en not_active IP Right Cessation
- 2014-03-14 EA EA201591757A patent/EA032227B1/en unknown
- 2014-03-14 EP EP18179904.0A patent/EP3401320B1/en active Active
- 2014-03-14 WO PCT/US2014/027005 patent/WO2014143643A1/en active Application Filing
- 2014-03-14 DK DK14764430.6T patent/DK2970346T3/en active
- 2014-03-14 CA CA2906680A patent/CA2906680A1/en not_active Abandoned
- 2014-03-14 RS RS20181142A patent/RS57796B1/en unknown
- 2014-03-14 CN CN201480026709.7A patent/CN105246902B/en not_active Expired - Fee Related
- 2014-03-14 US US14/211,235 patent/US8835630B1/en active Active
- 2014-03-14 US US14/211,002 patent/US9629860B2/en active Active
- 2014-03-14 JP JP2016502307A patent/JP6462659B2/en active Active
- 2014-03-14 CN CN201710272746.1A patent/CN107056838A/en active Pending
- 2014-08-20 US US14/463,908 patent/US9156867B2/en active Active
-
2015
- 2015-09-10 IL IL241554A patent/IL241554B/en active IP Right Grant
- 2015-10-02 US US14/874,027 patent/US9387217B2/en active Active
-
2016
- 2016-06-10 US US15/179,209 patent/US9775852B2/en active Active
- 2016-06-24 HK HK16107381.4A patent/HK1219279A1/en not_active IP Right Cessation
-
2017
- 2017-03-20 US US15/463,962 patent/US20170189430A1/en not_active Abandoned
- 2017-06-08 US US15/617,841 patent/US10076532B2/en active Active
- 2017-11-10 US US15/809,400 patent/US10076533B2/en active Active
- 2017-11-14 US US15/812,814 patent/US10195222B2/en active Active
-
2018
- 2018-08-24 US US16/111,378 patent/US10449207B2/en active Active
- 2018-10-30 CY CY181101116T patent/CY1120839T1/en unknown
- 2018-11-08 HR HRP20181871TT patent/HRP20181871T1/en unknown
- 2018-12-26 JP JP2018242188A patent/JP2019069984A/en active Pending
-
2019
- 2019-03-22 AU AU2019201990A patent/AU2019201990B2/en not_active Ceased
- 2019-09-11 US US16/567,092 patent/US20190388442A1/en not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11344555B2 (en) | 2014-09-15 | 2022-05-31 | The Regents Of The University Of California | Nucleotide analogs |
US11572377B2 (en) | 2015-09-15 | 2023-02-07 | The Regents Of The University Of California | Nucleotide analogs |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10449207B2 (en) | Acyclic nucleoside phosphonate diesters | |
US9475832B2 (en) | Phosphonates with reduced toxicity for treatment of viral infections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT, MARYLAND Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF CALIFORNIA SAN DIEGO;REEL/FRAME:061047/0678 Effective date: 20200121 |